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Abstract:  
The contractile function of the heart depends on efficient β adrenergic receptor (βAR) 
signalling which involves cycling nucleotides as second messengers. Correct secondary 
messenger signalling is only possible in healthy, well structured cardiac myocytes. Of the three 
βAR subtypes present in human cardiomyocytes β1AR and β2AR classically signal via 3'-5' 
cyclic adenosine monophosphate (cAMP) to regulate contraction after catecholamine 
administration, whereby the second isoform may also be cardioprotective. The far less 
characterised β3AR has been controversially associated to both increasing contraction 
through cAMP and protecting the heart through 3'-5' cyclic guanosine monophosphate (cGMP) 
signalling. During the progression of heart failure following myocardial infarction (MI) both the 
normal cell structure and the regulation of cAMP and cGMP signalling are changed. This 
happens in part due to changes in catecholaminergic stimulation of the βARs and in 
mechanical load, as well as due to a progressive development of hypertrophy. Some of the 
alterations initially appear to be of a compensatory nature but escalate into HF by worsening 
cardiomyocyte function and cell survival.  
The work presented here (1) investigates the structural integrity of healthy, isolated, single 
cardiomyocytes by looking at the surface topography via Scanning Ion Conductance 
Microscopy (SICM) imaging and by examining the internal Transverse Axial Tubule (TAT) 
network via confocal imaging; (2) elucidates the cyclic nucleotide response to catecholamine 
stimulation following either global (in the solution) or  local (in the SICM pipette) stimulation of 
either β2ARs or β3ARs and measuring either cAMP or cGMP levels via Förster Resonance 
Energy Transfer (FRET) sensors in a combined FRET/SICM imaging setup; (3) determines 
how both the structure and β2AR and β3AR dependent second messenger signalling change 
in a progressive rat model of HF 4, 8 and 16 weeks after the induction of chronic MI. 
The major findings of the presented work are as follows: 
In control cardiomyocytes the structure is highly intricate with regular Z-grooves and crest 
areas. In MI cells the normal suface topography progressively deteriorates, with the eventual 
disappearance of Z-grooves by week 16, which correlates with the disorganisation of the 
cardiomyocyte’s internal transverse axial tubule (TAT) network of T-tubules emanating from 
the cell surface and traversing into the cell centre. This is accompanied by the gradual 
redistribution of β2ARs from their normal position inside the T-tubules to the unstructured areas 
on the cardiomyocyte membrane. The regularity and density of the TAT network is already 
severely compromised at 4 weeks post MI; at the same time a significant drop in the 
expression of the structural protein Junctophilin 2 (JPH2) occurs. At 4 and 8 weeks post MI a 
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potentially compensatory increase in the number of longitudinal elements takes place which 
was no longer detectable at 16 weeks. The production of cAMP following local stimulation of 
β2ARs in the T-tubule openings was already suppressed at 4 weeks post MI and a β2AR 
response becomes detectable after local stimulation at the cell crests (areas between Z-
grooves) at 8 weeks post MI. At 16 weeks post MI the β2AR-dependent cAMP level following 
both global and local stimulations was reduced due to an overall decrease in the adenylate 
cyclase (AC) activity. 
The production of the second cyclic nucleotide, cGMP, following β3AR stimulation is evident 
in control cells and to a significantly lesser extent in myocytes isolated from hearts at the end 
stage of HF. These β3AR-cGMP levels were degraded mainly by phosphodiesterases (PDE) 
2 and 5. Local stimulation through the SICM pipette reveals that functional β3ARs are primarily 
localized inside T-tubules in control cells but redistribute equally in between T-tubules and 
crests in cells isolated from failing hearts.  
To improve the accuracy and reliability of local application of agonists via the SICM 
nanopipette voltage was applied to the pipette, as opposed to previously employed 
displacement of the liquid in the pipette via air pressure. Mathematical modelling served to 
determine the correct settings for this voltage driven application. It shows that the SICM 
nanopipette can reliably and precisely unload the βAR agonist ISO onto the nanoscale 
structure of cardiomyocytes via voltage. 
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1. Introduction: 
1.1 Heart failure: definition, progression and current treatment 
According to the Office for National Statistics of the U.K. the average life expectancy of UK 
citizens lies around 78 years for men and 82 years for women and is continually increasing by 
about 2 years every decade (UK government website: http://www.ons.gov.uk; accessed 
January 2015). This increase in life expectancy brings with it a rise in age-related 
cardiomyopathies and chronic heart failure (HF), which our increasingly aging population has 
to face. In addition to age other known risk factors for the occurrence of HF are hereditary 
disorders, diabetes, hypertension, smoking and obesity. By definition HF is the inability of the 
heart to efficiently pump blood throughout the cardiovascular system and is the consequence 
of various, complex causes including, among others, neuro-hormonal overstimulation and/or 
mechanical overload of cardiomyocytes (Mudd, Kass 2008). In most cases of HF the clinical 
symptoms are due to impairment of the left ventricle and can be manifold. As the heart’s ability 
to efficiently pump blood decreases HF patients oftentimes suffer from dyspnea and fatigue, 
which heavily affects or even inhibits the patient’s tolerance to exercise. The kidneys react to 
a reduction in the blood flow by retaining more fluid and salt. As a consequence the patient 
may experience pulmonary congestion and or peripheral edema (Dunlay et al. 2014). Though 
there are exceptions, such as physically-induced heart arrest or stress-induced 
cardiomyopathies, HF has generally been recognised as a progressive disorder, which at first 
is asymptomatic before escalating into a symptomatic disease in a time-dependent manner. 
Depending on the stage of disease progression the risk factors and symptoms require 
differential treatment (Dickstein et al. 2008). As a consequence patients are classified into 4 
different stages of severity. These stages are clinically assessed according to risk factors 
which might lead a patient to develop HF as well as already developed structural and 
functional indicators of HF (see table 1). The major contributor to the progression of HF is the 
irreversible loss of cardiomyocytes. Hence MI is the most troublesome of potential cardiac 
interferences as it leads to the death of approximately a billion cardiomyocytes and to fibrotic 
scarring (Laflamme and Murry 2005). MI occurs as a result of interrupted blood flow to a part 
of the heart and mainly affects the myocardium of the left ventricle (LV). Treatment strategies 
to deal with the occurrence of HF by slowing it’s progression depend on the symptoms of the 
respective patient but range from angiotensin converting enzyme (ACE) inhibitors and β-
blockers to diuretics and mild exercise (Dunlay et al 2014). If the disease has progressed too 
far the only option to save a patient’s life is a heart transplant (Dickstein et al. 2008). Although 
the advances in cardiovascular science and therapeutic strategies have been manifold the 
prognosis of HF remains grim with an estimated 65% mortality rate of patients of fewer than 5 
years and a significant decrease in their quality of life (McMurray, Stewart 2000). 
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Table 1 Classification, symptoms and treatment strategies of HF stages adapted from (Dunlay et al. 2014) 
HF stage  Risk factors/symptoms Diagnosis Treatment strategy  
 
 
A 
Hypertension, obesity, 
diabetes, atherosclerosis, 
intake of cardiotoxins, 
hereditary disorder 
At heightened 
risk, but without 
structural or 
functional HF 
symptoms. 
Treatment of hypertension, 
increased exercise, 
discouragement of alcohol 
intake, smoking, drug abuse,   
treatment of other disorders  
 
 
B 
Remodelling of the LV 
due to occurrence of MI 
or valve disease and 
myopathies   
Structural 
alterations of the 
heart without HF 
symptoms   
As defined for stage A 
Additionally: defibrillator, 
ACE inhibitors, angiotensin II 
receptor and β-blockers 
 
 
C 
Evident structural heart 
disease in combination 
with fatigue and 
dyspnoea, 
decreased capacity for 
exercise    
Structural 
alterations of the 
heart with past or 
present HF 
symptoms 
As defined for stages A, B 
Additionally: salt restriction, 
diuretics, specialised drugs 
for specific patients i.e. 
nitrates   
 
 
D 
Severe HF symptoms 
even at rest despite 
medical attention 
Evident HF which 
urgently requires 
specialised 
intervention 
As defined for stages A, B, C 
Additionally: heart transplant, 
permanent mechanical 
support, experimental 
surgery 
 
1.2. Ventricular assist devices 
In order to counteract the consequences of a weakened heart during cardiomyopathies 
patients can be outfitted with right (RVAD) or left ventricular assist devices (LVAD). These 
devices are artificial, mechanical pumps implanted into the patient’s chest which help to 
maintain blood flow and heart function (Giveritz 2011). It has been shown that the introduction 
of LVADs can re-establish contractility of diseased hearts and lead to reverse structural 
remodelling of cardiomyocytes via the normalization of microRNA (miR) expression patterns. 
These miRs, which are small pieces of non-coding RNA, achieve cardiac regulation by binding 
to mRNAs and marking them for degradation so that the respective protein expression is 
inhibited (Matkovich et al. 2009).   
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1.3. Animal models of HF 
To look for potential treatment strategies experiments with animal models have proven to be 
indispensable. Animal models are utilised for testing and optimising cardiac assist devices as 
well as for elucidating new therapeutical targets or biomarkers, which indicate HF (HF) 
progression. As the disease itself is highly complex and arises from a number of molecular 
and physical insults, induction of acute and chronic HF has been achieved in animal models 
by a variety of means. These include overloading the heart with volume or pressure, 
administering cardio-toxic drugs or inducing MI. In order to be appropriate for the study of HF 
an animal model should possess the same pathological features as a human being. MI animal 
models of HF generated by ligation of the left anterior descending artery (LAD) are fairly 
reproducible. They generate a localised ischemic insult in the left ventricle and reproduce 
acute and chronic clinical symptoms of human HF (Monnet, Chachques 2005). In our group 
we have established an adult rat model of chronic MI via the ligation of the LAD (Lyon et al. 
2009), which incorporates the major symptoms of human HF: fibrotic scarring after ischemic 
myocardial injury, extensive cell death at the site of the injury, a decrease in the left ventricular 
ejection fraction (LVEF), hypertrophy, adverse remodelling of cardiomyocyte morphology and 
function and alterations in the sensitivity of βARs to catecholamine stimulation (Lyon et al. 
2009; Nikolaev et al. 2010). Most of the work described in this thesis deals with 
cardiomyocytes isolated from this LAD MI model, for the examination of cardiomyocyte 
structure and secondary messenger signalling.  
 
1.3. Cardiac regulation via the sympathetic and parasympathetic nerves 
The physiological function of the heart depends on its regulation by the sympathetic (SNS) 
and parasympathetic nervous system (PNS) with their pre.- and postganglionic neurons at 
separate anatomic positions. As two of the three parts of the autonomic or involuntary nervous 
system (the third being the enteric nervous system) the SNS and PNS are generally said to 
fulfil opposing, but complementary functions. For this the SNS and PNS are able to inhibit 
each other presynaptically (Goldstein 2011). Physically the preganglionic nerves of the SNS 
emerge from the top and the lower part of the spinal cord and connect via nerve cell clusters, 
the so called ganglia, to the postganglionic nerves. These nerves then reach out to the target 
organs, including the heart. The nerves of the PNS emanate from the medial part of the spinal 
cord and end as postganglionic nerves at the cardiac atria where they modulate cardiac 
function through neurotransmission via nicotinic receptors (Shaffer et al. 2014). While the 
preganglionic nerves of both the SNS and the PNS secrete acetylcholine (ACH) for 
neurotransmission the postganglionic nerves of the SNS and PNS secrete different hormones 
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at different levels. These include adrenaline (ADR) and noradrenaline (NOR) which are the 
effectors of the β adrenoreceptors (βAR) (Zipes, Jalife 2009). In healthy individuals the SNS 
is effectively modulating cardiomyocyte responses such as the increase of the heart rate, 
cardiac contractility and the constriction of cardiovascular vessels via the βARs. Cardiac 
modulation is achieved by postsynaptic nerve fibres of the SNS at the sinus atrial node (SAN), 
the atrioventricular (AV) node and the sub-epicardium of the ventricles. These fibres release 
negligible amounts of the catecholamine ADR and higher amounts of the catecholamine NOR, 
which makes NOR the main regulator of the cardiac SNS response (Zipes, Jalife 2009). The 
main way to inactivate NOR released from nerve fibres is its reuptake into sympathetic nerves 
and consequent storage in vesicles (Goldstein 2011). In the heart NOR’s overall effect is the 
shortening of the cardiac action potential in the ventricle as well as the shortening of the 
refractory period of cells, which is  the time it takes for cells to be excitable again. NOR and in 
higher quantities ADR are also released by endocrine cells at the adrenal glands above the 
kidneys (Lymperopoulos et al. 2007). Both hormones are secreted into the bloodstream and 
circulate to reach their effector organs and to regulate the “fight-or-flight” response. On the 
other hand the PNS counteracts the effects of the SNS by slowing down the heart rate and by 
inhibiting responses of the SNS to induce the “rest-and-digest” state (Shimizu, Okabe 2007). 
The vagal nerves of the PNS do so by releasing ACH, which binds to the muscarinic receptors 
in the heart and increases the threshold for spontaneous, electrical impulse (=action potential) 
generation in the SAN. The prevalent muscarinic receptor isoform in the heart is M2, which is 
coupled to inhibitory G (Gi) protein and scales down cAMP production. Hence M2 receptors 
exercise negative inotropic (decreased contractility) and chronotropic (decreased heart rate) 
effects via direct or indirect regulation of ion channels like the L-type Ca2+ channels (LTCC) 
(Brodde, Michel 1999). This allocation of regulation allows our organisms to adapt to the 
specific state they are in. While we are at rest it is the PNS which will maintain most of our 
functions. If we are however exerting ourselves or have been afflicted by a wound and suffer 
from blood loss the nervous system will increase cardiac output by a proportional increase in 
βAR dependent inotropy (increased heart contractility), chronotropy (increased heart rate) and 
lusitropy (increased heart relaxation) (Nagai and Komuro 2012).  
 
1.3.1. Changes in the nervous system regulation during HF progression 
After the occurrence of ischemic injury to the heart, or due to restricted blood flow, the SNS 
adapts to the decreased cardiac output by elevating its activity. Through heightened 
catecholamine release as well as increased reuptake into the nervous fibres the SNS tries to 
compensate for the loss of the heart’s contractility (Brum et al. 2006). On the one hand SNS 
hyperactivity throws the Renin-Angiotensin-Aldosterone system into overdrive, which retains 
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the organism’s fluid and increases the arterial blood pressure. On the other hand it leads to 
heightened levels of the catecholamines ADR and NOR to be released into the bloodstream 
and a subsequent increase in heart rate (Kishi 2012). Satisfying the acute need for heightened 
catecholamine levels however turns into a cardiotoxic, vicious circle if those levels are 
maintained chronically. One of the consequences of constantly occurring catecholaminergic 
stimulation is that the sensitivity and the actual number of the β1 adrenergic receptors (β1AR), 
which are the main receptors to translate the catecholaminergic stimuli into cellular responses, 
decreases (Bristow et al. 1982; Kishi 2012). At the same time the level of Gi proteins, which 
inhibit positive inotropy, increases (Lohse et al. 2003). Furthermore overstimulation of the β1 
subtype of the βAR family has been shown to induce hypertrophy and expedite cell apoptosis 
(Zhu et al., 2003). As a result the already injured cardiac structure deteriorates further, while 
the cardiac function plummets to lethal depths (Tomita et al. 2003). Abnormalities in the 
regulation of cardiovascular function by the SNS and PNS - especially SNS hyperactivity and 
excessive hormonal stimulation – have therefore become indicative of MI and HF (Kishi 2012).  
 
1.3.2. Catecholamines  
Human plasma contains three catecholamines which serve as chemical messengers and 
neurotransmitters: dopamine, ADR and NOR. Catecholamine biosynthesis takes place by 
hydroxylation of tyrosine into dihydroxyphenylalanine (L-DOPA), decarboxylation of L-DOPA 
to dopamine, hydroxylation of dopamine to NOR and finally methylation of NOR to ADR. The 
latter conversion takes place mainly in the chromaffin cells in the adrenal glands whereas the 
preceding conversional steps also occur in nerve fibres (Goldstein 2011). As mentioned earlier 
catecholamines bind to βARs and thereby mediate the effects of the SNS. Clinical tests allow 
the measurement of plasma catecholamine levels, in particular increased NOR levels, as a 
marker of disease progression (Brodde, Michel 1999). Under HF conditions human 
catecholamine plasma levels of around 80 picogram per ml of ADR and 500 picogram per ml 
of NOR were observed (Yan et al. 2008).   
 
1.3.3. βAR agonists and antagonists 
Though ADR and NOR are full agonists at all 3 βAR subtypes present in the heart it is 
noteworthy that ADR and NOR possess different affinities for the different βARs. While ADR 
and NOR bind with same affinity to the β1AR subtype, ADR is 35 times more potent than NOR 
at the β2ARs. The opposite applies to β3ARs which has a 30 times higher affinity for NOR 
(Hoffmann et al. 2004). This disparity of catecholamine preference by the β2ARs and β3ARs 
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could be indicative of an intricate regulatory mechanism during heightened stress conditions. 
Different affinities to the βARs have also been determined for artificial analogues of the 
catecholamines as well as for βAR blockers. Isoproterenol (ISO), used clinically to treat too 
slow heart rates (bradycardia), is a full agonist on all 3 βAR subtypes with highest affinity for 
β1ARs, about two times lower affinity for β2ARs and five times lower affinity for β3ARs. The 
most efficient, available β1AR and β2AR blockers are CGP20712 and ICI118511, respectively 
(Hoffmann et al. 2004). Human and rat β3ARs differ from each other both structurally as well 
as in their regulation (Granneman and Lahners 1994) (this is the only Granneman reference I 
made, and it wasn’t missing in the reference list) and in consequence of these differences the 
SR59230A serves as a highly selective β3AR blocker in rodents (Mongillo et al. 2006;Nikolaev 
et al. 2010) while it exhibits less specificity in human preparations (Candelore et al. 1999).  
 
1.4. The setup and function of the myocardium   
In its basic state the human heart is a highly responsive and highly adaptive circulatory, blood 
pump, which supplies our whole organism with vital nutrients and oxygen and clears away 
waste products. It is mainly made out of connective tissue and cardiac muscle cells (Weber 
1989). The adult cardiac muscle cells are unable to regenerate after injury such as MI which, 
through substitution of cardiomyocytes with connective tissue, leads to the formation of scar 
tissue (Laflamme, Murry 2005). The mammalian heart is dividable into four cardiac chambers, 
two atria and two ventricles. These chambers orchestrate the blood flow in-series via systolic 
(from the Greek word stello=shortening) and diastolic (from the Greek word 
diastello=lengthening) movements (Torrent-Guasp et al. 2004) according to electrical 
impulses, which are spontaneously generated by the cells of the SAN in the right atrium 
(Shaffer et al. 2014). From outside to inside the tissue of the heart walls can furthermore be 
divided into three different cell layers: the pericardium, the myocardium and the endocardium 
(Sanchez-Quitana et al. 1990). The myocardium is the layer responsible for the regulated 
pumping of the heart and is primarily consisting of cardiomyocytes. Through the rhythmical 
contraction of the left ventricular (LV) cardiomyocytes the heart efficiently distributes blood 
throughout the circulatory system and supplies our organism with necessary nutrients and 
oxygen. When the LV cardiomyocytes contract, starting from the apical tissue to the basal 
tissue, this leads to a wringing motion of the LV chamber. During the phase of systole this 
motion increases the pressure inside the chamber and ejects the blood from the LV. The same 
motion results in a decrease of the pressure during cardiomyocyte relaxation and a filling of 
the LV chamber during diastole. Only recently the ventricular myocardial fibers have been 
shown to form one cohesive muscular band which twists twice and then helically folds in on 
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itself to form the left and right ventricular chambers (Torrent-Guasp et al. 2004). However, 
despite this unified, anatomical arrangement, the ventricular wall is not a uniformly functioning 
and aligned structure (Dorri et al. 2010). Due to the heterogeneity of its laminar layers the 
ventricular wall possesses macroscopically observable differences in its transmural orientation 
(LeGrice et al. 1995) as well as microscopically determinable variations in force production 
(Haynes et al. 2014), electrical conductance (Zygmunt et al. 2001) and Ca2+ activity (Cordeiro 
et al. 2004) of single cardiomyocytes. Furthermore differences according to the anatomical 
position (Wan et al. 2003) as well as due to species affiliation have become evident (Soeller 
et al. 2007). Therefore it is important to note that the biggest part of this work deals with the 
structure and function of cardiomyocytes from the basal part of the left ventricle of adult human 
and rat hearts.    
 
1.5. The cardiac action potential 
 
Figure 1 The 4 sequential phases of the action potential of cardiomyocytes. The cardiac action potential 
depends on ion currents, which set in at specific membrane potential values as indicated in the schematic 
which was taken directly from Grigoriy Ikonnikov and Eric Wong, Copyright © 2012-2015 McMaster 
Pathophysiology Review. 
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The intracellular and extracellular space of cardiac cells possesses disparate levels of ionic 
constituents, which leads to a disequilibrium of the electrical potential on both sides of the 
cellular plasma membrane. This disequilibrium is maintained by a distinct ion distribution and 
steady exchange of Na+, K+, Cl- and Ca2+ ions. The cell membrane itself however is only 
selectively permeable for these ions and regulates the exchange between the extra and intra 
cellular ion content via specific ion channels. It does so either passively, i.e. through voltage 
gated channels, or actively through energy expenditure in the form of adenosine triphosphate 
(ATP). In healthy hearts it takes special pacemaker cells in the SAN of the right atrium to 
initiate the stepwise opening of these ion channels. The pacemakers generate small 
depolarizations in surrounding cardiomyocytes through the gap junctions and thereby start the 
phases of the so called cardiac action potential. As soon as the relative negative membrane 
potential at rest (-90 mV) inside the adjacent cardiomyocytes reaches the threshold potential 
(-70 mV) necessary to open the fast voltage gated Na+ channels, it depolarises even further 
(to +20 mV) due to the influx of Na+ ions into the cell cytosol. At this point voltage gated K+ 
channels open up and an increased K+ efflux out of the cell cytosol takes place. This slightly 
repolarises the cardiomyocytes (back to +5 mV) until the opening of voltage gated Ca2+ ion 
channels and subsequent Ca2+ flux into the cells sets in. For a short time the K+ efflux and the 
Ca2+ influx counterbalance each other and keep the membrane potential at a relative plateau. 
This ends via a sudden reclosing of the voltage gated Ca2+ ion channels. The K+ efflux however 
continues until the membrane potential is repolarised back to its resting state (at -90mV) until 
the next depolarization is initiated (Nerbonne, Kass 2005). The interval between the overall 
ventricular depolarization and repolarization has been clinically termed as the ST segment 
according to the position it upholds on a clinical electrocardiogram, which measures the heart’s 
electrical activity. If persistently elevated this ST segment can be indicative of MI (Dickstein et 
al. 2008).   
  
1.6. Cardiomyocyte excitation-contraction coupling (ECC) 
The term excitation-contraction coupling (ECC) is a synonym for how the sequential flux of 
ions across the surface of excitable, electrically connected cardiomyocytes during the action 
potential results in intracellular Ca2+ cycling processes which lead to linear cell contraction of 
single cardiomyocytes in-series, in a highly regulated manner (Bers 2002). The opening of 
LTCCs during the action potential elicits a relatively small increase of the intracellular Ca2+ 
levels which in turn trigger the opening of cardiac Ryanodine receptors (RyR2) on the 
sarcoplasmic reticulum (SR). The SR is a major, intracellular Ca2+ store and subsequently 
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releases much higher levels of Ca2+ into the cytosol. This process is referred to as Ca2+ 
induced Ca2+ release (CICR). The now abundantly available Ca2+ in the cytosol binds to the 
myofilament Troponin C in the Troponin complex which, together with Tropomyosin, keeps 
the actin and myosin filaments from sliding along each other. The binding of Ca2+ releases the 
myosin heads which then use and hydrolyse ATP to ADP to generate energy. Through the 
consumption of this energy the filaments change their conformation and walk along the actin 
filaments to produce the energy dependent motion of contraction. For the cardiomyocyte to 
relax again it is necessary that Ca2+ detaches from Troponin C and is removed from the cytosol 
again. This happens gradually by decreasing the Ca2+ concentration through 
sarcoendoplasmic reticulum Ca2+-ATPase (SERCA2A) driven reuptake into the SR, the 
sodium calcium exchanger (NCX) and the Ca2+-ATPase in the sarcolemma expelling Ca2+ into 
the extra-cellular space and to a very small degree by Ca2+ uptake into the mitochondria via 
the Ca2+ uniporter (Bers 2002; Nerbonne, Kass 2005).       
 
Figure 2. Ca2+ cycling and excitation-contraction-coupling related molecules in cardiomyocytes adapted 
from (Grandi, Herren 2014).  Ca2+ cycling is indicated by green arrows. LTCC dependent Ca2+ cycling 
regulates CICR from the SR via RyRs. SR released Ca2+ facilitates contraction by binding to contractile 
myofilaments. Extrusion of Ca2+ from the cytosol and disassociation from contractile myofilaments is 
necessary for cardiomyocyte relaxation and is performed by SERCA dependent reuptake into the SR as 
well as Na+ and Ca2+ exchanger (NCX) and Ca2+ ATPase dependent expulsion into the extracellular space. 
A small amount of Ca2+ is furthermore taken up by the mitochondria for increased ATP production 
(Brandes, Bers 1997) or binds to Calmodulin (CaM) which goes on to activate Ca2+/calmodulin-dependent 
protein kinase II (CaMKII). CaMKII phosphorylates a variety of downstream targets and has been implicated 
in hypertrophy and apoptosis (Zhang, Brown 2004).  
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1.7. Ventricular cardiomyocyte structure in health 
In their healthy state human, ventricular cardiomyocytes are striated, at times branched or rod-
shaped and binucleated cells. Cardiomyocytes are furthermore connected to each other via 
the intercalated disks. This allows intercellular exchange of cytosolic molecules, like Na+ and 
Ca2+, between cardiomyocytes via the gap junctions. The gap junctions themselves are small 
channels, which are made up of the appropriately named connexin proteins (Goodenough and 
Paul 2009), that reside in the intercalated disk. In vivo ventricular cardiomyocytes are arranged 
in laminar layers of 28 up to 48 microns thickness (2 to 4 individual cells) surrounded by 
extracellular matrix, collagen and blood vessels (LeGrice et al. 1995). Single, human 
cardiomyocytes are around 120µm in length and 25µm in width (Severs 2000) and like rat 
cardiomyocytes they exhibit highly organised and regular surface and internal structures (Lyon 
et al. 2009). These structures are in part facilitated by the cytoskeleton, whose filaments are 
composed of actin and desmin while its protein transporting microtubule consists of 
polymerising α and β tubulin (Hein et al. 2000). The smallest structural and functional units of 
a cardiomyocyte are the sarcomeres. Sarcomeres contain the contractile myosin and actin 
filaments, necessary for force production and contraction. Depending on the state of cell 
contraction the sarcomeres are around 2 microns in length. They are delimited via the Z-lines, 
which are made out of a vast amount of different proteins (Solaro, Stull 2011). The surface 
structures of cardiomyocytes can be identified as Z-grooves, crests, transverse tubule (T-
tubule) openings, which lead into the Transverse Axial Tubule (TAT) network. As their name 
indicates the Z-grooves are grooves in the surface sarcolemma of cardiomyocytes and they 
are separated from each other by intermediate dome-like structures, the crests (Gorelik et al. 
2006). T-tubules are invaginations on the sarcolemmal surface of cardiomyocytes (Sperelakis 
and Rubio 1971), which usually open up to the extracellular space from within the Z-grooves 
via T-tubule openings. In healthy adult, rat ventricular cardiomyocytes the T-tubules openings 
the Z-grooves and the crest areas occur at a regular interval of about 2 microns distance 
(Gorelik et al. 2006). It is noteworthy that all structures mentioned above are also present in 
the atria, however to a more variable degree, as well as in the right ventricle. However, the 
major focus of the presented work lies on the investigation and characterisation of left 
ventricular cardiomyocytes in health and disease.  
 
1.7.1. The cardiomyocyte TAT network  
The TAT network is an important structural and functional feature of adult cardiomyocytes in 
the left ventricle. It stretches in a highly regular constellation throughout the whole body of 
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ventricular cells in axial and in transverse (T-tubule) directions along the Z-lines 
(approximately every 2 microns). To a less regular degree the TAT also forms longitudinal 
elements that connect the T-tubules with each other. In contrast to adult ventricular 
cardiomyocytes, neonatal cells completely lack a TAT network (Richards et al. 2011). The 
generation of the TAT network and its maintenance during adulthood is not yet fully 
understood but an array of various molecules has been implicated. These molecules include 
caveolin 3 (Cav3), presumably responsible for T-tubule formation and maintenance 
(Woodman et al. 2002), BIN1 for T-tubule formation through inducing curvature in membranes 
and for LTCC shuttling (Hong et al. 2010), tropomyosin for T-tubule maintenance (Vlahovich 
et al. 2009), Tcap for load dependent formation of T-tubules at least in skeletal muscle (Zhang 
et al. 2009) and junctophilins for correct T-tubule and SR association (Han et al. 2013). Recent 
studies ascribe junctophilins an additional and important role in the orientation of tubules in 
the TAT network (Bennett et al. 2013; Pinali et al. 2013). The diameter of fully developed TAT 
network tubules in ventricular cells is around 20 to 450 nm and many of the proteins necessary 
for the process of excitation-contraction coupling are concentrated within the TAT network, 
including β2ARs at the T-tubule openings as well as Na/Ca
2+
 exchanger (NCX) and LTCCs 
inside the T-tubules (Ibrahim et al. 2011; Brette, Orchard 2003).This positions the LTCCs 
directly across from the RyRs on the SR (approximately 10-12nm apart) (Franzini-Armstrong 
et al. 1999). After electrical excitation this arrangement facilitates fast and homogenous CICR 
from the SR into the cytosol throughout the whole cardiomyocyte as well as microdomain 
specific Ca
2+ 
removal via NCX. This setup allows for rapid cardiomyocyte contraction and 
relaxation (Richards et al. 2011). It also allows for microdomain specific formation of β2AR 
signalosomes by arranging them in close proximity to their downstream signalling 
components, which are distinct to β1AR signalling targets (Nikolaev et al. 2010). The TAT 
network furthermore limits the diffusion of ions which can enter into them and thereby 
establishes a microenvironment with relatively constant ion content (Brette et al. 2006). T-
tubule disruption in end stage HF in human and animal ventricular cells is well documented 
(Lyon et al. 2009) and serves as substrate for dysfunctional βAR and Ca
2+ 
signalling (Nikolaev 
et al. 2010). Artificial detubulation by formamide treatment in vitro also functionally affects both 
β1- and β2-AR responses and Ca2+ signaling in cardiomyocytes (Nikolaev et al. 2010; Brette 
et al. 2005). As a result the remodelling or partial loss of the TAT network in ventricular 
cardiomyocytes is heavily implicated in the pathology of HF. Most of the cardiomyocyte 
structure can satisfactorily be visualised with SICM and parallel confocal imaging of structures 
visualised via fluorescent molecules, as was done for this study.   
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1.7.2. Caveolae 
Caveolae are cholesterol and glycosphingolipid enriched lipid rafts which form flask or cave-
like indentations in the membrane of cells, including left ventricular cardiomyocytes. Though it 
has been hypothesised that the caveolae might be precursors of the T-tubules they are only 
found outside of the TAT network (Harvey and Calaghan 2012; Wong et al. 2013). With only 
50 to 100 nm width, the caveolae are smaller than other surface structures of cardiomyocytes 
and the state of the art technique of localising caveolae remains the electron microscope 
(Wright et al. 2014). Like other lipid rafts the caveolae are able to organize proteins with the 
necessary affinity, like palmitoylated transmembrane proteins, the β2ARs, AC 5/6 and the α-
subunit of G-proteins in close proximity (Brown and Borutaite 2007; Balijepalli et al., 2006). 
The caveolae are also the exclusive residence of β2ARs in neonatal cardiomyocytes (Xiang et 
al. 2002) and eNOS in adult cardiomyocytes (Petroff et al. 2001). They have been shown to 
modulate β2AR signalling (Calaghan and White 2006) and Ca2+ signalling complexes in 
cardiomyocytes (Bossuyt et al. 2002). Caveolae are furthermore reported to gather mechano-
sensitive ion channels in their structure, including a subpoulation of LTCC and to be involved 
in increasing or decreasing their activity depending on mechanical stimuli which the cells 
receive and the consequent post-translational modifications, like phosphorylation, which occur 
as a result (Petroff et al. 2001). The flask-like appearance of caveolae, which is assumed to 
work as an ion reservoir, is due to the structural caveolin coat proteins (Caveolin 1, 2, 3) which 
they incorporate to varying degrees depending on the tissue. In cardiomyocytes Cav3 is the 
dominant caveolin form (Song et al. 1996) and is assumed to be involved in a number of 
cardiomyopathies. Complete knockdown of the protein has been shown to lead to HF 
(Woodman et al. 2002).   
 
1.7.3. Cardiomyocyte hypertrophy 
Hypertrophy is an increase in cell size which cardiomyocytes undergo in order to adept to 
altered mechanical load i.e. during the progression of HF to compensate for decreased cardiac 
output. If hypertrophic signalling is maintained at a continuous level it can further the 
development of dilated cardiomyopathy. The observable increase in cardiac cell size occurs 
as a result of increased protein expression, altered sarcomere organization and a return to a 
more fetal phenotype (Yue et al. 2000).  
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1.8. G-protein coupled receptors 
With over 800 known family members, the superfamily of G-protein coupled receptor (GPCR) 
molecules is one of the biggest protein families present in the mammalian genome 
(Fredriksson et al. 2003). GPCRs are a key player in translating a huge variety of stimuli, 
which they receive via extracellular ligand binding, into intracellular signals and physiological 
reactions (Hill 2006). GPCRs are identifiable by a sequence of seven α helices with high 
hydrophobicity, which form seven transmembrane (7TM) spanning domains, as well as by 
their ability to interact with guanine-nucleotide binding proteins (G proteins) (Fredriksson et al. 
2003). The heterotrimeric G-proteins with their α, β and γ subunits can influence downstream 
effector targets like ACs and GCs. In their inactive state the G-proteins are bound to GDP. 
They are activated through the exchange of this GDP with GTP, which leads to their 
conformational change and allows their G α subunits to dissociate from β and γ and to initiate 
a signalling cascade. The different types of G α subunits known to date are: stimulatory (Gs), 
Gi, the phospholipase C activating (Gq) and G12/13 (Audet, Bouvier 2012). βAR coupled Gs 
increases cAMP. In contrast Gi blocks βAR dependent cAMP production and is implicated in 
reduced contractility during HF progression. In failing human cardiomyocytes (Brown, Harding 
1992) and a model of MI in the rat (Kompa et al. 1999) inactivating of Gi via pertussis toxin 
partially restored β1AR-mediated contractility. Interestingly, despite increased Gi expression 
(El-Armouche et al. 2003) this appears not as the result of increased Gi activity in HF as this 
has been reported to be unchanged in comparison to healthy hearts (Hussain et al. 2013). It 
is possible for a GPCR to be coupled to multiple G-proteins as is the case for β2AR, which are 
associated to Gs but switch to Gi after phosphorylation by PKA (Zhu et al. 2001). GPCR 
agonists and antagonists can bind with varying affinity and elicit a variable amount of signal 
amplification depending on their expression level and the tissue in which they are found (Hill 
2006). Also the function and downstream signalling of the GPCRs is regulated by a group of 
kinases, the G-protein receptor coupled kinases (GRKs), which are also known in context with 
βARs as the βAR kinases (βARKs) (Ungerer et al. 1993). Owing to the fact that most of the 
polypeptide chain of the GPCRs is sitting inside the plasma membrane of the respective cell, 
their detection and the determination of their structure initially posed a big challenge to the 
scientific community. The first step of cracking this conundrum was achieved through the use 
of chemical synthesis. By generating radioactive ligands that specifically bind various GPRC 
receptors Lefkowitz et al. detected the receptors for ADR, the βARs (Lefkowitz et al. 1970). 
On the basis of the knowledge obtained thus Lefkowitz et al. then proposed that GPCR signal 
transduction is based on a ternary complex with high and low affinity states that is composed 
of the extracellular ligand, a transmembrane component and the intracellular G-protein which 
exists in an equilibrium of 2 states: active or inactive. The ternary complex model had to be 
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expanded when basal activity of some GPCRs became apparent (De et al. 1980). It required 
another three decades to find a suitable method to determine the three dimensional structure 
of GPCRs. The breakthrough was achieved by Okada et al. who determined the three-
dimensional structure of inactive rhodopsin via a sophisticated purification process and x-ray 
crystallography (Okada et al. 1998). Ultimately determining the three-dimensional structure of 
an active GPCR, namely the β2AR, was successfully performed by the Kobilka group. This 
discovery allowed for unprecedented insight into conformational changes occurring from the 
inactive GPCR to the activated GPCR (Rasmussen 2007). With the newfound insight also 
came the realisation that the GPCRs adapt to different stimuli by undergoing desensitisation, 
internalisation and phosphorylation. Due to the multitude of biological processes and 
pathologies in which the GPCRs are involved, they represent a major target for potential 
pharmaceutical intervention and therapy (Hill 2006).  
 
1.8.1. Adrenergic receptors (ARs): subtypes and their specific functions  
The 9 subtypes (α1A, α1B, α1D, α2A, α2B, α2C, β1, β2, and β3) of ARs that are currently known 
are all members of the GPCR family. α1A, α1B, α1D are coupled to the phospholipase C (PLC) 
activating Gq protein and to a very small extent increase cardiac contractility and hypertrophic 
remodelling while α2A, α2B, α2C are coupled to Gi and might play a role in presynaptic inhibition 
of NOR release at the atria (Brodde et al. 1999; Hofmann et al. 2006). The role of βARs in the 
heart is far better understood. βAR are the major translators of catecholamine binding into a 
cellular response that regulates heart rate and contractility according to the organisms needs. 
β1ARs and Gs coupled β2ARs elicit positive inotropic, chronotropic and lusitropic effects. β1AR 
stimulation can furthermore lead to cell apoptosis, while β2AR in its Gi coupled state exhibits 
anti-apoptotic signalling characteristics (Xiang 2011). The role and even the actual presence 
of functional β3ARs in cardiac cells is still very controversial. This controversy is fuelled by the 
fact that only some mammals, including humans (Gauthier et al. 1996) and rats (Birenbaum 
et al. 2008) do express β3ARs in the ventricle while others, like mice, only express it to a very 
low extent (Belge et al. 2014). Reports of both cardio-protective (Niu et al. 2012) as well as of 
potentially cardiotoxic effects via β3AR signalling have been published (Zaugg 2008).  
 
1.8.2. Cardiac β1 and β2 AR signalling in health 
cAMP is produced via ACs after the binding of catecholamines to the βARs. In cardiomyocytes 
there are two β AR subtypes capable of initiating the cAMP signalling cascade: β1ARs and 
β2ARs. In health β1ARs and β2ARs are present at an approximate ratio of 70:30 (Wallukat 
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2002). The cAMP produced by the two βARs is however localised to differential compartments 
and will elicit different effects depending on its original site of stimulation, its degradation and 
regulation by PDEs and its concentration (Stangherlin, Zaccolo 2012). In healthy adult 
cardiomyocytes β1ARs are detectable throughout the cell surface in caveolar and 
extracaveolar membrane fractions (Agarwal et al. 2011), while β2ARs are exclusively localised 
inside T-tubule openings (Nikolaev et al. 2010) and/or caveolae (Calaghan, White 2006). Once 
produced cAMP acts by binding and activating spatially segregated targets. These targets 
include exchange proteins directly activated by cAMP (EPAC), protein phosphatases and 
cAMP-gated ion channels. But the major cAMP downstream targets are PKAs. In their inactive 
from PKAs consist of two catalytic (C) subunits with 3 different components (Cα,Cβ,Cγ) and 
two regulatory (R) subunits with four isoforms (PKA RIα and RIβ or PKA RIIα and RIIβ). They 
are activated upon cAMP binding and dissociation of the C subunits. PKA RI and RII act in 
two separate signalling compartments (Stangherlin et al. 2011). βAR-dependent cAMP acts 
via PKA RII, which phosphorylates and thereby activates various downstream targets 
including the PKA RII subunit itself (Zakhary et al. 2000), In human hearts autophoshorylation 
of the RII subunit is pivotal in regulating PKA binding to specific AKAPs and has been shown 
to be significantly decreased in HF (Zakhary et al. 2000). Furthermore the protein levels of 
both regulatory subunits, RI and RII, were shown to be decreased in human failing hearts 
(Zakhary et al. 1999). LTCCs (Keef et al. 2001), the RyRs, Troponin I (Zakhary et al. 1999), 
Phospolamban (Xiao 2001) and Glycogen Synthase Kinase 3 (GSK3) (Sudgen et al. 2008). 
PKA also activates cAMP response element-binding (CREB) proteins involved in cardiac 
hypertrophy (Sudgen et al. 2008). Hence the activation of the cAMP signalling cascade via β1 
and β2ARs generally leads to positive inotropy and increased contractility of cardiomyocytes 
(Wallukat 2002). While β1ARs exclusively signals via Gs proteins and their respective cAMP 
signals traverse the whole cytosol, β2ARs can switch between Gs and the Gi and their 
respective cAMP signals are very confined and localised to small subcellular compartments 
(Nikolaev et al. 2010). This switch, which is prefaced by PKA and GRK phosphorylation of the 
β2ARs, followed by receptor internalization and recycling (Zamah et al. 2002), allows 
differential signalling via downstream targets. These targets include Akt1 and Akt2 kinases 
present in cardiomyocytes, which are involved in the regulation of cellular growth, apoptosis 
and cell metabolism. Both Akt1 and Akt2 phosphorylate GSK3 which acts as a restraint against 
hypertrophy (Sudgen et al. 2008). Also β2AR have been associated with Gs independent 
signalling over the ERKs involved in hypertrophic signalling cascades (Yue et al. 2000). The 
effects of cardiac β1AR stimulation seem to be relatively uniform across various species, the 
function of β2ARs however appears to underlie species differences. Depending on the species 
cardiac tissue specific β2ARs either elicited both increased inotropy and lusitropy or only one 
of the above (Afzal 2011). β2ARs in rodents have exhibited either no effect on contractility 
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(Jiang and Steinberg, 1997) or lead to increased cardiac inotropy without increased relaxation 
(Xiao et al. 1999).    
 
 
 
Figure 3 Role of β1 and β2 ARs dependent signalling in healthy cardiomyocytes via differential subcellular 
compartmentation and differential coupling to Gs or Gi protein α subunits. β1ARs bound to Gs induce 
cAMP production via AC type 6 and activate PKA which leads to heightened contractile protein as well as 
LTCCs phosphorylation and hence increased cardiomyocyte contraction, but can also lead to cell 
apoptosis. β2ARs activation can also lead to cAMP production via AC type 5 and the activation of the cAMP 
dependent PKA pathway. Alternative β2AR coupling to Gi inhibits cAMP signalling and induces anti-
hypertrophic signalling pathways. 
 
1.8.3. β2AR switch from Gs to Gi 
As mentioned before the β2AR is able to switch between the Gs protein, which allows it to 
function via cAMP production, to the pertussis toxin sensitive, Gi protein, which causes 
differential cell internal signalling in cardiomyocytes (Xiao et al. 1999). This switch is induced 
via catecholamine binding to the receptor followed by PKA dependent phosphorylation of the 
β2AR, which induces a conformational shift and leads to the activation of the MAP/ERK 
signalling pathway (Daaka et al. 1997; Kohout and Lefkowitz 2003). Phosphorylation of β2AR 
by PKA furthermore initiates the process of receptor desensitisation and internalisation which 
is described in the following paragraph. The ability of β2ARs to switch between Gs and Gi also 
clearly reveals, what is known in pharmacology as “biased agonism” or “functional selectivity” 
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of receptors. The term “biased agonism” describes the preference of a receptor to signal over 
specific pathways depending on the bound ligand and the receptors resulting conformational 
shift. In the case of the β2AR this means that i.e. in mouse cardiomyocytes NOR leads to full 
activation of the β2AR coupled Gs pathway but only ADR can also elicit Gi receptor coupling 
and signalling (Wang et al. 2008). The biased agonism of the β2AR in cardiomyocytes might 
underlie a further regulation namely its compartmentation in caveolae in neonatal cells or, if 
the caveolae are indeed the precedors of T-tubules, compartmentation via the TAT network 
(Xiang et al. 2002; Harvey and Calaghan 2012; Wong et al. 2013).    
 
1.8.4. β2AR desensitization and internalisation 
An important mechanism to control cell signalling is the desensitisation process of G-protein 
coupled receptors (GPCRs). From a functional perspective this desensitization tempers the 
responsiveness of receptors to hormonal stimulation. The desensitisation process has best 
been described in β2ARs and is primarily orchestrated by G protein-coupled receptor (GPCR) 
kinase (GRK-2 or βARK) and β-arrestins. As soon as β2ARs are activated and elicit signalling 
via the G stimulatory (Gs) proteins the counteracting, desensitisation process will set in. As 
one of PKA’s downstream phosphorylation targets the GRK-2 will be activated and bind to the 
β and γ subunits of the Gs proteins. From there the GRK-2 will phosphorylate a regulatory site 
on the active β2AR, which enables β-arrestins to bind to the receptor and to internalise the 
receptor via endocytosis into the cytosol to presumably make it sterically impossible for G-
proteins to recouple with β2ARs (Kohout and Lefkowitz 2003). However, despite the 
assumption that GPCRs can no longer signal over Gs-proteins once internalised, recent 
findings show that the β2ARs, at least in HEK293 cells, can still participate in the Gs dependent 
production of cAMP which sets in slightly later than the response of uninternalised receptors 
(Irannejad et al. 2013). Also, independently of Gs protein coupled signalling, the internalised 
β2AR has been shown to participate in the activation of ERKs (Kaya et al 2012), which has 
been shown to be involved in cardiac hypertrophy signalling (Yue et al. 2000). The extent of 
β2AR desensitisation and internalisation and GRK-2 dependent phosphorylation has 
furthermore been shown to be sensitive to the concentration and partial agonism of βAR 
ligands. As a result partial agonists like the sympathomimetic ephedrine lead to a slower 
desensitisation of about 30 min in comparison to full agonists like ADR who achieved receptor 
desensitisation in about 1 min (January et al. 1997). A further mechanism to improve the 
efficiency of β2AR signalling desensitization is introduced by PDE4 isoform 4D5 enzymes, 
which are localised close to the receptors. These enzymes have been shown to bind to β-
arrestins in order to be recruited to the respective β2AR and regulate the cAMP pool in the 
associated, subcellular β2AR compartment (Lynch et al. 2007). β3ARs only share about 50% 
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sequence homology to β1ARs and β2ARs and appear to be excluded from desensitization as 
they lack the necessary PKA or GRK phosphorylation sites (Ligget et al. 1993) but they may 
exert a further, highly localized suppressing effect on β1 and β2AR-dependent cAMP signalling. 
 
1.8.5. MAPK/ERK signalling pathway and its role in hypertrophy 
β2ARs can activate the MAP/ERK pathway via the dissociation of the receptor coupled Gi α-
subunit from the β and γ subunits. The latter subunits then go on to activate tyrosine-protein 
kinase c-Src and signalling over the GTPase protein Ras (Daaka et al. 1997). In a signalling 
cascade the Ras protein then goes on to activate various Raf proteins, which in turn activate 
MAPKs, which activate ERKs. The MAPK/ERK kinase pathway has been shown to induce 
catecholamine dependent hypertrophy via increased gene expression (Yue et al. 2000).  
 
1.8.6. β1 and β2 AR signalling in HF 
As was alluded to before, SNS system becomes rampant during HF progression. As a result 
cardiomyocytes and βARs together with their associated signalling pathways undergo drastic 
modifications. Persistent β1AR-cAMP signalling leads to aggravated loss of cardiomyocytes 
and maladaptive cell remodelling. Possibly to counteract these consequences β1ARs are 
increasingly desensitized, internalized and degraded during HF progression (Xiang 2011). In 
parallel β2ARs abandon their exclusive T-tubular position and are rearranged over the whole 
sarcolemma. Despite the fact that this redistribution occurs together with proportionally 
increased coupling to Gi and β2AR desensitization it has been surmised, that the β2ARs 
outside of T-tubules could temporally acquire cardiotoxic β1AR signalling traits by abruptly 
reaching β1AR-cAMP downstream targets (Nikolaev et al. 2010).      
 
1.8.7. ACs and cAMP signalling 
ACs are enzymes responsible for converting ATP into cAMP. Once generated the cAMP 
messenger molecules diffuse at an estimated 700 to 780 µm2 per second and are involved in 
several biochemical processes (Heijman et al. 2011; Nikolaev et al. 2004). ACs are activated 
through the binding of the Gs α-subunit and inhibited by the binding of the Gi α-subunit. In the 
heart the prevalent AC isoforms responsible for βAR-dependent cAMP production in separate 
subcellular locations are AC5 and AC6 (Timofeyev et al. 2013). AC5 is situated mainly inside 
the T-tubule, where it is associated with Cav3 and β2ARs and potentially a subset of β1ARs. 
In contrast the AC6 isoform is bound to the sarcolemmal membrane outside of the T-tubules 
and carries out β1AR associated cAMP production (Timofeyev et al. 2013). There are clear 
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differences in the actual concentration of cAMP pools generated by the ACs in the specific 
subcellular microdomains present in cardiomyocytes (Iancu et al. 2008). The microdomain 
specific concentration depends on the level of cAMP production as well as its confined 
diffusion inside the cytoplasm before being degraded by PDEs or meeting its molecular 
targets. It appears that β2AR associated AC5 dependent cAMP pools are much more 
stringently regulated than those generated by β1AR associated AC6 (Timofeyev et al. 2013). 
The expression of AC6 mRNA has been shown to decrease in age (Tobise et al. 1994) and 
HF (Espinasse et al. 1999)  
 
1.8.8. A-kinase anchoring proteins (AKAPs) 
PKAs as well as other protein kinases (protein kinase C) and phosphatases (i.e. calcineurin) 
are localised to specific compartments and their interaction partners via AKAPs (Mauban et 
al. 2009; Klauck et al. 1996). Even though the 17 members of the currently identified cardiac 
AKAP family are structurally quite different from each other they are identifiable by their ability 
to bind PKA regulatory subunits at nanomolar affinity and to localise them close to their specific 
downstream targets. This is necessary to facilitate compartmentalised and highly specific 
cAMP/PKA signalling which leads to distinct physiological cell responses and modulates acute 
and chronic cardiac function (Soni et al. 2014). The different members of the AKAPs family 
possess a conserved α helical structure which binds to a hydrophobic pocket at the regulatory 
(R) subunits of PKAs isoforms PKA-RI and PKA-RII, Most identified AKAPs preferentially bind 
to RII though there are also AKAPs with dual specificity and preference for RI binding. As a 
result PKA-RII is localised at multiple, specified sites within cardiomyocytes including to the 
plasma membrane by AKAP79 or the nuclear membrane by mAKAP (Kapiloff et al. 1999), 
while PKA-RI is primarily localised to the soluloble cell fractions by AKAPs such as the dual 
AKAP Ezrin (Di Benedetto et al. 2008; Stangherlin et al. 2011). The crucial role of AKAPs in 
cardiomyocyte regulation was proven by disrupting AKAP–PKA-RII binding using the 
anchoring domain of AKAP13 as a blocking peptide (Ht31), which lead to a significant 
reduction in Troponin I (TnI) and Myosin binding protein C phosphorylation by PKA (Fink et al. 
2001). By tethering PKA RI and RII as well as other kinases to differential subcellular locations 
in the vicinity of specific membrane bound or soluble ACs the AKAPs facilitate highly restricted 
and functionally separable signal compartments and phosphorylation events. A prime example 
for this regulation are the different effects elicited by the drugs ISO and prostaglandine E1 in 
cardiomyocytes. Though both drugs generate comparable levels of cAMP only ISO leads to 
β2AR and phospholamban (PLB) phosphorylation and increases contractile force. This 
disparity arises from AKAP tethering the PKA activated by cAMP to particulate cell fractions 
whereas PGE1 activated PKA in soluble cell fractions which did not alter cell contractility 
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(Hayes et al. 1980; Di Bendetto et al. 2008). AKAPs also limit the amount of molecules 
tethered to specific subcellular domains, as it was shown at the hand of mAKAP. The amount 
of mAKAP molecule localisation to the cell membrane is not unlimited and overexpression of 
the AKAP targeting sequence can lead to displacement of the endogenous protein (Kapiloff et 
al. 1999). Hence AKAPs significantly add to the complexity of cAMP-dependent cell signalling.          
 
1.8.9.  cGMP signalling in cardiomyocytes 
Like cAMP, cGMP is an ubiquitously present second messenger, which mediates the 
translation of cell stimuli into physiological responses (see figure 4). In contrast to cAMP 
however these responses are primarily of a negative inotropic nature in cardiomyocytes (Feil 
and Kemp-Harper 2006). Elevated levels of cGMP appear to be cardioprotective by preventing 
hypertrophy and adverse remodelling of ventricular cardiomyocytes (Belge et al. 2014). The 
how and when cGMP production takes place in cardiomyocytes will be dealt with in the 
following paragraphs. 
 
Figure 4 cGMP signalling in cardiomyocytes. cGMP is produced after binding of NPs to pGC and binding 
of NO to soluble (sGC). NO itself can be endogenously produced via NOS which can be activated by the 
β3AR via the Gi α-subunit. Once produced cGMP activates downstream targets, including PDE forms 2,3 
and 5 as well as PKGI, which in turn phosphorylates PLB and TnI. Other downstream targets though 
present are not shown. Only cGMP produced by sGC regulates β1 and β2AR dependent cAMP levels via 
PDE2 and PDE3 and thereby effects βAR regulation of LTCCs.     
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1.8.10. Secondary messenger signalling of cGMP 
The secondary messenger cGMP is generated by GCs. This occurs as a result of NO and 
controversially also by carbon monoxide (CO) binding to the sGC in the cytoplasm (Pyriochou 
and Papapetropoulos 2005; Ryter et al. 2006). Alternatiely cGMP is produced via the binding 
of NPs to the pGC situated on the plasma membranes (Potter et al. 2006). Pools of cGMP will 
form in distinct cellular compartments depending on which GC is activated (Castro et al. 2010) 
and can differentially influence cAMP generated by the βARs (Stangherlin et al. 2011). Once 
cGMP is produced it goes on to bind and activate its downstream targets including PDEs and 
PKGs (also known as cGKs). Besides the PDEs it is these PKGs which influence cGMP levels 
strongly by affecting the productivity of the GCs differentially in specific subcellular 
compartments and by regulating protein phosphatases (Hofmann et al. 2006). In adult rat 
cardiomyocytes for instance PKG amplifies cGMP depletion when NO is the cause for its 
production. At the same time PKG allows for higher cGMP accumulation after natriuretic 
peptide signalling. In adult, rat cardiomyocytes the cGMP generated by the two pGCs stays 
close to the plasma membrane and is controlled by PDE2. In comparison cGMP, which is 
produced remote from the plasma membrane in the cytosol appears to be degraded by PDE2 
as well as PDE5 (Castro et al. 2010). Mammals possess two types of PKG, which are localised 
to different subcellular compartments via PKG anchoring proteins (Casteel et al. 2008). These 
PKGs are PKGI with isoforms Iα and Iβ and PKGII. There are low levels of PKGI in the 
myocardium and probably no PKGII (Hofmann et al. 2006). Work in transgenic knockout mice 
showed PKGI to be the primary mediator of cGMP’s negative inotropic effects in the 
myocardium, via inhibition of the LTCCs, as well as a hypertrophy decreasing factor 
(Kuznetsova et al. 2013).  
 
1.8.11. Particulate guanylyl cyclases and natriuretic peptides 
To this day we are aware of three distinct particulate guanylyl cyclases (pGC) and as many 
natriuretic peptides (NPs) to activate them. In cardiomyocytes the specifically present pGCs 
are GC-A, which is activated by atrial (ANP) and brain natriuretic peptides (BNP), and GC-B 
which requires C-type natriuretic peptide (CNP) stimulation. Natriuretic peptides (NP) are 
important regulators of cardiac contractility (Hofmann et al. 2006). The three types of 
natriuretic (=urinary Na+ excretion) peptides (NPs) emerge from separate cellular sources. 
ANP is generated in/ and secreted from atrial cardiomyocytes. Besides its electrolyte 
balancing, vasorelaxant and anti-inflammatory roles ANP inhibits the secretion of aldosterone 
and renin and decreases blood pressure and volume (Pandey 2014). Thus it is vital for 
maintaing cardiovascular homeostasis. The major source of brain natriuretic peptide (BNP) is 
provided by the ventricles. In contrast, CNP is produced by endothelial cells in the vasculature. 
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This conveniently allocates CNP close to the smooth muscle cells, its major target, to cause 
vasodilation. CNP can also yield positive inotropic effects which are executed via PKG 
(Pandey 2014). Activation of GC-A and GC-B increases cGMP levels depending on the 
stimulatory NP and compartment which leads to a decrease in positive inotropic molecules 
such as cAMP and Ca2+ (Pandey 2014). In neonatal rat cells the ANP dependent cGMP pools 
were shown to specifically affect those cAMP molecules in the respective PKA RII 
compartment via increasing PDE2 activity but not those in the RI compartment (Stangherlin et 
al. 2011). Further studies in adult ventricular rat cardiomyocytes revealed that only CNP but 
not BNP effectively elicited negative inotropy and positive lusitropy despite the fact that both 
NPs lead to an increase in cGMP levels. CNP conveys this effect by phosphorylation of PLB 
and Troponin I increasing the speed of Ca2+ reuptake into the SR or by increasing Ca2+ 
extrusion into the extracellular space (Moltzau et al. 2014). GC-C, the third GC subtype, is 
activated by binding of all three NPs but possesses no catalytic GC domain. Interestingly GC-
C activation has demonstrated a capacity to lead to raised cAMP, Ca2+ and inositol 
triphosphate (IP3) levels (Pandey 2014).  
During the development of various cardiomyopathies a clinically measurable rise of all NPs 
was reported (Moltzau et al. 2013; Pandey 2014). This rise is detectable early and serves as 
a diagnostic and prognostic tool of disease progression (Mukoyama et al. 1991; Pandey 2014). 
Additional administration of NPs as a therapeutical substance (Boerrigter et al. 2009) however 
has not been proven helpful (Shah et al. 2011). 
 
1.8.12. Soluble guanylyl cyclase (sGC) and nitric oxide synthases (NOS) 
sGC is made up of the heterodimeric α and β subunits with catalytic domains. The α1 and β1 
isoforms of these subunits are almost ubiquitously expressed. In opposition the α2 subunit is 
sparser but can be found highly expressed in heart tissue, while the β2 subunit is mainly found 
in kidney. A splice variant of the α2 subunit can bind with β1 subunits and deactivate sGCs 
function. As a member of the Heme-Nitric oxide and OXygen binding family (H-NOX) the sGCs 
possess a heme domain for ligand binding. Though sGC appears to not bind to oxygen it is 
not yet fully established if its intrinsic H-NOX domain physiologically binds to nitric oxide (NO) 
only or both NO and carbon dioxide CO2 (Derbyshire and Marletta 2009). NO releasing drugs 
have produced beneficial, therapeutic effects in the treatment of HF. Though the role of NO 
dependent cGMP in physiology is controversial the molecule also exhibits modulatory effects 
on cardiac contractility and cardiomyocyte remodelling (Hofmann et al. 2006). When NO binds 
to the sGC protein’s heme domain this leads to an extensive 200 fold rise in cGMP production 
from GTP (Cary et al. 2005). It was furthermore shown, that sGC but not pGC-dependent 
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cGMP signalling can decrease the βAR-dependent cAMP response in cardiomyocytes. This 
occurs by sGC dependent cGMP blocking of PDE3 activity in the PKA RI compartment and 
increasing of PDE2 activity in the PKA RII compartment (Stangherlin and Zaccolo 2012) and 
by inhibiting LTCCs (Castro et al. 2010). Physiological sources of NO are provided by the 
NOS. The NOS produce NO via the oxidisation of L-arginine to NG-hydroxy-L-arginine and 
further to L-citrulline and NO through the utilization of NADPH and oxygen. In vivo the NO 
which stimulates sGCs in cardiomyocytes potentially has autocrine origins from endogenous 
NOS or is derived from paracrine sources such as the endothelium. As the NO molecule is so 
small it can easily diffuse through the sarcolemma of cardiomyocytes. There are currently 
three isotypes of NOS which have been identified: the neuronal (nNOS), the endothelial 
(eNOS) and the inducible (iNOS) isoform (Derbyshire 2009). eNOS and nNOS are regulated 
partially by Ca2+ and calmodulin and are to a degree constitutively active (Barouch et al. 2002). 
The activity of eNOS can be increased via its phosphorylation on its Serine residue 1177 and 
decreased by phosphorylation of Serine 114 (Niu et al. 2012). Similarly nNOS activity will be 
increased by post translational phosphorylation of Serine 1412 and inhibited by Serine 847 
phosphorylation (Watts et al. 2013). iNOS activity however needs to be induced and has been 
shown to be upregulated in HF. The NOS which are expressed endogenously in 
cardiomyocytes have different subcellular locations, which are assumed to facilitate their 
different functions (Barouch et al. 2002). eNOS is localised inside the T-tubules and 
sarcolemmal caveolae (Zaugg 2008). By contrast nNOS is situated at the SR together with 
the RyRs (Brown, Borutaite 2007). It has been shown to become translocated from this 
position to the sarcolemma where it binds to Cav3 in the case of a MI and HF (Kulandavelu, 
Hare 2012). Detectable iNOS levels only appear in the cytosol of cardiomyocytes after 
inflammation or due to ischemic injury (Brown et al. 2007). In health eNOS presumably is the 
most important NOS in relation to cardiomyocyte contractility (Massion et al. 2004). Despite 
the cGMP/PKG pathway dependent NO effects the gas also elicits cGMP independent effects 
(Hofmann et al. 2006). Via cardiomyocyte restricted overexpression in mouse it has been 
shown that eNOS dependent NO signalling not only attenuates βAR dependent cAMP 
signalling and its inotropic effects but it also increases the negative chronotropic effect on the 
heart rate of muscarinic receptor signalling and protects against ventricular arrhythmia 
(Massion et al. 2004). NO dependent cGMP is furthermore able to activate PDE2 to degrade 
βAR cAMP levels (Mongillo et al. 2006).  
 
1.8.13. Cardiac β3AR signalling in health and HF 
Unlike β1ARs and β2ARs the β3ARs induce negative inotropic effects in cardiomyocytes by NO 
associated production of cGMP. Another special feature of β3ARs in contrast to β1ARs and 
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β2ARs is their resistance to receptor desensitization (Nantel et al. 1993) as they do not possess 
any PKA or GRK phosphorylation sites (Ligget et al. 1993). In healthy hearts the β3AR is 
expressed preferentially in the left ventricle but at relatively low levels. It might also be 
noteworthy that β3AR are less expressed in female tissue and that NO appears to be 
differentially regulated in males and females (Zaugg 2008). According to various studies the 
β3AR expression increases two- to threefold in aging myocardium (Birenbaum et al. 2008), 
diabetes (Amour et al. 2007), sepsis (Moniotte et al. 2007) and HF (Moniotte et al. 2001). 
There are reports of β3AR coupling to Gs and associated production of cAMP (Xiang 2011; 
Kohout et al. 2001) but the majority of studies shows cardiac β3AR coupling to Gi and with it 
the production of cGMP (Kulandavelu, Hare 2012). At least in rat there appears to be no β3AR-
dependent cAMP production on top of β1AR and β2AR as was determined previously by our 
group (Nikolaev et al. 2010). As cGMP production has been associated with anti-hypertrophic 
effects and appears to be cardioprotective against adverse remodeling (Lukowski et al. 2014) 
β3ARs are likened to a biological “brake” which protects the heart from catecholamine 
overstimulation (Niu et al. 2012; Belge et al. 2014). Through their coupling to Gi it is speculated 
that the β3ARs are involved in blunting the β1AR dependent cAMP signalling (El-Armouche et 
al. 2003; Massion et al 2004). β3ARs can reduce contractility via Gi protein and act via eNOS 
dependent NO and hence via NO dependent cGMP production via sGCs (Watts et al. 2013). 
β3AR-dependent eNOS activity has been linked to Akt kinase (also known as protein kinase 
B = PKB) dependent signalling and cell survival (Napp et al 2009). Cell survival is induced by 
Akt binding to SMAD signal transduction proteins. This inhibits SMAD phosphorylation by 
TGFβ and the TGFβ induced apoptosis pathway (Yuan, Jing 2010). In the case of chronic HF 
eNOS has been shown to be deactivated by phosphorylation and nNOS becomes the 
prevalent NOS to generate β3ARs dependent effects (Niu et al. 2012). It has yet to be 
determined if this switch and nNOS consecutive translocation to the sarcolemma is detrimental 
to or protective against HF progression. Presumably it might lead to LTCC blockage and a rise 
in free O2- radicals by nNOS dependent NO no longer inhibiting an oxidoreductase situated at 
RyR2. O2- radicals can lead to irreversible RyR2 activation which in turn would lead to 
uncontrolled Ca2+ leakage from the SR and a reduction in cardiac contractility (Kulandavelu, 
Hare 2012). Various studies attest β3ARs beneficial effects though and β3ARs have been 
shown to protect against pressure overload (Niu et al. 2012) or neurohormone induced 
hypertrophy (Belge et al. 2014). β3ARs also appear to alleviate infarct size and risk of 
apoptosis and fibrosis of the myocardium during ischemic reperfusion experiments and MI in 
mouse (Aragon et al. 2011; Niu et al. 2014). Therefore the β3AR may not be of high relevance 
at physiological, resting function but could play a crucial role under HF conditions, where an 
increased amount of Gi α-subunits and βARKs (= G-protein coupled receptor kinase, GRK2) 
has become evident (El-Armouche et al. 2008). In advanced aging (Birenbaum et al. 2008) or 
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in HF (Kulandavelu, Hare 2012) an upregulation of β3ARs together with an upregulation of 
nNOS and iNOS expression and increased catecholamine plasma levels have been observed 
while β1ARs are downregulated (El-Armouche et al. 2003). In the context of aging β3AR’s 
purely beneficial effects are once more called into question as β3AR dependent nNOS and 
iNOS signalling worsens ischemia related myocardial dysfunction in older rats and actually 
leads to increased infarction size (Zaugg 2008). Another intriguing finding made in β3AR 
knockout mice was that β3AR deletion lead to improved SERCA2a function by increasing its 
expression and simultaneously increasing PLB phosphorylation (Ziskoven et al. 2007). The 
exact plasma-membrane location of functional β3AR in adult ventricular cardiomyocytes is not 
yet conclusively determined but putatively appears to be the T-tubules or caveolae according 
to a study that performed myocyte-specific overexpression of the human β3AR in mouse. 
Fractionation and western blotting detected colocalisation of the artificially expressed β3AR 
with eNOS, nNOS and Cav3 (Belge et al. 2014). The observations regarding β3AR which are 
detailed in this thesis were made in adult rat cardiomyocytes after 16 weeks of chronic MI and 
in age matched control cardiomyocytes.   
 
1.8.14. The interplay of cAMP and cGMP signalling pathways in cardiomyocytes 
In cardiomyocytes cAMP and cGMP are able to regulate physiological processes such as 
cardiac rate and contractility (Beavo and Brunton 2002). In the last few decades evidence has 
accumulated suggesting that cAMP and cGMP are not distributed homogenously throughout 
the cytoplasm of myocardial cells (Buxton and Brunton 1983) and that the two signalling 
pathways are strongly linked to each other via feedback signalling. The interplay of the cAMP 
and cGMP signalling pathways in cardiomyocytes depends primarily on the 
compartmentalisation of the secondary messenger molecules by its original site of production, 
the activity and specificity of PDEs (Stangherlin et al, 2011) as well as the respective 
secondary messenger concentration (Zaccolo and Movsesian 2007). Hence the 
compartmentalisation of the second messenger molecules allows for a concentration-
dependent processing of multiple stimuli to elicit specific and highly regulated cell reactions 
(Fischmeister et al. 2006).  
 
1.8.15. Cardiac PDEs 
PDEs are a family of hydrolases which catalyse the hydrolysis of the cyclic phosphate bond 
from the cyclic nucleotides cAMP and cGMP. Hence both cAMP and cGMP are degraded and 
therefore regulated by PDEs. Out of the 11 mammalian PDE families known today (Conti and 
Beavo 2007) there are 7 with relevant activity inside cardiomyocytes: PDE1 (Vandeput et al. 
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2007), PDE2 (Mongillo et al. 2006), PDE3 (Ahmad et al. 2015), PDE4 (Richter et al. 2011), 
PDE5 (Lee et al. 2010), PDE8 (Gamanuma et al. 2003) and PDE9 (Lee et al. 2015) (see figure 
5). These PDEs exhibit different specificity for cAMP or cGMP and are distributed distinctively 
at various intracellular locations. While some of these PDEs are selective for either cAMP 
(PDEs 4, 7 and 8) or cGMP (PDEs 5 and 9) others can bind and degrade both cyclic 
nucleotides (PDEs 1, 2 and 3) (Stangherlin and Zaccolo 2012). In cardiac myocytes the 
predominant locations of various isoforms are as follows: PDE1 is mainly reported to be 
cytosolic (Bender and Beavo 2006), PDE2 is associated to the cardiomyocyte sarcolemma 
together with the LTCCs, PDE3A with PLB and hence the SR, PDE4A1 with the Golgi 
apparatus, PDE4D5 with the β2ARs after arrestin binding, PDE4D3 with the RyRs and the 
nuclei, PDE 5 along the Z-discs together with PKG and with sGCs (Fischmeister et al. 2006; 
Kass 2012), PDE8 is primarily cytosolic and PDE9 both cytosolic and nuclear (Bender and 
Beavo 2006). The PDEs themselves are highly regulated via multiple factors like their 
phosphorylation, their subcellular location due to the presence or absence of specific 
anchoring proteins and their interaction with regulatory proteins. It is their N terminal and their 
catalytic units which convey the characteristics of the specific PDE family. The catalytic 
domain of PDEs consists of 16 alpha helices, which generate a binding pocket for substrates 
and inhibitors (Conti and Beavo 2007). In some cases the activity of the catalytic domain of 
PDEs is controlled via the inhibiting or activating binding of the cyclic nucleotides themselves 
or other proteins to respective N-terminal binding domains. These binding domains include 
the Ca2+/Calmodulin binding domains present on PDE1 or the cGMP binding domains GAF-A 
and GAF-B present on PDE2 and PDE5 (Zaccolo and Movsesian 2007; Francis et al. 2011), 
named after cGMP-activated PDEs, AC and the Fh1A enzymes in which they were first 
discovered (Conti and Beavo 2007). As a result the cAMP and cGMP signalling pathways 
interact at multiple points via PDE regulation and can modulate each other by means of their 
localisation, concentration and the activity of their downstream signalling targets (Stangherlin 
and Zaccolo 2012). This is clearly demonstrated by cGMP binding to the GAF-A domain of 
PDE2, which primes the PDE for cAMP degradation (Martinez et al. 2002). Another example 
for cyclic nucleotide signalling pathway interaction via the PDEs is PDE3. Though PDE3 
possesses comparable affinity for both second messengers it degrades cGMP at a slower 
pace and hence allows for it to temporally block the PDE while cAMP levels increase (Shakur 
et al. 2001). 
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Figure 5 Schematic of cardiovascular PDEs directly taken from (Stangherlin and Zaccolo 2012) to illustrate 
variable binding and regulating domains and second messenger specificity. 
 
1.8.16. Species differences in cardiac PDEs 
Unfortunately the presence and function of PDEs underlies strong species differences and 
findings in animal models cannot be translated directly to humans (Johnson et al. 2012). For 
the aim of the present introduction it is important in particular to distinguish between rat and 
human cardiomyocytes. One example for the differences between species is the presence of 
the PDE1 variants 1A,1B and 1C which are present in human hearts but appear to be only at 
very low levels expressed in rats where the PDE1C isoform has a particular activity, namely, 
it only hydrolyses cGMP but not cAMP (Miller et al. 2009). Similarly, PDE3 isoforms are highly 
expressed in humans but only marginally present in rat. Still, while PDE3 exhibits higher 
expression in human than in rat it shows higher cGMP-degrading activity in rat than in humans 
(Johnson et al. 2012). Another well-studied example is PDE4, which is the predominant 
degrader of global, catecholamine induced cAMP responses in rodents (Verde et al. 1999), 
but despite its highly conserved function and expression is less important in humans where 
PDE1, PDE2 and PDE3 are also highly active (Richter et al. 2011). Under HF conditions PDE4 
expression and activity has been shown to be downregulated in both humans and rodents 
(Richter et al. 2011).   
 
1.9. Mathematical modelling 
Though the advancement of microscopic techniques and quantitative, biological methods at 
the nanoscale level has been vast in the last decades, there are spatiotemporal processes 
that we are not yet able to resolve. Additionally, progress in microscopy techniques leads to 
the acquisition of ever larger amounts of data, which cannot be analysed manually (Schindelin 
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et al. 2012). Hence the introduction of mathematical modelling approaches is required, which 
combine quantitative and qualitative data in a manner that allows one to predict or test a 
mechanism for a biological phenomenon, meaning that data can be fitted to the model and 
trends or phenomena predicted. Mathematical models are generally either strongly specified 
and highly simplified to solve very specific problems or can be multi-scale to elucidate 
physiological processes and pathophysiological occurences both at the macroscopical and 
the microscopical level in the heart (Pullan et al. 2005; Land et al. 2013). Mathematical 
modelling starts with the identification of a problem and the generation of a hypothesis followed 
by the development of a mathematical model to test the hypothesis and solving it. The next 
step is to interpret the solution, and to ascertain whether or not it validates the original 
hypothesis based on the biological data. If the available data and the model are in agreement 
then the mathematical model can be used for additional predictions (Pullan et al. 2005).   
 
1.9.1. Investigating the TAT system via modelling 
The microscopical structure of the TAT network and its variablity in cardiomyocytes throughout 
the heart or under disease conditions prompts many questions in regard to its function which 
are hard to answer sufficiently well via experimental approaches alone. It is known that many 
proteins seem to specifically home to the T-tubules to form signalosomes in specific 
subcellular compartments (Scriven et al. 2000) and that the TAT network acts as a reservoir 
which can maintain a certain level of ionic concentrations (Pasek et al. 2012). But how many 
proteins and ions are actually situated inside the TAT network in health and disease is unclear 
(Pasek et al. 2008). It is furthermore well established that the TAT network is an important part 
of the excitation contraction coupling machinery in ventricular cardiomyocytes and that the 
network together with efficient excitation contraction coupling is impaired in HF (Sacconi et al. 
2012). However it is not completely clear which alterations take place to disrupt both the 
structure and their associated function. There are so many possible reasons and disruptive 
alterations that could take place in the various cardiomyopathies that it is almost impossible 
to pinpoint those changes which are decisive to worsen the respective disease during 
experimentation (Polakova and Sobie 2013). Mathematical modelling has tried to address 
these questions in a more controllable way by integrating what is already known about the 
TAT network and its role in physiological processes, such as Ca2+ handling and βAR signalling 
(Hatano et al. 2012) or the general electrophysiology of cardiomocytes (O'Hara et al. 2011), 
and then focussing specifically on a subset of potential causes and effects. Our own group 
recently used advanced mathematical modelling based on a compartmental model of βARs 
and their electrophysiological effects in cardiomyocytes (Heijman et al. 2011) to better 
understand the effect of T-tubular loss and disruption of Cav3 dependent signalling domains 
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on β2AR-mediated cAMP signaling. We thereby established that Cav3 is important for β2AR 
localisation and β2AR related cAMP signalling levels and that β2AR signalling complexes 
inside T-tubules are more prone to be disrupted than β2AR signalling complexes which are 
associated to caveolae (Wright et al. 2014).   
 
1.9.2. Modelling to validate experimental methods 
Despite explaining biological data that is too intricate and manifold to be easily interpreted 
mathematical modelling can also help to validate the technical approaches used to obtain 
biological data. The study presented in this thesis uses a relatively novel scanning technique, 
namely SICM in hopping mode (Novak et al. 2009) to apply molecules onto the surface of 
cardiomyocytes via a nanopipette. In the past this relatively slow, but precise, application 
occurred via pressure unloading of the respective molecules (Nikolaev et al. 2010). However 
this pressure-driven application is relatively slow and occasionally leads to the unwelcome 
blockage of the respective pipette in use. Therefore the application mode has been changed 
to a more reliable, voltage-driven substance unloading from the SICM nanopipette. Though 
this technical improvement is advantageous, because of its easier and more reliable use it still 
needed to be validated in regard to the amount and precision of agonist which is applied under 
differential system settings. The application of a fluorescent marker, though possible, would 
not yield the correct answer for the application of particles which possess a slight electrical 
charge like the agonist (ISO) used in this thesis. Hence, the precision of this advanced voltage-
driven application mode as well as the averaged concentration of the applied agonist needed 
to be simulated and determined via mathematical, finite element modelling.        
 
1.10. Aims of the study 
The preceding paragraphs tried to show what is already known about the ventricular 
cardiomyocyte structure and βAR signalling in healthy control conditions and at the end stage 
of HF. There are studies which have looked at structural alterations during the progression 
from hypertrophy to decompensated HF in animal models with LAD aorta ligation (Wei et al. 
2010; Wagner et al. 2012). However these studies did not look specifically at the effect of 
these progressive structural alterations on the βAR dependent second messenger signalling 
alterations. Our own group showed that the β2ARs might be the βAR subtype which is most 
important in causing the phenotype of end stage HF by leaving their T-tubular position at some 
point during HF progression (Nikolaev et al. 2010). But when and why exactly this relocation 
takes place has not yet been described in a time dependent manner. The β3AR subtype has 
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only recently been shown to be present in both human and rat cardiomyocytes (Zaugg et al. 
2008; Niu et al. 2012) but its cardiac function and importance in health and disease are still 
very controversial and a lot of research is still necessary to elucidate it (Kulavandelu et al. 
2012). In order to thoroughly study alterations in cardiomyocyte structure and βAR dependent 
cyclic nucleotide signalling in health and disease, techniques like the SICM microscope, which 
are available to our group are necessary and their improvement is of high importance. In the 
past we used pressure-induced displacement of agonists inside the SICM nanopipette onto 
the cardiomyocyte surface (Nikolaev et al. 2010), but have now changed to voltage-driven 
application of agonists. This change required us to find out how much and how precise the 
consecutive application of agonists proceeds out of the SICM nanopipette onto the 3 
dimensional structure of cardiomyocytes.       
The main objectives of this thesis are therefore as follows: 
- Investigate surface and internal TAT network structures in single, left ventricular 
cardiomyocytes in health and during the progression of HF in an adult rat model of 
chronic MI. Investigate the aforementioned structures in human ventricular cells 
obtained from various cardiomyopathies and compare them between the two species.   
- Investigate β2AR dependent cAMP signalling using FRET in health and during the 
progression of HF. 
- Detect if there is functional β3AR dependent cGMP signalling in adult rat 
cardiomyocytes in health and HF and study disease dependent alterations.  
- Generate a mathematical model to investigate the precision and concentration of 
agonist unloading onto the cardiomyocyte surface using voltage-driven nanopipette 
application. 
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2.1. Materials 
Most of the reagents used for this project were obtained from the company (Sigma-Aldrich 
Company Ltd.Dorset, England) unless otherwise specified or listed in the table below. 
Table 2 List of reagents, which were not purchased from Sigma Aldrich  
Reagent Company / Collaborator   Catalogue # 
Atrial Natiuretic Peptide (ANP) Bachem, Germany # H-2100 
β3AR-GFP  Prof. Nikolaev, Germany - 
Bovine Serum Albumin (BSA) Fisher Scientific, UK # BPE9704 
8-Br-2´-O-Me-cAMP Biolog Life Science, UK # B022 
CGP 20712 Tocris, UK # 1024 
Cilostamide Tocris, UK # 0915 
Di-8-amino-naphthyl-ethenyl-pyridinium  Biotium, UK # 61012 
Dulbecco Modified Eagle Medium Fisher Scientific, UK # 10567 
Fetal Bovine Serum (FBS) Fisher Scientific, UK # 10270 
Cytosolic Epac2-camps Prof. Nikolaev, Germany - 
Goat Serum Fisher Scientific, UK # 31872 
Luminata Forte Western HRP substrate Millipore, UK #WBLUF0100 
M199 Medium Invitrogen, UK #11150 
MgCl2 G-Biosciences, USA # R004 
NaCl Fisher Scientific, UK # S/3160/63 
1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one  Abcam, UK # 120022 
Partly frosted coverslides  Thermo Scientific, UK # 6776108 
Plasma-membrane Epac2-camps Prof. Nikolaev, Germany - 
Polyclonal donkey anti-goat HRP antibody  Abcam, UK # 97110 
SR 59230A hydrochloride Tocris, UK # 1511 
Tadalafil Santa Cruz, USA # sc-208412 
Vectashield Mounting Medium Vector Labs, UK # H-1200 
 
2.2. Animals and HF model 
 
2.2.1. Animals and animal care 
Sprague Dawley rats for research use were obtained from Harlan Laboratories (Wyton, UK).  
All animals, which were bred and used for the work described hereafter were treated and 
cared for upholding the standards stated in the Guide for the Care and Use of Laboratory 
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Animals (NIH publication No. 85–23, revised 1996) as well as the Animals in Scientific 
Procedures Act of 1986 (ASPA 1986, UK) and its amendments (ASPA1986 Amendments 
Regulations 2012) including the EU directive 2010/63/EU. The animals were exposed to a 
standard 12-hour light-dark cycle at 21°C and obtained standard food at self-regulated periods 
by the animal facility staff members.      
 
2.2.2. HF model generation 
For the study of single cardiomyocytes during their progression towards HF a model of chronic 
MI in adult Sprague-Dawley rats was generated. This was done via the ligation of the left 
anterior, descending coronary artery by Dr. Markus Sikkel (Imperial College London) and Mr 
Adam Mills (Imperial College London) as described previously (Lyon et al. 2009). In short the 
procedure is as follows: The animal is anaesthetised and has been given antibiotics as well 
as buprenorphine for pain relief, before both the chest and the pericardium are opened 
surgically and a suture is bound around the left anterior descending (LAD) artery and tightened 
to constrict the blood flow. In sham control animals the suture is bound only loosely around 
the artery so no constriction of the blood flow occurs. After the ligation the animal is closed up 
again and the in vivo ejection fraction volume is determined in sham and age matched control 
animals as well as at 4, 8 and 16 weeks post the surgical procedure via echocardiography 
recordings generated in M-mode (Vevo 770 Micro-Imaging System, Visualsonics) to obtain an 
indicator of wall contractile function (see Figure 6). Subsequently the animals are sacrificed 
and the ratio of the heart weight to the length of the tibia is determined as a marker of heart 
hypertrophy. The echocardiography and phenotype measurements were performed by Dr. 
Markus Sikkel (Imperial College London). In accordance to prior published work and the 
information gathered in this thesis the chronic MI model undergoes 3 different stages during 
the progression of HF: a compensated, a decompensated and a failing stage (Monnet and 
Chachques 2005; Lyon et al. 2009; Nikolaev et al. 2010). For more information about this 
model please refer to (Lyon et al. 2009).  
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Figure 6 Progressive increase in the rat heart size is accompanied by progressive decrease in contractile 
function, at different time-points post-MI in comparison to sham-operated control. (A) Echocardiography 
data; Top panel: Echocardiography image indicating the plane (white punctuated line) in the left ventricle 
(LV) from which echocardiography data represented in the bottom panel was collected, over time. LA 
marks the location of the left atrium and AO marks the aorta. Bottom panel: echocardiography data 
showing the anterior wall (AW) and the posterior wall (PW) function of the left ventricle. (B) 
Echocardiography data at different time points after MI; (C) Heart weight corrected to tibia length (n=10, 
p<0.01); (D) Ejection fraction (n>8, p<0.01).  
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2.3. Cell isolation 
 
2.3.1. Adult rat cardiomyocyte isolation  
Adult rat cardiomyocytes isolation: Cells were isolated from the atria and the left ventricle of 
the aforementioned model of chronic MI by Mr. Peter O’Gara via enzymatic digestion as 
described previously (Gorelik et al. 2006). For this the rats were anaesthetised and 
heparinized to stop blood coagulation before being sacrificed by cervical dislocation. Then the 
chest and the pericardium were opened up to excise the heart and put it into ice cold 
oxygenated Krebs solution (pH 7.4) containing MgSO4(0.94 mM), KCl (4.7 mM), NaCl (119 
mM), NaHCO3 (25mM), Glucose (11.5 mM), KH2PO4 (1.2 mM) and CaCl (1mM). The heart 
was then Langendorff perfused for 5 min using the same Krebs solution, before switching to 
oxygenated low Ca2+ solution (pH 6.95) containing Ca2+ (12mM), MgSO4 (5mM), KCl (5.4mM), 
NaCl (120mM), Glucose (20mM), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES, 10mM), nitrilotriacetic acid (NTA, 5mM), taurine (20mM) and pyruvate (5mM). After 
this the heart was perfused for 10 min with a slightly modified low Ca2+/ enzyme solution (pH 
6.95) by not adding any NTA (=chelating agent) to the aforementioned list of ingredients but 
an additional amount of Ca2+ (200µM) and the enzymes collagenase (1mg/ml) and 
hyaluronidase (0.6mg/ml). Now the left ventricle and the atria were separated from the rest of 
the heart and chopped into bits with scissors before being shaken in oxygenated enzyme 
solution at 37°C for 5 min. The digested tissue was then filtered through a piece of gauze 
before repeating the enzyme digest for a further 5 min and filtering through another piece of 
gauze. The resulting digested tissue solution was spun down at 700 rpm and while the 
supernatant was discarded the cardiomyocyte pellet was resuspended in buffer without the 
enzymes. For further investigation a part of the resuspended cells was shock frozen in liquid 
nitrogen and stored at -80°C.   
       
2.3.2. Human cardiomyocyte isolation  
Permission to obtain human heart tissue samples was received from the respective patient 
and patient anonymity was secured by holding up the criteria of the human tissue act (Human 
Tissue Act 2004, UK). Human ventricular cardiomyocytes were isolated by Dr. Peter Wright 
and Dr. Jose Sanchez Alonso-Mardones. Human cardiomyocytes were obtained either from 
mitral valve (MV) surgery from patients with sinus atrial fibrillation or from bypass surgery as 
well as from dilated (DCM) and ischemic cardiomyopathy (ICM) heart transplant patients (see 
table 3) with and without LVADs. For reasons of patient anonymity identification data is not 
available to this thesis but to the respective departmental authority at Imperial College London 
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(in this case the Royal Brompton database for heart transplants and Dr. Prakesh Punjabi for 
MV operations). Before the tissue arrived 40ml of low Ca2+ solution (pH 6.95) (Ca2+ (12mM), 
MgSO4 (5mM), KCl (5.4mM), NaCl (120mM), Glucose (20mM), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES, 10mM), nitrilotriacetic acid (NTA, 5mM), taurine 
(20mM) and pyruvate (5mM)), 10ml of protease solution (0.36mg/ml protease in 100ml 
Millipore H2O with 7.5µl of 1M CaCl2) and 20 ml of collagenase solution (1mg/ml collagenase 
in 100ml Millipore H2O with 7.5µl of 1M CaCl2) were oxygenated and warmed up to 37°C. 
Upon its arrival the human tissue was removed from cardioplegia solution and pieces of 
around 500mg of muscle tissue, which still appeared intact, were separated from adherent fat 
and connective tissue. Then the tissue was quickly (in under 5min) chopped into smaller 
pieces and transferred into 10ml of oxygenating low Ca2+ solution for 3 min. Afterwards the 
solution was filtered through gauze retaining the sample and the sample was put into a further 
10ml of low Ca2+. This washing step was repeated a further 2 times, before the cleaned sample 
was transferred into 10ml of protease solution and shaken at 37°C for 30 min. Subsequently 
the digested sample was filtered through a piece of gauze. Then the solution containing the 
cardiomyocytes was put into 10 ml of collagenase and shaken for a further 45 min at 37°C 
before being filtered through a piece of gauze again. Finally the filtrate was spun down at 700 
rpm and the supernatant containing human fibroblasts was separated from the pellet 
containing the cardiomyocytes. The cardiomyocyte pellet was then resuspended in enzyme 
buffer solution without enzyme for further experimental processing.   
 
Table 3 Details of human cardiomyocyte donors: gender, age and type of cardiomyopathy 
Donation Date Gender Age Type of cardiomyopathy 
29042014 Female 42 DCM+LVAD, left ventricle 
11062014 Male 49 DCM+LVAD, left ventricle 
09092014 Male 63 DCM, left ventricle 
23092013 Female 26 DCM, left ventricle 
24092013 Male 33 DCM, left ventricle 
26092013 Male 48 ICM, left ventricle 
09062014 Male 58 ICM, left ventricle 
12092014 Male 51 ICM, left ventricle 
24042014 Female 70 MV 
09012014 Female 78 MV 
13012014 Male 69 MV 
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20062014 Female 43 MV 
 
2.4. Cell culture and medium/buffer preparation   
 
2.4.1. HEK293 cell culture 
Though most work described here was performed in cardiomyocytes, some work also required 
the culture of Human Embryonic Kidney 293 (HEK 293) cells. These cells were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) at 37°C and 5% CO2. The medium was made 
up of 500ml DMEM with 4.5 mg/ml glucose, FBS 50 mg/ml, 50mg L-glutamine/ml and 10,000 
IU Penicillin/mL plus 10,000 µg Streptomycin/mL. 
 
2.4.2. Cardiomyocyte culture  
After their isolation both adult rat and human cardiomyocytes were plated onto laminin-coated 
glass bottom dishes (MatTeK Corporation, Ashland, USA) or laminin-coated glass coverslips 
(Thermo Scientific, VWR International, # 12392108). All rat cells were immediately incubated 
at 37°C and 5% CO2 in modified M199 culture medium and underwent differential treatment 
after at least 1h to properly attach to the culture dish. Modified M199 culture medium was 
made up from 500ml M199 medium supplemented with creatine 5mM, taurine 5mM, carnitine 
5mM, 1g bovine serum albumin, ascorbate 100mM and penicillin/streptomycin 100mM. 
Human cells however were first incubated for 1h in recovery medium (M199 with additional 
fetal bovine serum 10ml/L) before this was also changed to modified M199 medium. The cells 
were then either designated for immediate investigation or for transduction with adenovirus 
FRET biosensors for 48h.  
 
2.4.3. Physiological buffer for experimentation 
For SICM/FRET imaging and Di-8-ANEPPS staining procedures of live cells physiological 
solution (pH7.4) was made up from ddH2O containing NaCl 144 mM, KCl 5mM, HEPES 10mM 
and MgCl2 1 mM.  
 
2.4.4. Experimentation temperature and solutions 
If not stated otherwise all experiments were performed at room temperature (~22oC) and all 
solutions were made up with purified Milli-Q water (EMD Millipore, Massachusetts, USA). 
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2.5. Structural investigation of cardiomyocytes 
For the visualisation and structural investigation of single, isolated cardiomyocytes two main 
techniques were used. The first of which is SICM and the second of which is confocal 
microscopy. 
 
2.5.1. Scanning Ion Conductance Microscopy  
 
Figure 7 The setup and working principle of SICM. A nanoscale pipette serves as scanning probe to 
elucidate sample surface structures. A piezo-electrical stage allows for the alignment of the pipette in the 
x,y and z direction. Two electrodes in the system measure the ionic current that passes through the pipette 
opening. The pipette remains at a constant distance to the sample surface as determined by the ion current 
(nA), which is able to pass unrestricted through the pipette opening. Picture taken from: 
http://www.parkafm.com/index.php/park-afm-technology/park-sicm Copyright © 2015 Atomic Force 
Microscopy, Park Systems  
 
SICM is a non-invasive, nano-scale resolution scanning modality which was invented by 
Hansma et al. in 1989. SICM used to be restricted to the scanning of relatively smooth surfaces 
for risk of colliding with vertical, protruding structures on various cell types. Hopping probe 
SICM a recent advancement in the field overcame this restriction and enabled the visualization 
of even highly convoluted, nano-scale cell surface structures (Novak et al. 2009). Hence SICM 
in hopping mode can be used to visualize the highly structured surfaces of live cardiomyocytes 
in solution by detecting the inwards and outwards current of ions passing through the opening 
of a nanopipette which serves as scanning probe. Briefly the scanning process of a cell’s 
surface i.e. a cardiomyocyte with SICM is performed by pulling a borosilicate glass capillary 
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(IntraCel, BF100-50-7.5) in a laser puller (IntraCel, Sutter Instrument Co, P-2000) to generate 
a nanopipette with the necessary tip size (with 80-100MΩ resistance) to resolve nano-scale 
structures like the T-tubule openings and crests on the cardiomyocyte surface. This 
nanopipette is then outfitted with an electrode and filled with electrolyte solution before being 
clamped into a pipette holder. The pipette holder can move up and down (in z direction) to 
lower the nanopipette directly above the sample cells. The sample dish sits on top of a 
piezoelectric stage, which can move the cells laterally in the x and y direction and is outfitted 
with a grounding electrode reaching into the physiological buffer with the sample cells. Both 
the electrode in the nanopipette and the electrode in the culture dish are connected to a 
feedback system. This system registers the flow of ions between the two electrodes and 
translates the electrical signal back into computer generated surface scans using the software 
IonView (IonScope, UK) while keeping the nanopipette at the exact same distance to the 
respective cell surface throughout all times. While the nanopipette moves along the cell body 
it is also continuously moved up and down in a “hopping” motion via a piezo-actuator stage to 
prevent it from colliding with taller cell surface structures (Novak et al. 2009).  After obtaining 
cell surface scans the scanning nanopipette can also apply agonists or antagonists to 
particular structures on the sample cell surface, given they were added into the pipette solution 
beforehand, by unloading part of its content. This unloading can either be achieved via 
pressure application (Nikolaev et al. 2010) or by reversal of the electric polarity of the two 
electrodes in the system given the respective agonist possesses a net charge in solution. The 
pressure application was used for the β2AR localization study, while the polarity reversal 
method was used for the β3AR localization studies described in this thesis.  
 
2.5.2. Di-8-ANEPPS staining of the TAT system of adult rat cardiomyocytes 
To prepare Di-8-ANEPPS 1.5 ml of DMSO were mixed with 0.5g of pluronic acid and then 
heated until the pluronic acid had dissolved. Then 630 microlitre of the warm concoction were 
mixed with 5mg of the Di-8-ANEPPS in powder form and 10 microliter each were aliquoted 
into Eppendorfs and stored at -20°C until used. For usage to stain cells one of the aliquots 
was dissolved in 1 ml of FRET solution or any other suitable physiological buffer (i.e. PBS) 
and put into a sonicator water bath (Fisher Scientific, model FB15047) at 55 degree Celsius 
under “sweeping” sonication mode for around 5 min. Adult rat cardiomyocytes were then 
stained with the lipophilic fluorescent dye for 1 min as described before (Lyon et al. 2009) and 
a Z-stack of optical images at every 0.49 microns was obtained using an inverted confocal 
microscope (Zeiss LSM-780). Images were processed with the freeware program Fiji 
(Schindelin et al. 2011) and a custom-made Matlab (The MathWorks, Inc., Natick, MA, USA) 
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code to assess T-tubule regularity and TAT network density. Longitudinal elements of the TAT 
network were quantified semi-automatically with a separate custom-made Matlab code which 
was provided by Mr. Aron Monzspart (University College London) according to my 
specifications. These specifications included, but were not limited to the following 
requirements: 1. that the pixel intensity and therefore the position of the stained TAT structures 
should be taken into account with a suitable threshold, 2. that the axial elements were oriented 
and hence only picked up as “axial” by the software code if the were not oriented in the 
direction of the transverse tubules of the TAT system and 3. that imaged structures with a 
pixel count which equalled more than 1 µm would not be picked up as valid axial tubules.     
 
2.6. Immunocytochemical staining of single cardiomyocytes: 
Immunocytochemical staining versus the structural, junctional protein JPH2, the caveolar 
protein Cav3, the cytoskeletal protein β-tubulin, the sGC molecule was performed as follows:  
After cardiomyocyte isolation cells were plated at an approximate number of 5000 into the 
middle of laminine coated 22mm borosilicate glass coverslips (Thermo Scientific, VWR 
International, # 12392108). The cells were quickly rinsed with PBS and then fixed for 15 min 
at room temperature with 40µl PFA/ml diluted in PBS. Then they were washed three times 
with PBS for 5 min before the application of blocking buffer (50µl donkey serum/ml, 3µl Triton 
X-100/ml diluted in PBS for JPH2 and β-tubulin and 50µl goat serum/ml, 3 µl Triton X-100/ml 
diluted in PBS for Cav3 and sGC) for 1h at room temperature. Afterwards the blocking solution 
was aspirated and without washing the cells the primary antibody was applied (diluted in PBS, 
3µl Triton X-100/ml) over night at 4°C. On the following day the samples were washed three 
times with PBS for 5 min each. Then the secondary antibody was applied (diluted in PBS, 3µl 
Triton X-100/ml) for 2 hours at room temperature and in the dark. As negative control cells 
were stained following the same protocol but with the application of the secondary antibody 
only. After the antibody incubation the coverslips containing the cells were mounted using 
mounting medium (Vector Labs, Vectashield mounting medium) onto partly frosted 
coverslides (Thermo Scientific, ShandonTM # 6776108). Finally the coverslips were sealed 
onto the coverslides with transparent nail polish to make them suitable for long time storage 
at 4°C and were then ready for imaging.   
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Table 4 Antibodies for immunocytochemical staining of adult cardiomyocytes 
Primary Antibody + 
concentration 
Species Company and Catalogue # Secondary Antibody 
(concentration) 
JPH-2 (Y-15) 
1:400 
polyclonal goat Santa Cruz # sc-51313 Alexa Fluor 488, 
Invitrogen, 1:1000 
Cav3 1:200 monoclonal 
mouse 
Sigma Aldrich Alexa Fluor 594, 
Invitrogen, 1:1000 
sGC 1:200 Polyclonal 
rabbit 
Provided by Prof. Nikolaev, 
Universitätsklinikum 
Hamburg, Germany 
Alexa Fluor 594, 
Invitrogen, 1:1000 
ß-Tubulin  1:100 polyclonal goat  Sigma Aldrich # t5201 Alexa Fluor 546, 
Abcam, 1:1000 
 
2.7. Confocal imaging of the cardiomyocyte structure or of structural and 
functional cardiomyocyte proteins 
For imaging of the TAT system after Di-8-ANEPPs staining and immunocytochemical staining 
molecules the Facility for Imaging by Light Microscopy (FILM) of Imperial College London 
provided the usage of a Zeiss LSM780 Laser Scanning Confocal Microscope (Carl Zeiss, 
Germany) equipped with a x63 magnification Zeiss DIC Plan-Apochromat oil-immersion 
objective (numerical aperture 1.4; Carl Zeiss, Germany). An Argon laser was used for specific 
excitation of the respective fluorophores. Z-stack images were recorded at a distance of 0.4 
µm using the microscope associated software ZEN 2011 (Carl Zeiss, Germany). Image 
processing was however performed with the freeware Fiji (Schindelin et al. 2011). 
 
2.8. Functional investigation of cardiomyocytes 
2.8.1.  FRET imaging 
FRET imaging is a technique based on the naturally occurring, physical phenomenon of 
partial, non-radiative energy transfer from one excited fluorophore at a higher energy state to 
another fluorophore at a lower energy state. For this phenomenon to occur the emission 
spectrum of the donor has to overlap with the excitation spectrum of the acceptor fluorophore. 
Also the two fluorophores have to be in close enough proximity (usually <10nm) as determined 
via the sixth power of the Förster radius R0 (R0=the distance at which 50% energy transfer 
takes place between the donor and acceptor fluorophore). Lastly the dipole moment of the 
fluorophores has to be aligned (Arai, Nagai 2013). To measure FRET in a scientific 
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environment the usual FRET imaging system consists of a microscope with an excitation light 
source to elicit fluorescence, a beam splitter to separate and lead the emission light into two 
separate detection channels, a shutter to restrict the amount and time the fluorophores are 
excited (as this can lead to their destruction and photo bleaching) as well as a high speed 
camera to record the signal from the donor and acceptor fluorophores in the two channels 
simultaneously. The setup used for the experiments described in this thesis was as follows: 
Our inverted Nikon TE2000 microscope had a 30WDia halogen lamp light source with a 
436/20nm excitation filter and a DM455 dichroic mirror. For the work in this thesis the cAMP 
biosensor Epac2-camps, based on the cyan and yellow fluorescent proteins and the cGMP 
biosensor Red cGES-DE5 based on a green (GFP) and red fluorescent protein (RFP) were 
expressed in cardiomoycytes. To record the respective biosensor FRET signals our system 
used an ORCA-ER CCD camera (Hamamatsu Photonics, Welwyn Garden City, UK). For 
splitting fluorescent emission our system had a Dual View (Optical Insights) beam splitter with 
two exchangeable filter cubes: the first cube consisted of BP535/40 and BP480/30 emission 
filters for cyan (CFP) and yellow (YFP) light detection during cAMP studies and the second 
cube consisted of BP515/30 and BP590/40 emission filters for green (T-Sapphire) and red 
(Dimer2) light detection during cGMP studies. The software for recording FRET signals was 
the 1.4 version of the programme Micro-Manager (Vale Lab, University of California, San 
Francisco http://www.micro-manager.org/wiki/Micro-Manager; accessed January 2015) and 
FRET signals were continually recorded at every 5th second. Despite the beam splitter and the 
light filters a remnant of light from the different fluorophores seeped into the other detection 
channels. To correct for this “bleed through” the amount of bleed through was determined by 
Dr. Peter Wright (Imperial College London) after transfection of HEK293 cells with either CFP 
or T-Sapphire plasmid DNA by establishing the relative intensity of fluorescence in the YFP or 
the RFP channel respectively (data not shown). 
When using FRET measurements to elucidate changes in cyclic nucleotide levels, without 
prior calibration of the FRET sensor, it is not possible to determine actual, absolute molecule 
levels but relative molecule levels only. Nor is it possible to detect the actual activity value of 
specific PDE in FRET experiments. To determine both cyclic nucleotide levels and overall 
PDE activity in absolute values it is necessary to disrupt the cell membrane and conduct 
quantitative second messenger and PDE activity assays. This however has the strong 
disadvantage of also disrupting the highly stringent compartmentation and signalling 
confinement present in cardiomyocytes. FRET experiments as the ones performed in this 
thesis do have the great advantage over other techniques of not requiring the disruption and 
homogenisation of cells. Therefore FRET experiments allow insightful conclusions on 
compartmentalised cyclic nucleotide levels and associated PDE activity.    
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2.8.2. SICM/FRET setup for localised detection of functional receptors 
Our laboratory is in possession of a custom-made combination of a SICM/FRET microscope 
(see figure 8). This combination allows for the targeted stimulation and real-time response 
detection of cyclic nucleotide production after the stimulation of receptors on the surface 
features of the respective sample after their visualisation by SICM scanning and transduction 
with a FRET biosensor (Nikolaev et al. 2010). Here the SICM/FRET combination was used to 
detect functional βARs present at different sites on the cardiomyocyte surface and their 
second messenger response to catecholaminergic stimulation and PDE inhibition.  
 
Figure 8 Schematic of the FRET and SICM combination microscopy system showing a cell expressing 
secondary messenger sensing FRET constructs, the process of fluorescent excitation and emission as 
well as recording of the respective FRET signal, the arrangement of the perfusion system and the SICM 
nanopipette.  
 
2.8.3. Cell transduction with cAMP or cGMP FRET biosensors 
Adenoviral transduction allows gene transfer into different cell types including human and 
rodent cardiomyocytes. After their isolation and attachment to a laminine coated dish (MatTeK 
corporation, Ashland, USA) cells were transduced with adenoviral vector encoding FRET 
constructs. Depending on the experiment these FRET constructs were either the cytosolic 
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cAMP biosensor Epac2-camps (Nikolaev et al. 2004), the plasma membrane bound Epac2-
camps (Sprenger, Nikolaev 2013) or the cytosolic cGMP biosensor Red cGES-DE5 (Niino et 
al. 2009). In either case rat cardiomyocytes were transduced at a multiplicity of infection (MOI) 
of approximately 300-500 virus particles and incubated in M199 media, without media 
exchange for 48h at 37°C and at 5%CO2.   
 
Table 5 cAMP and cGMP FRET biosensors used for cardiomyocyte transduction (Sprenger, Nikolaev 2013)  
FRET biosensor half maximal effective  
concentration 
FRET pair 
Cytosolic Epac2-camps cAMP EC50= 0.9 µM CFP/YFP   
Plasma membrane bound Epac2-camps cAMP EC50= 0.9 µM CFP/YFP 
Cytosolic Red cGES-DE5 cGMP EC50= 40 nM T-Sapphire/RFP 
 
2.9. Finite element modelling 
Finite element modelling (FEM) is a term for one of the most widely used mathematical 
techniques to solve differential equations describing an engineering or biological problem 
through the use of a set of algorithms and mathematically stated boundary conditions. “Finite 
element” refers to the fact that the domain (which can have any number of dimensions) is 
subdivided into simpler “elements” and that the governing equations in weak form are solved 
on each one. In this thesis finite element modelling was used to describe the concentration 
distribution of the agonist ISO after its voltage-driven application onto the 3-dimensional 
structure of cardiomyocytes via the SICM nanopipette. The FEM was solved for different 
parameters using the software COMSOL Multiphysics® 4.4 (COMSOL AB, Stockholm, 
Sweden).     
 
2.10. Statistical analysis  
Significant statistical differences of data sets were analysed using OriginPro 8.6 (OriginLab 
Corporation) and GraphPad Prism 5 (GraphPad Software Inc., La Jolla, California). Normal 
data distribution was determined by Kolmogorov-Smirnov testing. If the data was normally 
distributed a two tailed T-test was used for the comparison of two independent groups. If the 
data had a skewed distribution a Mann-Whitney U test was used instead. If more than two 
groups were compared with each other a one-way ANOVA with Bonferroni correction testing 
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was applied. Data was considered significant at a p-value under 0.05. All data are presented 
as means with standard errors. 
 
 
2.11. Special remark about the data collected from HF progression samples   
The data collection for β2AR-dependent cAMP levels and cardiomyocyte structure during HF 
progression started well before the PhD project, which is summarised in this thesis 
commenced. The postdoc who conducted the measurements before the arrival of the student 
left Imperial College at the beginning of 2013. His records were not made available to the 
student. Hence the allocation of control cells to hearts from rats which underwent sham 
operations or rats which were age matched but underwent no operation was not always 
possible.  Whenever data from control cells with uncertain origin is shown in the result sections 
it is therefore, as far as possible, depicted in scatter blots and/or indicated as “age matched 
control and sham-operated control cardiomyocytes” in the figure legend.      
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter 3: The TAT network and surface structure of 
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Chapter 3: Cardiomyocyte Structures 
 
 
3.1. Introduction 
Chapter 3 focusses exclusively on the structural assessment of single, isolated, mammalian 
cardiomyocytes. Especially ventricular cardiomyocytes have shown to possess a unique and 
highly intricate plasma membrane structure consisting of the Z-grooves and sarcolemmal 
crests (Gorelik et al. 2006) which are more readily in contact with their extracellular 
environment than the also present Tranverse Axial Tubule (TAT) network (Orchard et al. 
2009). This ventricular TAT network provides a framework for coupling the electrical impulse 
of the action potential at the cardiomyocyte surface to cell internal responses such as the  
LTCC CICR through RyRs at the SR (Wagner et al. 2012). The highly structured appearance 
of ventricular cardiomyocytes is in part due to its underlying cytoskeleton, which consists 
primarily of the microtubuli and actin filaments (Nishimura et al. 2006). These microtubuli home 
molecules like the LTCC subunits to the T-tubules of cardiomyocytes (Hong et al. 2010). It has 
been shown in previous studies that the microtubule content in the cytoskeleton of 
cardiomyocytes increases in hypertrophy and HF (Nishimura et al. 2006). Furthermore the 
TAT network has been shown to be affected by this increase in microtubuli through the related 
JPH2 trafficking dysfunction of the disturbed microtubule cytoskeleton (Zhang et al. 2014). 
Conversely to the increase in microtubuli, the expression of JPH2 has been shown to be 
decreased in hypertrophy and HF and its knockdown lead to aberrant Ca2+ signalling 
properties of cardiomyocytes (Wei et al. 2010). Treatment with the gout medication colchicine, 
which binds to the microtubule and thereby prevents their polymerisation, however appeared 
to prevent microtubule and JPH2 associated adverse cardiac TAT network remodelling and 
has been linked to a lowered HF risk (Zhang et al. 2014).  
It is well established that the TAT network is strongly decreased in end stage HF, in both rat 
and human cardiomyocytes (Lyon et al. 2009) and its deterioration has been associated with 
abnormal Ca2+ handling (Sacconi et al. 2012) as well as aberrant βAR-dependent cyclic 
nucleotide signalling (Nikolaev et al. 2010). The abnormal Ca2+ handling associated to TAT 
network alterations is thought to, among other causes, derive from “orphaning” of RyR2 
clusters by a disparate configuration of disrupted T-tubules which no longer reach the vicinity 
of these RyR2 clusters (Song et al. 2006; Wagner et al. 2012). In contrast, aberrant βAR-
dependent second messenger signalling associated to TAT network alterations is assumed to 
derive, among other things, from the physical redistribution of the β2AR subtype out of the TAT 
network at the end stage of HF (Nikolaev et al. 2010). Most studies on the TAT network and 
its role in excitation-contraction coupling concentrate solely on elucidating the differences 
between control cardiomyocytes and cardiomyocytes at the end stage of HF and miss to test 
time-dependent progressional changes. Though it has been shown in prior publications that 
the cardiomyocyte structure undergoes step-wise alterations during the progression from 
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hypertrophy towards end stage HF (Wagner et al. 2012; Wei et al. 2012) these gradual 
alterations have not been brought into the context of localised β2AR-dependent cAMP 
signalling alterations as was done in this thesis in chapter 3 and 4. Some of the alterations, 
like the reported increase in longitudinal elements of the TAT network could be of a 
compensatory nature and could be reflected in maintained βAR signalling despite myocardial 
injury or they could simply be the return of the cardiomyocyte protein expression profile to a 
more immature phenotype (Wagner et al. 2012). Therefore it is important to investigate the 
gradual alterations in the TAT network at the incremental stages of HF progression.  
In summary the beginning of chapter 3 deals with the structure of adult, ventricular 
cardiomyocytes during the progression of HF. For this we studied the progressive alterations 
in the cardiomyocyte surface and TAT network at 3 different stages post the induction of MI in 
the rat. We associated these stages with a compensatory phase (4 weeks post-MI), a 
decompensated stage (8 weeks post-MI) and the end stage of HF (16 weeks post-MI). 
Furthermore the expression of the structural protein JPH2 was assessed during the 
progression of HF. Then structural alterations due to chemical manipulation of the 
cytoskeleton were examined. 
Last but not least chapter 3 tries to elucidate potential differences in structural intactness of 
ventricular cardiomyocytes obtained from human patients. These patients either underwent 
MV surgery or obtained a heart transplant after ICM or DCM and consented for their cardiac 
tissue to be used in scientific studies. Some of these ICM or DCM patients were in possession 
of a LVAD which enabled a structural comparison between LVAD carriers and non-LVAD 
carriers.  
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3.2. Materials and Methods 
  
 
3.2.1. Cardiomyocyte isolation during the progression of HF 
To examine the structural integrity of cardiomyocytes in health and during the progression of 
HF cells were isolated by Mr. Peter O’Gara (Imperial College London) from the left ventricle 
of age matched control rat hearts and hearts at 4, 8 and 16 weeks post induction of MI via the 
ligation of the LAD aorta by Dr. Markus Sikkel (Imperial College London).    
 
3.2.2. Cardiomyocytes surface structure assessment 
For the investigation of cardiomyocytes surface structures, the SICM was used purely as a 
scanning tool on the day of the respective cell isolation, to obtain 3D, high resolution 
topography images. For this 10x10µm cardiomyocyte surface scans were obtained using 
SICM as described previously (Novak et al. 2009), with nano-pipettes of resistance around 
80-100 MΩ. From these SICM surface scans the Z-groove index was calculated. This index 
quantifies how many Z-grooves are present on the cell surface and allows to detect changes 
in surface structures (Gorelik et al. 2006). In short it is calculated by measuring the total length 
of the T-tubules which are actually present in a scan and dividing it by the length of the 
optimally possible Z-grooves on a surface scan (see figure 9). Given that Z-grooves of the 
most highly structured cells, the ventricular cardiomyocytes, lie in about 2µm distance to each 
other the maximally possible length of Z-grooves in a 10x10µm area scan is 50µm, which 
would correlate to a Z-groove index of 1. 
 
Figure 9 Illustration of the Z-groove index calculation at the hand of a 10x10 SICM surface scan. The Z-
groove index value results from dividing the maximally possible amount of the Z-groove length (red) by 
the actually present Z-groove length (black).  
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3.2.3. Cell surface topography investigation during HF progression 
To study the surface structure integrity of cardiomyocytes during the development of HF, cells 
were isolated from age matched control rat hearts and after 4, 8 and 16 weeks post-MI. 
Furthermore the number of T-tubule openings per scan for the ventricular rat cardiomyocytes 
was determined using the SICM image viewer software (Ionoscope). This was done by 
processing the scans using the correctional “destripe” and “remove line” options to remove 
artefacts from the scans and by using its deconvolution option to normalize the height of scans 
to each other (see Figure 10). Then an automated threshold was run over the SICM scans 
which made the T-tubule openings visible as red spots (see Figure 10). The width and length 
of T-tubule openings were determined by drawing profile lines through the T-tubule openings 
which were visualized in this manner (see Figure 10).    
 
Figure 10 SICM scan processing depiction. Exemplary SICM scan with high noise shown (A.) unprocessed 
(B.) after destripe processing (C.) after removal of noise (D.) after deconvolution. (E.) Schematic of T-tubule 
opening investigation steps to determine T-tubule number and size. Left side: Surface scans are 
consistently processed and thresholded to show T-tubule openings (red spots) before a profile line is laid 
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through them (white line). Right side: The profile line allows to estimate the dimension of the opening of 
the T-tubule to the surface.  
 
3.2.4. T-tubule regularity and TAT network density assessment 
The TAT network of single cardiomyocytes was stained with the lipophilic dye Di-8-ANEPPS 
and imaged with confocal microscopy at x63 magnification. For this the Argon laser excited 
Di-8-ANEPPS at 488nm. The resulting images of the TAT network were analysed using the 
freeware Fiji (Schindelin et al. 2012) by choosing areas in the middle of Z-images (at least 
2µm away from either the top image or the bottom image) and far from the cell nuclei or cell 
edges (at least 2µm apart). This also allowed to evaluate if the TAT network damage was 
more likely to occur close or remote from the sarcolemma (see Figure 11). Chosen areas of 
40x5 µm were automatically thresholded into binarised images using the default binary 
threshold from the Fiji software and then plotted into waveforms. The waveforms were 
converted into power-frequency peaks through a single dimension Fast Fourier transformation 
(see Figure 12) using a custom-written macro for Matlab (The MathWorks, Inc., Natick, MA, 
USA) as described before (Ibrahim et al., 2010). The output for each power calculation is an 
arbitrary number that  serves as an indicator of how regular T-tubules appear at a physiological 
distance of ~2µm as was described before (Wei et al., 2010). The higher the peak the more 
intact and regular is the structure. Simultaneously 40x5 µm binarised areas of the confocal 
images were used to define the TAT density by calculating the percentage of black pixels in 
each chosen area (see Figure 12). 
 
Figure 11 Testing to determine if there is a higher damage proneness of cardiomyocytes close or remote 
to the sarcolemmal membrane. To the left: representative confocal image of TAT network staining with 
indicated areas of investigation close or remote from the plasma membrane. To the right: Power peaks of 
the Transverse Tubule (TT) regularity of the chosen areas close and remote from the plasma membrane 
after 1dimensional Fast Fourier Transformation. 
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Figure 12 Schematic of TAT System investigation steps to determine TAT density and T-tubule regularity  
 
3.2.5. Number of longitudinal elements:  
A less studied and far more irregular feature of cardiomyocytes are the longitudinal elements 
that connect some T-tubules but not all. After their visualization with confocal microscopy one 
could go through each consecutive confocal image manually and determine the number of 
longitudinal elements but that would be a very labor intensive step by step procedure. Due to 
the variability in the position and occurrence of longitudinal elements it is hard to design a fully-
automatic program that will calculate longitudinal elements. Still to avoid the completely 
manual approach an image processing algorithm was designed for semi-automatic 
quantification of longitudinal elements. For this confocal Z-stacks were taken of 
cardiomyocytes stained with Di-8-ANEPPS at various time points post-MI.  An area of 40x10 
micron was chosen on 10 consecutive confocal Z-stack images with 1µm separation between 
each of the images. Then the areas were processed as follows: 1) the overall TAT structure 
was detected using Canny edge detection 2) the detected edges were filled and thinned down 
to 1 pixel width using low-level, morphological operations 3) transverse oriented tubule 
candidates were collected by applying adaptive thresholds to the histograms over the 1D 
projections of the detected structures 4) the detection of spatial regularity/repetition of the 
transverse tubules was used to make the method more robust towards the errors introduced 
by the quantization in z-direction 5) all transverse tubule elements were identified and 
automatically removed from the images 6) the remaining longitudinal elements were verified 
by eye and quantified. The last step has to be performed by eye since real life TAT structure 
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proved to be much more curvilinear than the straight elements which were assumed initially 
for image processing, especially in cardiomyocytes at 16 weeks post-MI. Indeed, in human 
cardiomyocytes the TAT network layout was too variable to use this semi-automated 
quantification method. 
 
Figure 13 Procedure to determine the number of longitudinal elements in chosen areas of confocal images 
of the cardiomyocyte TAT network. A 40x10 µm area of a confocal image is chosen and loaded into the 
Matlab software, which then detects the structural edges by canny edge detection, closes all the edges 
and thins the structures to 1 pixel thickness before substracting the transverse oriented structures and 
leaving only the longitudinally directed structures for quantification.  
 
3.2.6. Cardiomyocytes volume determination 
Cardiomyocytes experience hypertrophy as an initially compensatory mechanism to 
counteract the loss of cardiac output tat is experienced by the heart due to myocardial injury 
(Yue et al. 2000). In order to measure the cellular hypertrophy exhibited at the progressive 
stages of HF the volume of cardiomyocytes was determined in control cardiomyocytes and 4, 
8 and 16 weeks post-MI. For this Z-stack images taken after Di-8-ANEPPS staining were 
analysed using the imaging software Zen 2012, which automatically translated pixels into 
microns. The cell volume was measured by determining and multiplying the length, the width 
and the height of cardiomyocytes.  
 
3.2.7. Culture induced cardiomyocyte structure alterations 
It is a well-documented observation that isolated cardiomyocytes lose their structural integrity 
in culture (Mitcheson et al. 1998). An important part of the experiments listed in this thesis are 
FRET experiments that are performed after cells have been transfected with adenovirus for 
up to 48h. To have an insight into how much of the surface and TAT network structure is lost 
after these 48h and if the application of virus magnifies the loss even further untreated control 
cardiomyocytes and cells treated with approximately 300 plasma membrane Epac2-camps 
(pmEpac2) adenoviral particles (provided by Prof. Nikolaev Viacheslav, Universitätsklinikum, 
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Hamburg-Eppendorf, Germany) were cultured for 48h and investigated using SICM scanning 
and Di-8-ANEPPS staining as described before (see 2.5.2).   
 
3.2.8. Colchicine and cytochalasin D treatment of cardiomyoctes 
For a more in depth study of structure in freshly isolated left ventricular control cardiomyocytes, 
cells were treated with the cytoskeleton affecting reagents colchicine or cytochalasin D.   
Colchicine treatment: Plated control cardiomyocytes were treated with and without 10µM of 
the microtubule disrupting agent colchicine, dissolved in DMSO, for 1h at 37°C and 5% CO2. 
Control cells were also treated with 1µl DMSO/ml only. Control cells and colchicine treated 
cells were then fixed and immunocytochemically stained with an antibody selective for β-
tubulin (see chapter 2, paragraph 2.6.).  
Cytochalasin D treatment: It was previously reported, that fungi-derived cytochalasin D, which 
affects the cytoskeleton via actin filaments, kept both structural and functional features of 
cardiomyocytes intact for 3 days (Tian et al. 2012).To test if the reagent was indeed able to 
preserve T-tubule structure control cardiomyocytes were treated with and without 0.5μM 
cytochalasin D for 48h at 37°C and 5%CO2..  
Cardiomyocytes treated with cytochalasin D, colchicine or DMSO only were stained with Di-
8-ANEPPS as described before (see chapter 2, paragraph 2.5.2) and imaged at 63x 
magnification using the confocal microscope at Imperial College London FILM facility as 
described before (see chapter 2, paragraph 2.7.). The relative amount of β-tubulin was 
determined in untreated and colchicine treated control cardiomyocytes after confocal imaging 
(see chapter 2, paragraph 2.7.) using the freeware Fiji (Schindelin et al. 2012) by choosing 
50x10 µm areas of interest in the middle of the cell from 10 confocal images at a distance of 
1 µm of each other, followed by binarising the images and measuring the % of black pixels in 
the images.   
 
3.2.9. Cardiomyocyte structures in human cardiomyopathies 
Cardiomyocytes from the human left ventricle from MV surgery patients or from patients with 
ICM or DCM with or without LVAD were isolated as described before (see chapter 2, 
paragraph 2.3.3). The cells were cultured for 1h before they were utilized for SICM surface 
scanning and TAT network investigations after Di-8-ANEPPS staining. Z-stacks of the TAT 
network were recorded at 63x magnification using the inverted Zeiss LSM780 Laser Scanning 
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Confocal Microscope at Imperial College London FILM facility as described before (see 
chapter 2, paragraph 2.7.).  
 
3.2.10. Quantitation of the structural protein JPH2 
JPH2 was quantified via Western Blotting both in Prof. Nikolaev’s laboratory in Göttingen, 
Germany as well as at Imperial College London. Therefore about a million isolated control 
cardiomyocytes and cardiomyocytes from hearts after 4, 8 and 16 weeks of MI were washed 
in ice-cold PBS and lysed in 100µl ice-cold Radio Immuno Precipitation Assay (RIPA) buffer 
30 minutes at 4°C and under constant agitation. The used RIPA buffer consisted of NaCl (150 
mM), 1µl Triton X-100/ml, 500µg sodium deoxycholate/ml, 1µg sodium dodecyl sulphate 
(SDS) /ml diluted in Tris (50 mM), pH 8.0. Afterwards the samples were centrifuged for 20 min 
at 4°C and 12,000 rpm (in an Eppendorf table top centrifuge, 5417R) before taking off the 
supernatant and transferring it into pre-cooled Eppendorf tubes for further processing. Next 
the protein concentration was determined using a standard Bradford assay on a 96 well plate. 
A concentration curve for normalisation was prepared with BSA as standard: putting ddH2O 
blanks only, 0.5 µl of 1mg BSA/ml plus 9.5 µl ddH2O, 1 µl of 1mg BSA/ml plus 9 µl ddH2O, 2 
µl of 1mg BSA/ml plus 8 µl ddH2O and 4µl of 1mg BSA/ml plus 6 µl ddH2O into two consecutive 
wells each, before setting up duplicates of 0.5 µl sample plus 9.5 ddH2O and duplicates of 1µl 
sample plus 9 µl ddH2O wells. Then the Bradford reagents (Bio-Rad) were added in the 
following order to each well: 25µl of Bradford Reagent A mixed with 20 µl Bradford Reagent B 
and 200 µl of Bradford Reagent C. Then the 96 well-plate was spun down gently on a 
centrifuge and allowed to incubate for 15 min at room temperature. Afterwards the plate was 
put into the plate reader and the assay was run using a basic endpoint protocol at a wavelength 
of 750nm. Sample concentrations were calculated automatically and allowed for the samples 
to be diluted to approximately 50µg of sample per 20µl ddH2O and put at -80°C until further 
use. For the electrophoretic separation of proteins a 10% sodium dodecyl sulphate (SDS) 
polyacrylamide (PA) separating and stacking gel was prepared. For this an ethanol-cleaned 
glass plate with a spacer was assembled in a gel sandwich holder (Bio-Rad). Then 1µl fresh 
ammonium persulfate (APS, Sigma, A3678)/ml solution was prepared before mixing 3.3ml of 
300 µl acrylamide/ml with 2.5ml of 1.5M Tris-HCl pH 8.8, 4ml ddH2O, 100µl of 100µg SDS/ml, 
80µl of 100µg APS/ml and 1µl Tetramethylethylenediamine (TEMED) /ml and pouring the 
mixture into the assembled gel sandwich till about 2cm to the top to create the separating gel. 
To smooth the top of the separating gel ddH2O was carefully pipetted on top of it. As soon as 
the separating gel had polymerised the stacking gel consisting of 0.5ml 300 µl acrylamide/ml, 
1ml of 0.5M Tris-HCl pH 6.8, 2.4ml ddH2O, 100µl of 100µg SDS/ml, 80µl of 100µg APS/ml 
and 1µl TEMED/ml was cast on top of it and equipped with a 10 well gel comb after the ddH2O 
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had been removed. Once the stacking gel had polymerised as well the gel was positioned 
inside a gel sandwich electrode assembly filled with running buffer consisting of 25mM Tris, 
192mM Glycine and 1µg SDS/ml. The gel comb was removed and the wells were gently 
cleaned by pushing through running buffer liquid with a pipette. Subsequently the samples 
were prepared by retrieving them from -80°C and mixing 20µl sample with 5 µl of 5x premade 
sample buffer consisting of 0.125M Tris-HCl pH6.8, 200µl glycerol/ml, 40µl SDS/ml, 20µl β-
mercaptoethanol (β-ME)/ml and 0.2µl bromphenolblue/ml. Then the samples were put onto a 
heating block for 5 min at 95°C and loaded onto the gel after a standard protein ladder had 
been loaded into the first well. Next the gel was attached to the power source and run for about 
1h at a voltage of 160mV. After the run had finished the gel was prepared for protein transfer 
onto a nitrocellulose membrane by building a wedge made up from bottom to top of the 
negatively poled side of the transfer holder plus 3 images of Whatman paper soaked in transfer 
buffer plus the gel containing the protein samples plus the nitrocellulose membrane cleaned 
with ethanol and afterwards also soaked in transfer buffer plus 3 more soaked Whatman paper 
images and the positively poled side of the transfer holder. Next the holder was put into the 
transfer apparatus filled with transfer buffer made of 30.2mg Tris base/ml, 144mg glycine/ml 
and 200ml ethanol in 1.8L Millipore water and the protein transfer was run over night. On the 
next morning the nitrocellulose membrane with the transferred protein was retrieved from the 
apparatus and blocked for at least 1h in milk made from 50mg milk powder/ml diluted in 100ml 
of Tris Buffer Saline Tween20 (TBST) at 4°C and under constant agitation. After the blocking 
the membrane was quickly washed with TBST before putting on a 1:3000 dilution with TBST 
of the primary JPH2 antibody overnight at 4°C on a shaker. The following day the membrane 
was washed 5 times for 10 min with TBST at 4°C on a shaker before putting on a 1:1000 
dilution of the secondary horse radish peroxidase (HRP) bound antibody for 1h at 4°C on 
under constant motion. Following the membrane was again washed 5 times for 10 min with 
TBST at 4°C on a shaker and then the Western blot was developed using Luminata Forte 
Western HRP activation substrate. 
 
3.3. Results: Cardiomyocyte structure in HF progression  
 
3.3.1. Cardiomyocyte cell volume in health and progressive HF 
The cell size of cardiomyocytes can be used as a marker of hypertrophy. On this occasion the 
volume of cells (length x width x height) was determined from whole cell, confocal Z-stack 
images after Di-8-ANEPPS staining taken from control cardiomyocytes and from 
cardiomyocytes isolated from a progressive HF model at 4, 8 and 16 weeks post-MI. Even 
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though the whole hearts of the animals, which were sacrificed for this study showed significant 
increase in size as soon as 4 weeks post-MI (see chapter 2, paragraph 2.2.2., figure 1), the 
cell volume of viable, single cardiomyocytes after their isolation was not significantly increased 
until 8 and 16 weeks post-MI (see figure 14) when they were on average 36% larger.      
 
Figure 14 Cardiomyocyte cell volume in health and during the progression of HF. Cell volume (in μm3) was 
determined via analysis of confocal Z-stack images in sham operated control cells and cardiomyocytes at 
4, 8 and 16 weeks post-MI. n= number of single cells measured. Animals utilised n=4 for each time point.  
Bars represent mean values ± standard error of the mean. Statistical one-way ANOVA test followed by 
Bonferroni correction post-hoc testing, p<0.001, p=ns; no significant difference. 
 
3.3.2. Cardiomyocyte surface structure during HF progression 
In end stage HF the surface structure of left, ventricular cardiomyocytes is severely disrupted. 
To study the progressive deterioration from health to end stage HF cells at 4, 8 and 16 weeks 
post MI were SICM scanned on the day of their isolations and their Z-groove index as well as 
the number of T-tubule openings was analysed. Topography images of the cardiomyocyte 
sarcolemma generated by SICM allowed clear distinction of T-tubule openings and the crests 
between the Z-grooves. Profile measurements of topographical images showed that in adult, 
healthy ventricular cardiomyocytes spacing between Z-grooves is ≈2μm, corresponding to the 
sarcomere length (Gorelik et al. 2006). While the Z-groove index as a marker of structural 
integrity decreased throughout the progression of HF by about 9% the number of T-tubule 
openings on the surface scans decreased significantly at 4 weeks post-MI and again at the 
end stage of HF (see figure 15).  
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Figure 15 Changes in the surface integrity of cardiomyocytes during the progression of HF. (A.) 
Representative 10x10µm SICM surface scans of left, ventricular cardiomyocytes from in age matched 
control and sham-operated control cardiomyocytes control and at 4, 8 and 16 weeks post-MI. (B.) The Z-
groove index of cardiomyocytes in control cells and at different time points post-MI. (C.) The number of T-
tubule (TT) openings in control cells and at different time points post-MI (to the right). n= number of single 
cells measured. Animals utilised n≥5 for each time point. Bars represent mean values ± standard error of 
the mean. Statistical one-way ANOVA test followed by Bonferroni correction post-hoc testing, 
***p<0.0001,*p<0.05. 
  
3.3.3. TAT system in rat during HF progression 
It is well documented that cardiomocytes from different species at the end stage of HF exhibit 
a loss of TAT presence and intactness (Ibrahim et al. 2011; Lyon et al. 2009). The gradual 
changes of the TAT system during the progression towards HF are less well documented 
(Wagner et al. 2012; Wei et al. 2012) and no one has studied them in the same rat HF model 
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with chronic MI at the 4 weeks, 8 weeks and 16 weeks post-MI stage. In healthy 
cardiomyocytes, the TAT network spans the entire cytoplasm and consists of periodically 
spaced T-tubules and irregular longitudinal elements that connect the T-tubules. Consistent 
with prior studies by our group (Ibrahim et al. 2010; Lyon et al. 2009) our calculations of T-
tubule regularity indicate that they are interspaced highly regularly at ~2µm intervals in healthy 
cardiomyocytes. The TAT structure assessment at the stages after MI induction shows that 
the regularity of the Transverse oriented tubules (T-tubules)  already decreases significantly 
by ~47% (p<0.001) at 4 weeks post-MI together with T-tubule density (~11%, p<0.01) and 
remains so until end stage HF (see figure 16). However at the 4 and 8 weeks post-MI stages 
the cardiomyocytes exhibit a significant increase (~41%) in the number of their longitudinally 
oriented T-tubules (see figure 17). Similar results have been observed in a mouse model of 
HF (Wagner et al. 2012).  
  
Chapter 3: Cardiomyocyte Structures 
 
84 
 
 
Figure 16 Changes in cardiomyocyte TAT structure during the progression of HF. T-tubule regularity and 
TAT density in sham-operated control cardiomyocytes and cells at different time points after MI. (A.) To 
the left: Representative confocal images of the TAT network with 10x5 µm areas of interest blown up 2.65 
times together with their binarised counterparts of cardiomyocytes in control and at 4, 8 and 16 weeks post 
MI; scale bars equal 10µm. To the right: Power peaks of the corresponding T-tubular regularity. (B.) TAT 
network density in control cells and different time points post-MI. (C.) T-tubule regularity in control cells 
and different time p Bars represent mean values ± standard error of the mean oints post-MI. n= number of 
single cells measured. Animals utilised n≥4. Bars represent mean values ± standard error of the mean. 
Statistical one-way ANOVA test followed by Bonferroni correction post-hoc testing, ***p<0.0001, *p<0.05. 
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Figure 17 Changes in the number of longitudinal elements of the TAT network during HF progression. A. 
Representative fragments of 40x10µm of the confocal images of cardiomyocytes in sham-operated control 
and at 4, 8 and 16 weeks post-MI. (B) Relative number of longitudinal tubules n= number of single cells 
measured. Animals utilised n=4 for each time point. Bars represent mean values ± standard error of the 
mean. Statistical one-way ANOVA test followed by Bonferroni correction post-hoc testing, ***p<0.0001, 
**p<0.001, *p<0.05. 
 
3.3.4. TAT damage occurs with similar frequency throughout the cardiomyocyte 
To assess a potential damage proneness of the TAT system close to the plasma membrane 
or remote from the plasma membrane the TAT network of single cardiomyocytes was 
quantified by consciously choosing areas close and remote from the plasma membrane for 
analysis after Di-8-ANEPPS staining and confocal imaging. As our investigation shows 
damage was not more likely to occur either close or remote from the sarcolemma but appeared 
equally at both sites in the cardiomyocytes (see figure 18). 
 
Figure 18 T-tubule (TT) regularity in areas close (plane boxes) and remote (hatched boxes) from the 
sarcolemma in sham-operated control cardiomyocytes and cardiomyocytes 4, 8 and 16 weeks post-MI. 
n=number of single cells measured. Animals utilised n=4 for each time point. Bars represent mean values 
± standard error of the mean. Statistical two-sided Student’s T-test, p= ns; no significant difference. 
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3.3.5. JPH-2 levels decrease early and drastically in HF progression 
Among other proteins JPH2 has been identified as a vital protein for both structural maturation 
of cardiomyocytes (Seki et al. 2003; Chen et al.2012) as well as for the structural and 
functional integrity of their TAT network. JPH2 has also been shown to be decreased in 
hypertrophy and HF (Wei et al. 2010; Lyon et al. 2012). For this reason we measured the 
expression level of JPH2 during the progression of HF at 4, 8 and 16 weeks post-MI and 
immunocytochemically stained with an antibody selective for the protein. The results show 
that JPH2 expression is already strongly reduced at 4 weeks post-MI and remains thus until 
the end stage of HF (see figure 19).    
Chapter 3: Cardiomyocyte Structures 
 
87 
 
 
Figure 19 Changes in JPH2 expression and localisation during HF progression. A. Representative Western 
blot provided by Prof. Nikolaev (Universitätsklinikum, Hamburg Eppendorf, Germany). The density of the 
respective JPH2 bands is normalized to corresponding house-keeping gene GAPDH bands (n=3-4 animals, 
3 replicates). B. Representative, immunocytochemical staining of JPH2 in an age-matched control 
cardiomyocyte and cardiomyocytes 4, 8 and 16 weeks post-MI as well as a secondary antibody (Alexa Fluor 
488) only stain. Staining in cells post-MI showed no JPH2 stain. Scale bars equal 10µm. Statistical one way 
ANOVA test followed by Bonferroni correction post-hoc testing, **p<0.01, *p<0.05. 
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3.3.6. Structural dedifferentiation of cardiomyocytes in culture  
Cardiomyocytes experience structural dedifferentiation in culture. To assess the extent of this 
dedifferentiation the TAT system of cells after 48 hours of culture was stained with Di-8-
ANEPPS and imaged using confocal microscopy (see figure 20). To furthermore see if 
adenoviral transduction exacerbates culture induced cell dedifferentiation cardiomyocytes 
treated with the EPAC2-camps adenovirus for 48h were also stained with Di-8-ANEPPS and 
their TAT structure was assessed after confocal imaging (see figure 20).      
 
Figure 20 TAT network in freshly isolated cardiomyocytes and myocytes after long term culture with and 
without addition of adenovirus. (A.) To the left: Representative confocal images of the TAT network with 
40x5 µm areas of interest blown up 2.65 times together with their binarised counterparts; scale bars equal 
10µm. To the right: Power peaks of the corresponding T-tubular regularity, (B.) density of the TAT network 
and (C.) regularity of the T-tubules in control cells after 1h in culture and cells with and without adenovirus 
kept in culture for 48h. n=number of single cells measured. Animals utilised n=2 each. Bars represent mean 
values ± standard error of the mean. Statistical Student’s two sided T-test, ***p < 0.0001, **p < 0.001; p=ns; 
no significant difference. 
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3.4. Results: cytochalasin D and colchicine effects on cardiomyocyte 
structure 
 
3.4.1. Cytochalasin D increases the number of longitudinal elements in culture 
Submicromolar levels of the fungal agent cytochalasin D, which acts by inhibiting filamentous 
actin from forming the microfilaments of the cytoskeleton, were previously reported to stop the 
structural deterioration of cardiomyocytes in culture (Tian et al. 2012). The application of 0.5 
µM of cytochalasin D and its effect on the cardiomyocyte TAT network were assessed after 
Di-8-ANEPPS staining and confocal imaging. Though the calculated regularity of the T-tubules 
was significantly decreased by around 29 % after the application of low levels of cytochalasin 
D the TAT density did not decrease significantly in the cytochalasin D treated cells at 48h of 
culture (see figure 21). This was due to a rise in longitudinal elements by approximately 55% 
in comparison to control cardiomyocytes after only 1h of culture (see figure 22).  
 
Figure 21 TAT network in freshly isolated cardiomyocytes and myocytes after long term culture treated 
with cytochalasin D. (A.) To the left: Representative confocal images of the TAT network with 40x5µm areas 
of interest blown up 2.65 times together with their binarised counterparts; scale bars equal 10µm. To the 
right: Power peaks of the corresponding T-tubular regularity, (B.) density of the TAT network and (C.) 
regularity of the T-tubules in control cells after 1h in culture and cells treated with cytochalasine D for 48h 
in culture. n=number of single cells measured. Animals utilised n=2. Bars represent mean values ± 
standard error of the mean. Statistical Student’s two sided T-test, **p < 0.001; p=ns; no significant 
difference. 
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Figure 22 Number of longitudinal elements in the TAT network of control cells after 1h of culture and cells 
treated with cytochalasin D for 48h. n=number of single cells measured. Animals utilised n=2. Bars 
represent mean values ± standard error of the mean. Statistical Student’s two-sided T-test, *P < 0.05. 
 
3.4.2 Colchicine decreases the TAT network but not the surface structure of 
cardiomyocytes 
The administration of the pharmacological compound colchicine, which acts as a microtubule 
polymerisation inhibitor in cardiomyocytes, has been shown to have beneficial effects on the 
myocardium, by preventing cell apoptosis (Saji et al 2007) and excessive T-tubule remodelling 
in failing cardiomyocytes by stopping increased microtubule polymerisation which occurs in 
HF (Zhang et al. 2014). 
To see how treatment with colchicine affects the microtubule skeleton of control 
cardiomyocytes and with it the surface structure and the TAT network of cardiomyocytes, cells 
were treated with colchicine for 1h at 37ºC and 5% CO2. The cells were then SICM surface 
scanned and stained with Di-8-ANEPPS and their TAT network was recorded with confocal 
imaging. Then control and colchicine treated cells were fixed and stained with an antibody 
selective for β-tubulin a microtubule marker, before being imaged with the confocal 
microscope again. SICM scanning of control and colchicine treated cardiomyocytes did not 
reveal any effect of microtubule polymerisation onto the surface membrane of cardiomyocytes 
(see figure 23).  However, cells treated with colchicine exhibited a significantly reduced 
amount of about 47% of the relative β-tubulin levels as determined from confocal images in 
comparison to control cardiomyocytes (see figure 24). Cardiomyocyte treatment with 
colchicine furthermore lead to a significant decrease in the integrity of the TAT network and 
reduced the TAT density by around 9% respectively while the T-tubule regularity dropped by 
approximately 28% (see figure 25).     
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Figure 23 Surface structure of ventricular, rat cardiomyocytes from control cells and cells treated with 
colchicine. Representative 10x10 SICM surface scans of (A.) a control cardiomyocyte and (B.) a 
cardiomyocyte treated with the microtubuli polymerisation inhibitor colchicine. (C.) Z-groove index of 
control cardiomyocytes and cells treated with colchicine. n=number of single cells measured. Animals 
utilised n=2. Bars represent mean values ± standard error of the mean. Statistical one-way Student’s two 
sided T-test, p=ns; no significant difference. 
 
Figure 24 TAT network dependency on the cytoskeleton in cardiomyocytes. (A.) Representative confocal 
image of Di-8-ANEPPS staining of a untreated control cardiomyocyte (to the left)) and a cardiomyocyte 
treated with the microtubuli polymerization inhibitor colchicine (to the right). (B.) Representative confocal 
image of β-tubulin staining in the same control and colchicine treated cardiomyocytes shown above with 
40x10 µm areas of interest, which were used to determine relativ β-tubulin levels; scale bars equal 10µm.   
(C.) Relative β-tubulin protein levels in control and colchicine treated cardiomyocytes. n=number of single 
cells measured. Animals utilised n=2. Bars represent mean values ± standard error of the mean. Statistical 
two-sided Student’s T-test, ***p<0.0001. 
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Figure 25. TAT network in untreated control cardiomyocytes and cardiomyocytes treated with the 
microtubuli polymerization inhibitor colchicine. (A.) To the left: Representative confocal images of the TAT 
network with 40x5 µm areas of interest blown up 2.65 times together with their binarised counterparts of 
control cells and cells treated with colchicine; scale bars equal 10µm. To the right: Power peaks of the 
corresponding T-tubular regularity, (B.) density of the TAT network and (C.) regularity of the T-tubules in 
control cells and cells treated with colchicine. n=number of single cells measured. Animals utilised n=3. 
Bars represent mean values ± standard error of the mean. Statistical Student’s two sided T-test, **p<0.001. 
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3.5. Results: Cardiomyocyte structure in humans 
3.5.1. Human ventricular cardiomyocyte structure  
Human ventricular cardiomyocytes possess structures similar to those observed in rat 
cardiomyocytes. Just like in rat these structures are severely disrupted in human 
cardiomyocytes at the end stage of HF (Lyon et al. 2009). Fortunately for this study we are in 
receipt of cardiac tissue from MV and heart transplant patients. These transplant patients have 
suffered from DCM and ICM and some of them were given a LVAD. From these hearts we 
obtained left ventricular cells. Though the MV replacement cells cannot be considered healthy, 
they are not in end stage HF. We here utilized them as our control case due to their slightly 
more intact structures. To see the extent of structural disruption in human cardiomyocytes 
their surface structures were visualised through SICM scanning and analysed together with 
Dr. Jose Sanchez Alonso-Mardones (Imperial College London) (see figure 26). 
Simultaneously the cardiomyocyte’s TAT network was stained with Di-8-ANEPPS before 
confocal imaging. The surface of left ventricular cardiomyocytes isolated from control patients 
possessed a relatively intact surface structure while cardiomyocytes from DCM and ICM 
patients, though practically at the end stage of HF, still exhibited a degree of visible surface 
structures. These surface structures were not increased by the presence of LVADs, but 
showed similar Z-groove index values to the cells from unsupported hearts (see figure 26). 
Ventricular cells from control patients exhibited the highest presence and order of TAT network 
structures, while cells from DCM and ICM hearts showed significantly lower TAT density 
(~51% and ~50% respectively) and regularity (~77% and ~72% respectively) in comparison 
to control patient hearts (see figure 27). The loss of TAT density and T-tubule regularity was 
comparable between the two cardiomyopathies without LVADs. It was however surprising to 
find that the TAT density in human cardiomyocytes from DCM patients who were equipped 
with a LVAD was actually slightly higher than in MV cardiomyocytes (~30%) whereas the 
LVAD had no significant effect on the T-tubule regularity nor on cardiomyocytes from ICM 
patients (see figure 28).     
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Figure 26 Topography of human, ventricular cardiomyocytes from MV surgery and transplant patients. 
10x10 µm SICM surface scans of a ventricular cardiomyocyte isolated from (A.) a patient who underwent 
MV surgery; (B.) patients with ICM without (to the left) and with (to the right) a LVAD or (C.) from patients 
with DCM without (to the left) and with (to the right) a LVAD. (D.) Z-groove index of cardiomoycytes isolated 
from MV surgery patients as well as ICM and DCM patients with and without LVADs. Surface scans of the 
ICM and DCM cardiomyocytes with LVADs and the Z-groove index histogramm were kindly provided by 
Dr. Jose Sanchez Alonso-Mardones (Imperial College London). Statistical one way ANOVA test followed 
by Bonferroni correction post-hoc testing, ***p<0.001, **p<0.01. 
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Figure 27 Human TAT structure in ventricular cardiomyocytes. (A.) From top to bottom: Representative 
confocal images of the TAT network with 40x5 µm areas of interest blown up 2.65 times together with their 
binarised counterparts of human ventricular cells from MV replacement surgery; a human ventricular cell 
from a DCM patient; a human ventricular cell from an ICM patient; scale bars equal 10µm. To the right: 
Power peaks of the corresponding T-tubular regularity. (B.) TAT network density in MV control cells, DCM 
cells and ICM cells. (C.) T-tubule regularity in MV control cells, DCM cells and ICM cells. n=number of single 
cells measured, number of donor patients n=2-4. Bars represent mean values ± standard error of the mean. 
Statistical one-way ANOVA test followed by Bonferroni correction post-hoc testing, ***p<0.0001, **p<0.001, 
*p<0.05. 
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Figure 28 Human TAT structure in ventricular cardiomyocytes from failing hearts with LVADs. (A.) From 
top to bottom: Representative confocal images of the TAT network with 40x5 µm areas of interest blown 
up 2.65 times together with their binarised counterparts of human ventricular cells from a DCM patient with 
a LVAD; from an ICM patient with an LVAD; scale bars equal 10µm. To the right: Power peaks of the 
corresponding T-tubular regularity. (B.) TAT network density in MV control cells, DCM cells and ICM cells. 
(C.) T-tubule regularity in MV control cells, DCM cells and ICM cells. n= number of single cells measured, 
number of donor patients n=2-4. Bars represent mean values ± standard error of the mean. Statistical one-
way ANOVA test followed by Bonferroni correction post-hoc testing, **p<0.001, *p<0.05. 
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3.6. Discussion: Cardiomyocyte structures 
 
3.6.1. Cardiomyocyte structure during HF progression: 
HF is generally a progressive disease (Dickstein et al. 2008). However, the majority of studies 
only concentrate on the TAT network disruption at the end stages of HF and fail to elucidate 
the progressive alterations in the TAT network, which occur during disease progression 
(Wagner et al. 2012; Wei et al. 2012). Chapter 3 described the structural alterations taking 
place in cardiomyocytes in the progression from compensated hypertrophy (at 4 weeks post-
MI) to decompensation (at 8 weeks post-MI) and at the end stage of HF (at 16 weeks post-
MI) in rat cardiomyocytes after the induction of a chronic MI by left anterior descending artery 
(LAD) ligation. The concept of an advancing course for HF in our MI model has been 
corroborated by reports from groups using the same experimental model where the advanced 
signs of HF were observed after 8 week post-MI in rat e.g. reduction of SERCA2 gene 
expression (Zarain-Herzberg et al. 1996), sympathetic nerve stimulation (Ganguly et al. 1997) 
and whole heart morphological and functional changes (Nahrendorf et al. 2001).  
In the acute period of cardiac injury, post-MI, cardiomyocytes are exposed to increased wall 
stress and neuro-hormonal activation (Yan et al. 2008; Clerfond et al. 2015). This instigates 
hypertrophic signaling and the development of a hypertrophic phenotype such as was 
observed already at 4 weeks post-MI in whole heart and at 8 weeks post-MI in single 
cardiomyocyte volume in this thesis. T-tubular structures are able to respond to load via a 
stretch sensitive complex (Knoll et al. 2002). The MI induced mechanical overload induced in 
this study via ligation of the left anterior descending aorta could trigger a decrease in T-tubule 
regularity and density as was also already observed at 4 weeks post-MI in this thesis and 
persisted until 16 weeks post-MI. Our SICM scans showed that Z-grooves reduced steadily 
over the 16 week observation period following MI. The formerly clear surface structures on 
cells were exchanged with areas of a smoother appearance and the gradual disappearance 
of T-tubule openings. Disruption of the highly ordered cardiomyocyte structure, in particular 
by disorganisation and partial loss of the TAT network in the LV, has been observed in a 
variety of MI models and was linked to the impaired contractility observed in HF due to 
asynchronous Ca2+ handling in cardiomyocytes (Heinzel et al. 2008; Wei et al. 2010; Wagner 
et al. 2012) as well as βAR dysregulation (Nikolaev et al. 2010). However, a recent study of 
the TAT network using a high resolution stimulated emission depletion microscopy (STED) 
system also reported a progressive reorganisation and partial elongation of T-tubules at 4 and 
8 weeks post arterial ligation in mice (Wagner et al. 2012). Such changes were undetectable 
by conventional confocal microscopy and hence could not be assessed in this thesis. The 
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significance of the localisation of βARs inside the TAT network and the consequences of TAT 
network alterations on βAR-dependent cyclic nucleotide signalling will be expanded upon in 
the following chapters 4 and 5. One intriguing observation made during the progressional 
stages of hypertrophy towards HF is the rise in longitudinal elements of the TAT network 
(Wagner et al. 2012) which was also observed in the study described herein: At 4 and 8 weeks 
post-MI an increased number of longitudinal TAT elements appeared which may reflect a 
compensatory alteration. This early increase in the number of longitudinal tubules is lost again 
at 16 weeks post-MI at the end stage of HF. HF has been shown to be accompanied by 
cardiomyocyte dedifferentiation and a reactivation of the fetal gene programme (Wagner et al. 
2012). Therefore the structural remodelling observed may also reflect a return to a more ‘fetal 
phenotype’. Interestingly, longitudinal elements have been shown to increase together with 
Cav3 protein expression (Wagner et al. 2012). A recent publication, which in HF shows 
increased formation of longitudinal depositions of α-actinin, a cytoskeletal protein vital for 
sarcomere formation might build a substrate along which the longitudinal tubules might form 
(Lichter et al. 2014). Hence after cardiac injury the TAT network undergoes progressive and 
complex structural remodelling which at first is compensatory but turns adverse at the later 
stages of HF. Investigating possible molecular mechanisms underpinning the early structural 
remodelling of cardiomyocytes, one of the proteins involved in the maintenance of T-tubules, 
JPH2, decreased dramatically as early as 4 weeks and remained low throughout the 
progression towards HF. JPH2 maintains the junctions between TAT elements and the SR 
(Gorelik et al. 2013). Structural proteins like JPH2 and Cav3 have been shown to be 
downregulated in hypertrophy and HF (Minamisawa et al. 2004). Though JPH2 and Cav3 
appear to be associated (Minamisawa et al. 2004), knockdown of JPH2 did not induce any 
changes in Cav3 (Chen et al. 2013). Recently JPH2 ovexpression was shown to attenuate 
TAT network damage due to pressure oveload (Guo et al. 2014). In this work JPH2 was 
already decreased early on and hence remodelling of the TAT network may in part be triggered 
by down-regulation of JPH2. This suggestion is corroborrated by the finding that junctophilins 
appear to be partly responsible for the orientation of tubules in the TAT network (Bennett et 
al. 2013; Pinali et al. 2013). The functional consequences of the observed alterations in the 
TAT network described in chapter 3 will be elaborated upon in chapters 4 and 5 in regard to 
cAMP and cGMP second messenger signalling. As was mentioned in the general introduction 
(see chapter 1, paragraph 1.7.1.) there are more possible candidates which could be crucially 
altered during HF progression such as tropomyosin, BIN1 and Tcap. Expression of two of 
these candidates, BIN1 and Tcap, has been shown to be decreased during HF (Lyon et al. 
2012). Tcap has been indicated as a regulator of T-tubule formation according to the 
mechanical load which the respective cells experience (Zhang et al. 2009), whereas BIN1 
appears to serve as T-tubule maintainer and membrane curvature inducer (Hong et al. 2010). 
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Interestingly gene therapy with SERCA2a in HF cells lead to structural reverse remodelling 
and a return of BIN1 and Tcap levels comparable to control cells but not of JPH2 protein levels 
(Lyon et al. 2012).  
 
3.6.2. Cardiomyocyte dedifferentiation due to long term culture: 
It is well established, that primary cells in culture suffer from dedifferentiation (Mitcheson et al. 
1998). Especially the FRET experiments described in this thesis in the following chapters have 
to be interpreted with this fact in mind. During the structural investigation of cardiomyocytes 
after only 1h of culture in comparison to cardiomyocytes after 48h of culture with and without 
viral transfection we revealed TAT network damage similar to that observed in cells freshly 
isolated from animals with myocardial infarction. This is a big limitation when it comes to the 
investigation of the physiological role of the cardiomyocyte structure in physiological function. 
At the same time the surface structures of cardiomyocytes were still intact. 
 
3.6.3. Colchicine and cytochalasin D effects on cardiomyocyte structure 
It has been shown repeatedly, that primary cell lines in culture progressively lose their 
physiological phenotype and dedifferentiate (Tian et al. 2012; Mitcheson et al. 1998). A recent 
study claimed that submicromolar levels of the filamentous actin polymerisation inhibitor 
cytochalasin D can counteract culture related cardiomyocyte dedifferentiation. While testing 
the validity of this claim it was evident, that the T-Tubule regularity of cardiomyocytes still 
decreased in culture. However at the same time cardiomyocytes treated with cytochalasin D 
created increased longitudinal elements between their T-tubules, which kept the TAT network 
density similar to that in control cardiomyocytes.This might explain why prior reports did not 
see a functional change in cytochalasin D treated cells, as the longitudinal cells could 
compensate for the observed loss loss in T-tubule regularity (Tian et al. 2012). A similar 
increase in longitudinal elements can also be observed in cardiomyocytes stemming from 
hearts during their progression towards HF but not at the end stage of HF. As a consequence 
the data obtained from the cytochalsin D treatment might be more insightful into the 
pathophysiology of chronic HF than expected. Interestingly, a recent study showed that α-
actin forms increased longitudinal depositions in the cytoskeleton during HF (Lichter et al. 
2014). The increased number of longitudinal tubules observed in this thesis after cytochalasin 
D treatment and in HF cells could therefore form along these α-actin depositions. So if the 
cytochalasin D used here solely affected the actin filament polymerisation and had indeed no 
other side effects, then it could be interpreted from the data presented here, that it is disturbed 
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actin filament polymerisation, which supports the generation of longitudinal elements in 
between T-tubules. This deduction is based on the assumption that the microtubuli are not the 
target of the drug cytochalasin D therefore they should be unaffected and potentially should 
still be able to rearrange the TAT network composition, while the actin filaments are blocked 
from polymerising. Another study approach in chapter 3 was to test the importance of the 
microtubule cytoskeleton in regard to the structural integrity of the TAT network by applying 
the microtubule polymerisation disruptor colchicine. Colchicine treatment of control 
cardiomyocytes significantly decreased the β-tubulin amount. Colchicine furthermore lead to 
a decrease in the TAT network density and T-tubule regularity but not of the surface structure 
of cardiomyocytes. In the case of HF where tubulin is supposedly increased it might not lead 
to TAT network deterioration but could indeed serve to conserve the cardiomyocyte structure 
(Nishimura et al. 2006). As colchicine was applied for 1h only before confocal imaging of the 
cells the colchicine data also implies that the TAT network is under constant reformation which 
is facilitated by the cytoskeleton. Therefore chapter 3 also demonstrated the importance of the 
microtubule and filament cytoskeleton in maintaining the TAT network structure. Through the 
treatment of the cytoskeleton in cardiomyocytes with colchicine and the aforementioned 
cytochalasin D one can affect the intactness of the TAT network and it can either be chemically 
deteriorated or to some degree stabilized for cell culture. The aforementioned results and 
discussion lead to the additional observation that the surface structures of cardiomyocytes do 
not depend on the internal TAT network structures and vice versa. It therefore should be 
concluded, that these two structural aspects arise and are maintained by different factors. In 
case of the TAT network the microtubule and filament cytoskeleton is a likely candidate of 
such a factor as was shown with the cytochalasin D and colchicine treatment of 
cardiomyocytes, whereas the surface structure determinants might be of a more mechanical 
nature. This deduction is based on the observation that surface structures are significantly 
decreased during HF progression but neither by chemical treatments nor by long term culture 
(48h) in which the cells are immobilized by the reduced presence of Ca2+ needed for 
contraction.  
  
3.6.4. Human cardiomyocyte TAT network structures from dilated cardiomyopathy 
patients benefit from LVADs 
Human cardiomyocytes from the left ventricle possess similar structures to rat 
cardiomyocytes. These structures however undergo strong structural deterioration in all types 
of defined human cardiomyopathies. Like in rat the loss of TAT network structures in humans 
was previously associated with decreased contractility and Ca2+ homogeneity (Lyon et al. 
2009).  In this thesis it is was hard to determine just how similar healthy human cardiomyocyte 
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structures are to healthy rat cardiomyocyte structures for lack of healthy, human control 
samples. In their stead cardiomyocytes from patients undergoing MV replacement surgery 
were obtained and designated as control. Prior work by our group showed that unfailing human 
cardiomyocytes possess a Z-groove index of approximately 0.82 (Lyon et al. 2009), which is 
twice as high as the value obtained in cardiomyocytes from MV patients. Unfortunately the 
same study did not measure the TAT network density and T-tubule regularity in a similar 
fashion as was done in this theses, but analogous decreases in the two values would be 
expected in cardiomyocytes from non-failing versus MV patient hearts. Failing human 
cardiomyocytes were obtained from patients with DCM or ICM with and without LVADs. Both 
DCM and ICM cardiomyocytes without an LVAD showed an even further decrease in the Z-
groove index and TAT network presence than MV cardiomyocytes. The most surprising finding 
during the investigation of human cardiomyocyte structures was the observation that DCM 
patients with LVADs had a slightly increased TAT network density but a decreased T-tubule 
regularity in comparison to MV patients. This was due to a change in alignment of the T-
tubules in the DCM plus LVAD patients. In ICM patients the LVAD showed no such effect on 
structure. This might be an indication that an LVAD in DCM patients is more beneficial than in 
patients with ischemic injuries. It would be interesting to observe if these differences can be 
reiterated to a differential microRNA expression profile between the two cardiomyopathies as 
it was reported that the LVADs can reinstate a less pathological microRNA profile in humans 
(Matkovich et al. 2009). 
 
3.6.5. Reverse structural remodelling 
As was elaborated upon in chapter 3 and in previous publications from our group (Lyon et al. 
2009; Ibrahim et al. 2012) structural deterioration of cardiomyocytes is a commonly observed 
feature in cardiomyopathies from various species, including human and rat cardiomyocytes. 
Though it is not yet fully understood if this structural deterioration is cause or effect (or both) 
of the functional insufficiency observed in HF, ways to reverse remodel the setup of the failing 
myocardium are thought to potentially remedy HF. Our own group has shown that SERCA2a 
gene therapy (Lyon et al. 2012) and mechanical unloading (Ibrahim et al. 2012) can rescue 
the structural phenotype as well as the functional efficiency of cardiomyocytes in regard to 
Ca2+ handling and contractility to some extent. The reason for this reverse structural as well 
as functional remodelling is thought to be a partial return of β2ARs, which had emigrated out 
of the T-tubules, as well as a return in expression of the structural proteins BIN1 and Tcap. 
Interestingly during the SERCA2a gene therapy study expression of the structural protein 
JPH2 was not reinstated (Lyon et al. 2012). A recent study in mouse which uses JPH2 
overexpression to determine its role in cardiac structure and function (Guo et al. 2014) yields 
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a complementary insight into our SERCA2a study. In this study JPH2 overexpression lead to 
a rise in physical bridging of the SR with the T-tubules and a rise in NCX1 protein levels in 
control cardiomyocytes. This was however not accompanied by a rise in SERCA2a showing 
that JPH2 and SERCA2a and their associated effects on the TAT network are independent of 
each other. The same study also showed that JPH2 overexpression is protective against 
pressure overload induced cardiac injury and damage to the TAT network (Guo et al. 2014). 
It remains to be determined if JPH2 overexpression in a model of end stage HF could lead to 
reverse functional and structural remodelling. 
3.6.6. Conclusion regarding cardiomyocyte structure 
The structural investigation in chapter 3 elucidated the progressional alterations which the 
surface membrane structures of cardiomyocytes experience during the progression from 
health towards HF after a MI and identified a drastic decrease in the structural protein JPH2 
early after myocardial injury. The potential consequences of the maintained lack in JPH2 levels 
on β2AR-dependent cAMP signalling will be reiterated in chapter 4 (see chapter 4, paragraph 
4.3.6). Chapter 3 furthermore showed that treatment with cytochalasin D can affect the TAT 
network via the cytoskeleton and that it is potentially the microtubule cytoskeleton which plays 
a role in forming longitudinal elements, which are transiently increased during HF progression. 
Interstingly a recent study showed that microtubule are also important for positioning JPH2 
proteins between the T-tubules and the SR (Zhang et al. 2014). The microtubule network has 
been shown to be increased in HF (Nishimura et al. 2006) and in this study we showed that 
colchicine treatment of cardiomyocytes can directly affect the TAT network by decreasing the 
number of microtubules. The focus of chapter 3 was on cardiomyocyte structure, however it 
only marginally investigated the involvement of various proteins in cardiac structure. Though 
a list of candidates have been identified (BIN1, Tcap, Cav3, etc.), definite information is still 
lacking on which proteins are the major factors for structural maturation, maintenance and 
reformation of the TAT network (Ibrahim et al. 2011). In our experimental animal model as well 
as in prior publications (Bennet et al. 2013; Zhang et al. 2014) the expression of the structural 
protein JPH2 decreased early after the induction of myocardial injury and therefore attracted 
our attention. We believe it is strongly involved in worsening the progression of 
cardiomyocytes towards HF. 
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4.1. Introduction 
The previous chapter established structural aspects of cardiomyocytes, which are important 
for the physiological arrangement of ARs on different sites of the sarcolemma and for efficient 
excitation-contraction coupling of cardiomyocytes. Utilizing SICM and FRET imaging our 
group recently showed that there is a clear segregation of the 1AR and 2AR location on the 
plasma membrane of healthy cardiomyocytes. While the 1AR are distributed throughout the 
sarcolemma 2ARs solely inhabit the T-tubule openings of cardiomyocytes (Nikolaev et al. 
2010). As was shown before these T-tubule structures are severely lost or altered during the 
progression of HF (Wagner et al. 2012; Wei et al. 2012). In healthy cardiomyocytes, ligand 
binding to the 2ARs generates highly localised cAMP pools, which regulate and are regulated 
by confined, functional compartments, which are different from those of the diffusive 1AR 
dependent cAMP pools (Nikolaev et al. 2006). These compartments consist, among other 
proteins, of PDEs, protein kinases and other downstream targets of cAMP and their 
arrangement changes drastically at the end stage of HF. This rearrangement is reflected in 
strongly downregulated 1AR levels (Lohse et al. 2003) as well as β2ARs receptor 
redistribution from the T-tubules to the crests (Nikolaev et al. 2010). Therefore, pathological 
remodelling of the TAT network at the end stage of HF is strongly associated with dysregulated 
AR-dependent cAMP signalling. In addition to the structural aspects of cardiomyocytes, AR-
dependent cAMP compartmentation is achieved by the position and activity of its producing 
ACs and its degrading PDEs, which are associated with them (Stangherlin and Zaccolo 2012). 
The spatial loss of β2AR-dependent cAMP compartmentation in end stage HF leads to the 
activation of unphysiological downstream signalling targets. When and to what extent β2AR 
redistribution and loss of compartmentation of its associated cAMP pools appears during the 
progression of left ventricular hypertrophy to the end stage of HF has not been investigated 
before. Therefore chapter 4 highlights the importance of stringently controlled and spatially 
confined 2AR dependent cAMP signalling and investigates the pathophysiological changes 
which occur in cardiomyocyte 2AR signalling during the progression of HF. As in the 
preceding chapter a model of progressive MI was used for single cell isolation and the 
progressive time points after MI were defined as compensatory (4 weeks post-MI), 
decompensated (8 weeks post-MI) and at the end stage of HF (16 weeks post-MI). The 
standard way of measuring the ubiquitous, second messenger molecule cAMP used to be 
biochemical studies such as radioligand binding after cell and tissue lysation. Though these 
studies proved informative in regard to the levels of total cAMP produced in various 
cell and tissue types as well as pathologies they could not reveal the convoluted, 
spatiotemporal 
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dynamics of second messenger signalling at specific locations and concentrations in live cells. 
Fortunately the requirement of second messenger detection approaches in live cells and in 
real time was increasingly realized by both the artificial introduction of cyclic nucleotide-gated 
channel (CNGC) based measuring approaches as well as the development of specific FRET 
biosensors (Sartiani et al. 2002, Nikolaev et al. 2004). For the investigation of the β2AR 
dependent cAMP signalling levels in control cardiomyocytes and the changes occurring during 
the progression of HF the cytosolic or plasma membrane bound FRET sensor Epac2-camps 
was used. Basal cAMP levels and maximally detectable FRET responses as well as the major 
cAMP degrading PDEs were assessed in control cardiomyocytes. Ensuing whole cell and 
localised cAMP FRET measurements were conducted in cardiomyocytes isolated from control 
hearts and at 4, 8 and 16 weeks post-MI to determine progressive alterations in cAMP levels 
and diffusion in the cytosol. 
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4.2. Methods and Materials 
 
4.2.1. Cardiomyocyte transduction with cAMP FRET biosensors  
After their attachment to the glass bottom of laminine coated, glass-bottom dishes adult 
cardiomyocytes from age matched control rats and rats at 4, 8 and 16 weeks post-MI were 
transduced with virus encoding the cytosolic cAMP FRET sensor Epac2-camps or the plasma 
membrane bound cAMP FRET sensor Epac2-camps (see figure 29) at a multiplicity of 
infection of 300-500 virus particles per cell for 48h to determine β2AR dependent cAMP levels 
and diffusion after local and global catecholaminergic stimulation. 
 
Figure 29. The FRET measurement principle of relative cAMP levels using the FRET construct EPAC2-
cAMPs.  At the top: The construct is based on a cyan fluorescent protein CFP, the cAMP binding domain 
of the type 2 exchange protein activated by cAMP (EPAC2) and a yellow fluorescent protein (YFP).   Left 
hand side: In the absence of cAMP the FRET donor CFP gives part of its energy in a non-radiative fashion 
to the proximal, FRET acceptor YFP. Right hand side: The presence and binding of cAMP leads to a 
conformational change of the FRET biosensor, which removes YFP from the proximity of CFP, which in 
turn can no longer transfer any energy onto YFP.   
 
4.2.2. Determining basal and maximally inducible cAMP FRET response 
The level of basal cAMP in primary, transgenic mouse cardiomyocytes expressing the cAMP 
FRET sensor Epac1-camps lies around 1µM (Börner et al. 2011). In order to determine how 
high the relative, basal cAMP levels are in rat cardiomyocytes after 48h of transduction with 
the cAMP FRET sensor Epac2-camps, ACs were blocked with 100µM MDL-12,330A 
hydrochloride while recording the FRET signal. Consecutively the maximally inducible cAMP 
FRET response of whole cells was measured by applying the non-degradable cAMP analogue 
8-Br-2′-O-Me-cAMP. Though it has to be mentioned that the affinity of the FRET sensors to 
cAMP analogues is different to actual cAMP molecules the analogue can still give an 
approximate indication of how high the FRET amplitude can become in a certain cell type and 
under certain conditions. It also allows determination of the variability of detectable basal and 
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maximally inducible cAMP levels in cultured cardiomyocytes, which might be a lot higher in 
transduced cells than in cells from transgenic animals due to uneven FRET sensor expression 
(Börner et al. 2011). 
 
4.2.3. Whole cell β2AR dependent cAMP FRET imaging in cardiomyocytes 
Whole cell β2AR dependent cAMP signals were measured in cardiomyocytes expressing the 
cytosolic Epac2-camps FRET biosensor. For this a custom-made, gravity based perfusion 
system was employed to deliver and remove drugs into and from the external solution. During 
calibrations, complete replacement of extracellular solution was achieved in less than 5 
seconds. To avoid cross-stimulation of β1ARs all FRET experiments were performed with 
solutions containing 100nM of the β1AR blocker CGP20712A.  Whole-cell β2AR stimulation 
was achieved with 100nM ISO; and subsequent whole cell AC stimulation was achieved with 
5µM NKH477. Experimental whole cell cAMP signal measurements were conducted together 
with Dr. Sergiy Tokar (Imperial College London). The analysis of the resulting FRET data was 
primarily performed by me. The FRET data was corrected for bleed-through of CFP emission 
into the YFP spectrum and analysed as it was described previously (Nikolaev et al. 2010). In 
short the Micro-Manager files were opened and regions of interest were drawn around the 
whole cell. Then the changes in pixel intensity of the recorded FRET images from the YFP 
and the CFP channel were calculated over the recorded time and their ratio was determined. 
The FRET signal was recorded using a Hamamatsu ORCA ER camera (Hamamatsu) and 
Micro-Manager 1.4 with custom-written FRET analysis plugins. The obtained raw data was 
processed with the use of baseline correction functions using Origin Pro 8.5 (Origin Lab 
Corporation) and recurring noise was reduced via 3 Median smoothing. The FRET response 
was calculated by averaging the values of 10 frames of the baseline signal and 10 frames of 
the response signal and by subtraction of the averaged response from the averaged baseline. 
 
4.2.4. Testing of whole cell PDE4 regulation of β2AR dependent cAMP levels during HF 
progression 
Measurements of β2AR-dependent cAMP FRET signals in control cardiomyocytes and 
cardiomyocytes 4, 8 and 16 weeks post-MI during the application of the PDE4 blocker 
Rolipram (ROLI) were conducted. For this cells were treated with 100nM of the β1AR blocker 
CGP207 12A for at least five minutes before 100nM ISO followed by a bolus of 10µM/L of the 
specific PDE4 blocker ROLI and 100µM of the non-selctive PDE inhibitor 3-Isobutyl-1-
methylxanthine (IBMX) were directly applied into the cell bath while recording the FRET 
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response. Measurements and analysis were conducted together with Dr. Sergiy Tokar 
(Imperial College London). Just as before the obtained raw data was processed by applying 
baseline correction functions from the software Origin Pro 8.5 (Origin Lab Corporation). 
Recurring noise was reduced via 3 Median smoothing. The FRET response was calculated 
by averaging the values of 10 frames of the baseline signal and 10 frames of the response 
signal and by subtraction of the averaged response from the averaged baseline. 
 
4.2.5. FRET/SICM imaging of locally stimulated β2AR dependent cAMP levels in T-tubule 
openings and on cell crests.  
Topography images of 10x10 µm areas of age matched control cardiomyocytes and 
cardiomyocytes 4, 8 and 16 weeks post MI were obtained using SICM to elucidate the position 
of T-tubule openings and crests. After blocking of β1ARs through the superfusion of 100nM 
CGP20712A for at least 5 min β2ARs were stimulated locally for 50 seconds via the SICM 
nano-pipette containing 50µM ISO and 50µM CGP20712A by applying pressure as described 
(Nikolaev et al. 2010) or via voltage application by switching the relative electrical potential 
inside the scanning nano-pipette from negative (-200 mV) to positive (400mV). A gravity based 
perfusion system continuously replaced the bath solution in less than 5 seconds. The drugs 
were applied either to the T-tubule openings or to the crest areas, the coordinates of which 
were determined by observing SICM topography images. All measurements were conducted 
together with Dr. Sergiy Tokar (Imperial College London) except for additional experiments in 
control cardiomyocytes and cardiomyocytes at 16 weeks post MI, which were exclusively 
performed by myself. For these the nano-pipette was lowered to approximately 500 nm above 
the respective surface structures before applying the agonist via the aforementioned voltage 
switch. The FRET signal was recorded and analyzed as before by the use of baseline 
correction functions from the software Origin Pro 8.5 (Origin Lab Corporation) and recurring 
noise was reduced via 3 Median smoothing. As before the FRET response was calculated by 
averaging the values of 10 frames of the baseline signal and 10 frames of the response signal 
and by subtraction of the averaged response from the averaged baseline. 
 
4.2.6. cAMP signal diffusion study 
To study cAMP diffusion inside the cytosol cardiomyocytes from age matched control hearts 
and hearts at 4, 8 and 16 weeks post-MI were transduced with virus encoding the cytosolic 
FRET sensor Epac2-camps.  To ascertain, that the FRET sensor itself did not lead to a further 
diffusion of the cAMP FRET signal by either its own movement or by helping cAMP to evade 
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degradation by PDEs seperate control cardiomyocytes were transduced with virus encoding 
the plasma-membrane bound FRET sensor Epac2-camps. Then propagation of the cAMP 
signal was studied after localized β2AR stimulation via the nanopipette at different distances 
from the original nano-pipette stimulation site. For this FRET data was opened in Micro-
Manager 1.4 and regions of interest (ROI) of about 15 microns width were drawn repeatedly 
at ever more distant areas to the nano-pipette. Then the FRET response amplitude was 
measured in these ROIs. The response was accounted as local when the amplitude of cAMP 
dropped by more than 50% when measured at a distance of 15 to 30µM from the pipette. 
Otherwise the response was considered as diffusing throughout the whole cardiomyocyte. As 
before the obtained data was processed by using the baseline correction functions in the 
software Origin Pro 8.5 (Origin Lab Corporation) followed by 3 median smoothing. Additionally 
data obtained in our group in a study of SERCA2a gene therapy in the same chronic, rat MI 
model used in this thesis was reanalyzed in regard to cAMP diffusion. In the study SERCA2a 
induced reverse structural remodeling in cardiomyocytes which lead to a reinstatement of the 
TAT network and a return of β2ARs from the crest into the T-tubules (Lyon et al. 2012).  Also, 
in order to test if coupling to Gi is involved in β2AR-dependent cAMP signal compartmentation, 
pertussis toxin (PTX) treated control cardiomyocytes from another prior study (Nikolaev et al. 
2010) were reanalyzed in regard to cAMP diffusion. PTX adds an ADP-ribose moiety onto the 
the α subunit of Gi and prevents β2AR coupling with Gi and has been shown to increase β2AR-
dependent cardiomyocyte contractility (Xiao et al. 1995). 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Cardiomyocyte β2AR signalling 
110 
 
4.3. Results:  
 
4.3.1. Measurable cAMP levels are relatively uniform in transduced cardiomyocytes  
Even in an unstimulated state cardiomyocytes in vivo and in vitro produce basal levels of 
cAMP. Due to culture conditions these basal secondary messenger levels could presumably 
be altered and skew cAMP measurements if the FRET sensor is differentially saturated at the 
beginning of FRET response measurements (Börner et al. 2011). Hence cardiomyocytes were 
treated with the AC inhibitor MDL-12,330A to deplete cAMP levels as far as possible through 
PDE degradation. This treatment was followed up with the application of the non-degradable 
cAMP analogue 8-Br-2′-O-Me-cAMP to elicit the maximally detectable FRET ratio response 
by the cAMP biosensor Epac-cAMPs. Though the sample numbers are quite low, the data 
shows that basal cAMP levels are low in comparison to maximally inducible cAMP levels (see 
figure 30).  
 
Figure 30 Determination of basal and maximally inducible FRET responses in isolated cardiomyocytes. 
(A.) Representative FRET signal curve of a cardiomyocyte expressing cytosolic Epac2-camps showing 
FRET signal under a cAMP depleted state (black dotted line) obtained by blocking all adenlylate cyclases 
with the inhibitor MDL-12, 330A, the level of basal cAMP (red dotted line) as is measured at the beginning 
of the recording as the baseline and the maximally inducible cAMP FRET signal (dotted green line) by 
consecutive cell perfusion with the cell membrane permeable, cAMP analogue 8-Br-2’-O-Me-cAMP. (B.) 
Basal and maximally inducible Epac2-camps FRET response.  n= number of single cells measured / 
number of animals utilised for testing. Bars represent mean values ± standard error of the mean.     
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4.3.2. β2AR-dependent whole cell cAMP levels alter during HF progression 
To assess relative, whole cell β2AR-dependent cAMP levels and their alterations during the 
progression of HF cardiomyocytes expressing the cytosolic cAMP FRET biosensor Epac2-
camps were stimulated with ISO and the AC activator NKH477 after β1AR inhibition with 
CGP20712A. The results showed that whole cell β2AR-dependent cAMP levels were 
decreased significantly by about 30% as soon as 4 weeks post-MI. Contrary to what might 
have been expected at 8 weeks post-MI the level of response recovered to the β2AR-
dependent cAMP levels observed in control cardiomyocytes. Ultimately at 16 weeks post-MI 
a significant decrease in both β2AR-dependent cAMP levels (~48%) and the overall AC 
produced cAMP levels (~63%) as compared to control cells was established (see figure 31).  
 
Figure 31 ß2AR dependent and maximally inducible, AC dependent cAMP FRET signal during HF 
progression in age-matched and sham-operated control cardiomyocytes and at 4, 8 and 16 weeks post MI 
after whole cell ß1AR inhibition with CGP 20712A and stimulation with ISO and NKH477. n= number of 
single cells measured. Animals utilised n≥4 for every time point. Scatter-blots with mean values indicated 
as black line. Statistical one way ANOVA test followed by Bonferroni correction post-hoc testing, ***p < 
0.0001; **p < 0.001; *p < 0.05. 
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4.3.3. PDE4 regulates FRET detectable β2AR-dependent cAMP levels during HF 
progression with unaltered activity 
The cAMP hydrolysing PDE4 plays an important role in β2AR-dependent cAMP signalling 
compartmentation (Lynch et al. 2007; Nikolaev et al. 2010). To uncover if PDE 4 activity in 
regard to β2AR-dependent cAMP degradation changes in our model of progressive HF control 
cells and cells at 4, 8 and 16 weeks post-MI were stimulated with ISO after β1AR inhibition 
with CGP20712A and then perfused with the specific PDE 4 inhibitor ROLI, before addition of 
the non-selective PDE blocker IBMX. According to our results the overall activity of PDE4 on 
β2AR-dependent cAMP levels did not falter nor increase during the progression of HF 
according to the FRET measurements (see figure 32). 
 
Figure 32 β2AR-dependent cAMP FRET response stimulated with ISO after β1AR inhibition followed by 
selective PDE4 inhibition. Activity of PDE4 determined as fold change increase in the cAMP FRET response 
induced by β2AR stimulation with ISO after β1AR inhibition and addition of the PDE4 inhibitor ROLI in age 
matched control and sham-operated control cardiomyocytes and cells at 4, 8 and 16 weeks post-MI. n= 
number of single cells measured. Animals utilised n≥4 for every time point.  Bars represent mean values ± 
standard error of the mean. Statistical one way ANOVA test followed by Bonferroni correction post-hoc 
testing. p= ns; no significant difference. 
 
4.3.4. Locally stimulated β2AR-dependent cAMP levels and the position of β2ARs change 
during HF progression  
In healthy cardiomyocytes the β2AR does not reside at the sarcolemmal membranes outside 
of the T-tubules. In end stage HF however this placing changes through the redistribution of a 
portion of the β2ARs to the whole sarcolemma (Nikolaev et al. 2010). Presumably this 
redistribution takes place gradually during the development of end stage HF. Utilizing the same 
SICM/FRET combination our group utilized in the past to initially reveal the migration of β2ARs 
out of the T-tubule openings (Nikolaev et al. 2010) the local β2AR-dependent cAMP FRET 
response was measured after local receptor stimulation via the SICM nanopipette in T-tubules 
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and on crest areas of age matched control cardiomyocytes and cardiomyocytes 4, 8 and 16 
weeks post-MI. As in a previous study from our group (Nikolaev et al. 2010) the β2AR-
dependent cAMP response in control cardiomyocytes was 5-fold larger in the T-tubule 
openings than when stimulated at the crests. At 4 weeks post MI the β2AR-dependent cAMP 
in T-tubule openings decreased to approximately 28% of the response observed in control 
cells while no alteration took place at the crest areas. Consecutively at 8 weeks post-MI β2AR 
stimulation at the cardiomyocyte crest elicited a surge of around 3 fold in cAMP levels 
compared to control cardiomyocytes. This indicates that the redistribution of β2ARs takes 
place at the stage of decompensation (8 weeks post-MI). No further significant changes in 
locally stimulated β2AR-dependent cAMP levels were observed at 16 weeks post-MI (see 
figure 33).    
 
Figure 33 Progressive changes in the β2AR dependent cAMP response to local stimulation at different time 
points after MI. (A.) Representative β2ARs-cAMP FRET response curves after local β2ARs stimulation either 
in T-tubule openings (red trace) or on crest areas (black trace) of age-matched and sham-operated control 
cardiomyocytes and cardiomyocytes 4, 8 and 16 weeks post-MI. Local β2ARs-cAMP FRET response after 
agonist application into (B.) T-tubule or (C.) crest. n= number of single cells measured. Animals utilised 
n≥4 for every time point.  Bars represent mean values ± standard error of the mean. Statistical one way 
ANOVA test followed by Bonferroni correction post-hoc testing, ***p < 0.0001; **p < 0.001; *p < 0.05. 
 
4.3.5. β2AR-dependent cAMP compartmentation is lost during HF progression 
Using the SICM/FRET combination described before (Nikolaev et al. 2010) allows for the 
determination of β2AR-dependent cAMP signal diffusion in cardiomyoctes after local 
stimulation in the T-tubule openings.  To determine when β2AR-dependent cAMP signal 
confinement is lost during the progression from health towards end stage HF the distance of 
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cAMP diffusion after local stimulation of β2AR in cardiomyocytes was assessed in control cells 
and during the progression of HF after cardiomyocyte transduction with the cytosolic, freely 
diffusible FRET sensor Epac2-camps. Additionally control cells were transduced with virus 
encoding the plasma membrane bound cAMP FRET sensor Epac2-camps to ascertain that 
the freely diffusible cAMP sensor did not carry cAMP molecules farther than would be the case 
with an immobile sensor. There was no significant difference in the recorded cAMP diffusion 
distances observed in cardiomyocytes expressing either the cytosolic or plasma membrane 
bound cAMP FRET sensor (see figure 34). The results furthermore indicate, that while β2AR 
dependent cAMP does not diffuse further than 15 up to 30µm after local stimulation in T-tubule 
openings in control cardiomyocytes the cAMP signal confinement is lost in cardiomyocytes as 
early as 4 weeks post-MI and remains this way until end stage HF (see figure 35).  
 
Figure 34 Diffusion of cAMP after local stimulation of β2ARs in T-tubule opening of a cardiomyocyte 
expressing the plasma membrane bound cAMP sensor Epac2-camps. (A.) representative, fluorescent 
image of a cardiomyocytes expressing the plasma mebrane bound Epac2-camps cAMP sensor to indicate 
areas of interest (coloured ovals) situated at various distances from the point of stimulation (indicated by 
white arrows) where FRET was measured after local stimulation of β2ARs; scale bars equal 20µm. (B.) 
corresponding FRET response curves in the four areas of interest as indicated on FRET cell images (same 
colours correlate to same areas of measurement) (n=6, from 2 animals).  
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Figure 35 Diffusion of cAMP after local stimulation of β2ARs in T-tubule openings at different time points 
after MI. (A.) representative, fluorescent images of cardiomyocytes expressing the cytosolic Epac2-camps 
cAMP sensor to indicate areas of interest (coloured ovals) situated at various distances from the point of 
stimulation (indicated by white arrows) where FRET was measured after local stimulation of β2ARs; Scale 
bars equal 20 µm. (B.) Corresponding FRET response curves in the four areas of interest as indicated on 
FRET cell images (same colours correlate to same areas of measurement) (n≥10, from 4-5 animals each). 
 
4.3.6. SERCA2a induced reverse structural remodelling does not confine β2AR dependent 
cAMP signalling  
Prior work conducted in our group introduced SERCA2a overexpression into the same rat HF 
model, which was used for this thesis, at 16 weeks post-MI (Lyon et al. 2012). This SERCA2a 
gene therapy led to reverse structural and functional remodelling, including the full to partial 
return of β2AR into the T-tubules. To obtain further insight into β2AR-dependent cAMP 
signalling after reverse structural remodelling, data from this prior work was re-examined in 
regard to cAMP diffusion as this had not been done before. Interestingly β2AR-dependent 
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cAMP diffusion was not stopped in SERCA2a gene therapy treated cardiomyocytes but still 
diffused throughout the whole cytosol (see figure 36).  
 
Figure 36 Diffusion of cAMP after local stimulation of β2ARs in T-tubule opening of a cardiomyocyte 
expressing the cytosolic cAMP sensor Epac2-camps from a rat with chronic MI after SERCA2a gene 
therapy. (A.) representative, fluorescent image of a cardiomyocytes expressing the cytosolic Epac2-camps 
cAMP sensor to indicate areas of interest (coloured ovals) situated at various distances from the point of 
stimulation (indicated by white arrow) where FRET was measured after local stimulation of β2ARs; Scale 
bar equals 5µm. (B.) corresponding FRET response curves in the four areas of interest as indicated on 
FRET cell images (same colours correlate to same areas of measurement) show no restoration of β2AR-
cAMP confinement to the restored TAT network (sample number n=14, from 4 animals). 
 
4.3.7. PTX induced cAMP signal diffusion in control cardiomyocytes 
It was shown that Gi protein is susceptible to receptor uncoupling via pertussis toxin treatment 
and that Gi uncoupling leads to an increase in β2AR dependent cardiomyocyte contractility 
(Xiao et al. 1995). In a prior study our group treated cardiomyocytes with PTX before 
stimulating β2AR-dependent cAMP signalling locally (Nikolaev et al. 2010). In order to 
investigate if Gi uncoupling might lead to the loss of β2AR-dependent cAMP confinement the 
data was reanalyzed and showed that cAMP confinement was indeed lost after PTX treatment 
of cardiomyocytes (see figure 37).  
 
Figure 37 Diffusion of cAMP after local stimulation of β2ARs in T-tubule opening of a control cardiomyocyte 
treated with pertussis toxin. (A.) representative, fluorescent image of a cardiomyocytes expressing the 
cytosolic Epac2-camps cAMP sensor to indicate areas of interest (coloured ovals) situated at various 
distances from the point of stimulation (indicated by white arrow) where FRET was measured after local 
stimulation of β2ARs; scale bar equals 5µm. (B.) corresponding FRET response curves in the four areas of 
interest as indicated on FRET cell images (same colours correlate to same areas of measurement) show 
β2AR-cAMP diffusion throughout the cytosol (n=9, from 3 animals). 
Chapter 4: Cardiomyocyte β2AR signalling 
117 
 
4.4. Discussion: β2AR-dependent cAMP signalling  
 
4.4.1. Whole cell and localised β2AR-dependent cAMP signalling 
In the FRET study of whole cell β2AR-dependent cAMP levels stimulated by ISO during β1AR 
inhibition a drop in cAMP levels was observed at only 4 weeks post-MI. At 8 weeks post-MI 
this decrease reversed into a slight increase of cAMP levels in comparison to control 
cardiomyocytes. Finally at 16 weeks post-MI the cAMP signal again receded to cAMP levels 
below those observed in control cardiomyocytes (see figure 31). According to literature β1AR 
expression declines in HF by up to 50% the number of β2ARs however appears to be stable 
(Madamanchi 2007). Hence changes in β2AR-dependent cAMP signalling can’t be reduced to 
a matter of receptor quantity but derives from different sources. Likely candidates to alter 
β2AR-dependent cAMP levels are the cAMP phospodiesterases (PDE), the β2AR position and 
its connected coupling to the Gs and Gi proteins as well as the receptor associated ACs. As 
we have shown here it is PDE4 which predominantly degrades the β2AR-dependent cAMP 
pools. According to FRET measurements the amount of β2AR-dependent cAMP being 
degraded by PDE4 does not change during HF progression (see figure 32). So changes in 
PDE4 activity are ruled out as the major factor for altering β2AR-dependent cAMP signalling 
during HF. The potential involvement of other PDEs in changed β2AR-dependent cAMP levels 
during HF progression however still remains to be determined. Next the β2AR position was 
determined during HF progression via a combination of FRET imaging and SICM scanning. 
The β2AR localisation studies showed that β2AR change their residence from the T-tubules to 
the crests at 8 weeks post-MI. This deduction is based on the observed drop of β2AR-
dependent cAMP levels in T-tubules at 4 weeks post-MI followed by an increase in β2AR-
dependent cAMP levels at the crest at 8 weeks post-MI (see figure 33). It is not entirely 
elucidated why β2AR-dependent cAMP levels decrease at 4 weeks post-MI but the β2ARs 
themselves could still be functional. By predominantly exhibiting Gi coupling at this stage 
β2ARs for example could still play a role in cell physiology/pathophysiology by activating ERK 
dependent signalling and gene expression pathways (Kaya et al 2012). One factor that 
influences β2AR-dependent cAMP levels during HF is the relocalisation of PKA which could 
potentially lead to increased receptor switching to Gi (Nikolaev et al. 2010). Also increased Gi-
α subunit levels can decrease cAMP production directly by acting on ACs 5 and/or 6 and 
sequestration of Gs-α through the β and γ subunits as Gi is in excess of Gs in HF (Xiao et al. 
2003). Hence the decrease of β2AR-dependent cAMP levels at 4 weeks post-MI is assumed 
to stem from β2AR uncoupling from Gs and potentially increased signalling over Gi in the T-
tubule compartment. In contrast the increased whole cell β2AR-dependent cAMP levels and 
local β2AR-dependent cAMP levels at the cardiomyocte crests at 8 weeks post-MI could derive 
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from increased Gs binding of β2ARs in new compartments that were formerly not occupied by 
β2ARs. In this thesis the total AC activity stimulated by NKH477 was not significantly affected 
at the earlier stages of remodelling (4 and 8 weeks post MI). However at 16 weeks post-MI 
the total AC activity was significantly reduced. According to a study conducted by Hussain et 
al. Gi protein expression is increased in a rat HF model but its activity is unchanged (Hussain 
et al. 2001). The depression in β2AR-dependent cAMP levels at 16 weeks post-MI is therefore 
assumed to derive from reduced AC activity and not from increased β2AR signalling over Gi.  
The reason why and the mechanism of how β2AR eventually redistribute from T-tubules to 
crest areas remain elusive. It has been speculated that β2AR might relocate in order to 
substitute for decreased β1AR activity during HF (Nikolaev et al. 2010). Such substitution has 
been shown to occur on a cAMP independent level through the activation of phospholipase 
A2 which can enhance cardiomyocyte Ca2+ handling and consequentially cell contraction 
(Madamanchi 2007). Here in the described FRET study of β2AR-dependent cAMP signalling 
β2ARs also appear to substitute for β1AR associated loss through their relocation to 
cardiomyocyte crests and increased cAMP generation at the crest and globally at 8 weeks 
post-MI. Hence β2AR relocation from T-tubules onto crests may compensate for the 
pronounced loss in β1AR activity at 8 weeks post-MI but ultimately contributes to the hearts 
decompensation and insufficiency at 16 weeks post-MI. These observations may explain how 
spatial and functional β2AR alterations can lead to an advanced HF phenotype and how β2ARs 
might be targeted therapeutically at different stages during HF progression. 
 
4.4.2. PDE4 degrades β2AR-dependent cAMP in health and disease 
The members of the cAMP degrading PDE4 family PDE4 A, B, C and D are expressed by 4 
different genes, which produce at least 20 different splice variants. PDE4’s role under 
physiological circumstances seems to serve as a fail-safe to keep cAMP pools in specific 
subcellular compartments (Richter et al. 2011). According to literature the overall PDE4 
expression and activity are decreased in hypertrophed rat hearts (Abi-Gerges et al. 2009) but 
no significant changes are seen in human cardiomyopathies (Richter et al. 2011). Alterations 
in PDE4D have furthermore been shown to lead to heightened phosphorylation of RyR2 and 
with it increased Ca2+ leak from the SR (Miller and Yan 2010). 
The work regarding PDE4 dependent regulation of β2AR-dependent cAMP levels described 
herein shows PDE4 activity on β2AR-dependent cAMP levels remains stable under HF 
progression, as far as is detectable via FRET measurements. However, ROLI, the drug of our 
choice used for FRET measurement of cAMP levels after PDE inhibition makes no distinction 
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between separate PDE4 isoforms or splice variants. Such distinction might be important as 
the PDE4 subtypes could be differentially affected during HF progression as was indeed 
shown for the PDE4D isoforms, which translocated to specific positions inside cells 
(Berthouze-Duquesnes et al. 2013). Hence in future experiments the location and activity of 
the PDE family members could be addressed, if specific blockers are made available.  
 
4.4.3. β2AR-dependent cAMP diffusion in control cardiomyocytes and during HF 
progression 
In the past our group has shown, that β2AR-dependent cAMP is confined in control 
cardiomyocytes but lost at end stage HF (Nikolaev et al. 2010). The cause for this loss in 
confinement could derive from multiple sources. In earlier work by our group unhindered cAMP 
diffusion in healthy, control cardiomyocytes was inducible by the inhibition of PDE4 (Nikolaev 
et al. 2010). The same study showed that cAMP diffusion throughout the cytosol was inducible 
via the disruption of PKA RII and AKAP. In the same study cardiomyocytes were furthermore 
treated with pertussis toxin (PTX) to detect differences in the β2AR-dependent signal 
amplitude after localised β2AR. The study however did not measure the respective cells in 
regard to β2AR-dependent cAMP diffusion after the PTX induced uncoupling of β2AR from Gi. 
Therefore data from the study was reanalysed and revealed that cAMP confinement was lost. 
During HF progression cAMP diffusion in the cytosol also became completely unconfined after 
only 4 weeks post-MI and remained thus until the end stage of HF (16 weeks post-MI). 
Reverse structural remodelling which was achieved through SERCA2a gene therapy of 
cardiomyocytes in prior work by our group lead to a physical return of T-tubule structures and 
of β2ARs into these T-tubules 16 weeks post-MI (Lyon et al. 2012). However a reanalysis of 
the data obtained during this SERCA2a study showed that the cAMP signal still diffused freely 
throughout the whole cytosol. The reason for this could be due to either one or all of the 
following factors: disrupted AKAP to PKA RII binding, reduced coupling of β2AR to Gi, reduced 
efficiency of PDE4 confinement of cAMP and lack of bridging of the SR with the T-tubules due 
to disrupted expression of the structural protein JPH2, as was described in chapter 3. Given 
that no changes in FRET measured cAMP levels were observed during HF progression after 
ISO stimulation and PDE4 inhibition this study concludes that it is probably structural 
deterioration linked with altered AKAP and PKA binding as well as Gi coupling and JPH2 
related changes which lead to unconfined cAMP diffusion in HF progression.  
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4.4.4. Conclusion in regard to β2AR dependent cAMP signalling in cardiomyocytes during 
their progression towards HF 
Our observations have potential implications for the optimal selection of treatment strategies 
to prevent the transition from hypertrophy towards HF. For example, beta-blockers with 
different β1AR: β2AR selectivity have different actions at progressive stages of HF 
development (Dunlay et al. 2014). The observations described herein could explain these 
differential actions and might urge the development of improved HF treatment strategies 
depending on the stage of disease. Intervening to prevent the structural remodelling of the 
TAT system early in the disease may maintain the spatial relationship of the TAT network with 
the SR. This could conceivably maintain or restore β2AR localization to the T-tubules, as we 
have shown before (Lyon et al. 2012). The native, spatial restriction of β2AR-dependent cAMP 
signalling is lost during HF progression, and may represent a new potential therapeutic 
avenue. We speculate that this is due to a plethora of factors including structural deterioration 
of the TAT network, β2AR-Gi uncoupling, changes in PDE4 dependent cAMP regulation, 
disruption of PKA RII to AKAP binding and loss of physical contact of the TAT network with 
the SR due to a lack in JPH2 protein levels. In order to validate the importance of JPH2 in 
cAMP signal confinement it would be especially interesting to reintroduce JPH2 expression 
into failing cardiomyocytes and to see if this alone or in conjunction with reverse structural 
remodelling induced by SERCA2a (Lyon et al. 2012) can lead to restored cAMP confinement 
and an ameliorated HF phenotype.  
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5.1. Introduction 
The presence and functionality of β3AR receptors in cardiomyocytes is a topic of controversy. 
Discordant reports either confirm or dispute the importance of this βAR subtype in human and 
animal hearts (Kulandavelu, Hare 2012). Furthermore, if deemed present, reports are not in 
complete agreement if the β3AR signals via the second messenger cAMP or cGMP and hence 
which potential effects it exerts on cells and tissues (Kohout et al. 2001; Kulandavelu, Hare 
2012). Using a FRET imaging approach our group did not detect any β3AR dependent 
contribution of cAMP in rat cardiomyocytes as tested through catecholaminergic stimulation 
with or without prior β3AR blockage (Nikolaev et al. 2010). Hence the possibility of β3AR 
dependent cAMP production in the course of the described study was assumed negligible or 
none existent. The reports linking β3ARs to cGMP production in the myocardium also link it to 
Gi and eNOS dependent NO production and hence to NO dependent cGMP production via 
sGCs (Watts et al. 2013). eNOS is localised inside the T-tubules and sarcolemmal caveolae 
(Zaugg 2008; Belge et al. 2014) and artificially overexpressed β3ARs also appear to localize 
to the T-tubules in mouse cardiomyocytes together with the caveolar protein Cav3 and eNOS 
(Belge et al. 2014).  Reports have shown an increase in β3AR expression levels during HF 
(Moniotte et al. 2001). Additionally a switch of β3AR-dependent cGMP production from eNOS 
derived NO to nNOS and iNOS derived NO has been observed in HF (Zaugg 2008), which 
may or may not indicate according changes in associated cGMP levels. So far direct 
measurements of accurate β3AR-dependent cGMP levels in live cardiomyocytes and at real 
time were prevented by the lack of suitable sensors. However the recent development of the 
high specificity and affinity cGMP FRET sensor Red cGES DE5 makes it possible to detect 
spatio-temporal changes even in low levels of cGMP (Niino et al. 2009).  
Hence chapter 5 concentrates on the detection of cGMP in cardiomyocytes. Besides 
informative studies of cGMP in cardiomyocytes it initially deals with general pretesting of the 
Red cGES DE5 FRET sensor. Consecutively it puts particular focus on the investigation of 
β3AR dependent cGMP levels by establishing if β3AR dependent cGMP signalling actually 
occurs in rat cardiomyocytes and if so which PDEs regulate these β3AR dependent cGMP 
levels. Furthermore chapter 5 attempts to elucidate potential signalling alterations taking place 
between control and end stage HF cardiomyocytes. Additionally it tries to elucidate the 
subcellular location of functional β3ARs and of the related signalling molecules eNOS and sGC 
in adult control and failing cardiomyocytes.  
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5.2. Methods and Materials 
 
5.2.1. 3′,5′-cyclic guanosine monophosphate (cGMP) FRET sensor 
Just like the cAMP response in cardiomyocytes the cGMP response to stimuli is transient and 
underlies subcellular compartmentation. Thus in order to study it thoroughly it is important to 
be able to monitor it continuously and in real time in living cells. For the work described in this 
thesis cGMP was measured with the high affinity red cGES DE5 FRET biosensor, which was 
recently developed and provided to our laboratory by Prof. Viacheslav Nikolaev 
(Universitätsklinikum Hamburg-Eppendorf, Germany). This FRET biosensor is based on the 
cGMP binding domain of PDE5 in conjunction with the GFP T-sapphire and the RFP Dimer2 
(see figure 38).  
 
 
Figure 38. The FRET measurement principle of relative cGMP levels using the FRET construct Red cGES-
DE5. At the top: The construct is based on the fluorescent protein T-Sapphire (T-S), the cGMP GAF binding 
domain of PDE5 (DE5) and the RFP Dimer2. Left hand side: In the absence of cGMP the FRET donor T-S 
gives part of its energy in a non-radiative fashion to the proximal, FRET acceptor RFP. Right hand side: 
The presence and binding of cGMP leads to a conformational change of the FRET biosensor, which 
removes RFP from the proximity of T-S, which in turn can no longer transfer any energy onto RFP.   
 
5.2.2. Testing if perfusion elicits RedDE5 cGMP FRET signals  
Endothelial cells are able to release NO in response to increased blood flow in vivo (Früh et 
al. 2013). The technique used for the isolation of primary, rat cardiomyocytes in this thesis 
should thoroughly remove endothelial cells (see chapter 2, paragraph 2.3.1). To exclude the 
possibility that the changes in fluid dynamics around the cells might lead to the production of 
NO and NO-dependent detectable cGMP levels, which could lead to a misinterpretation of the 
obtained data, cardiomyocytes expressing the cGMP sensor Red DE5 were “mock” perfused 
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with nothing but FRET solution and volumes of up to 1ml of simple FRET buffer were applied 
via an Eppendorf pipette. Simultaneously the FRET response was recorded. 
 
5.2.3. Testing if DMSO elicits RedDE5 cGMP FRET signals  
DMSO is commonly used as a solvent of non-water soluble compounds. In this study some of 
the PDE inhibitors (Vinpocetine and Cilostamide) used for FRET experimentation needed to 
be dissolved in DMSO. Therefore it was important to test if DMSO itself can elicit cGMP levels 
in the cardiomyocytes, which were used for experimentation. As a result cardiomyocytes were 
treated with 1µl/ml DMSO while the cGMP FRET signal was recorded.  
 
5.2.4. Whole cell cGMP stimulation with NO donors, NPs and ISO 
After successful transduction with the cGMP FRET biosensor Red cGES DE5 adult, rat, 
control cardiomyocytes were perfused with 20µM of the NO donor sodium nitroprusside 
(=SNP, dissolved in double distilled water) or with 50µM of S-Nitrosoglutathione (=GSNO, 
dissolved in double distilled water). Similarly control cardiomyocytes were perfused with 1µM 
of the natriuretic peptides ANP and CNP (both reagents dissolved in double-distilled water) 
respectively. Also control cardiomyocytes and cardiomyocytes at 16 weeks post-MI were 
perfused with 100nM ISO (dissolved in double-distilled water).  
 
5.2.5. Determining relative, basal sGC dependent cGMP levels  
After adult cardiomyocyte transduction with the cytosolic cGMP FRET biosensor cGES Red 
DE5 for 48h, the respective FRET response of whole cells was measured after inhibiting sGC 
dependent cGMP production with 50µM of 1H-[1,2,4] oxadiazolo [4,3-a] quinoxalin-1-one 
(=ODQ, dissolved in ethanol). Attempts to measure maximally inducible levels of cGMP in 
cardiomyocytes by applying the membrane permeable cGMP analogue Br-2′-O-Me-cGMP 
were unsuccessful.   
 
5.2.6. Testing the source of the cGMP signal after ISO stimulation  
Against expectation a cGMP FRET signal response was obtained in the aforementioned 
experiments after ISO stimulation of Red cGES DE5 transduced cardiomyocytes (see 
paragraph 5.2.4.). In order to establish the source of the measured cGMP cardiomyocytes 
were preincubated with either 100nM CGP 20712A and 50nM ICI118551 (both reagents 
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dissolved in double-distilled water) for 5 min to block β1ARs and β2ARs or with 100nM 
SR59230A (dissolved in double-distilled water) to block β3AR for 5 min or with 300 µM Nω-
Nitro-L-arginine methyl ester hydrochloride (=L-NAME, dissolved in double-distilled water) for 
10 min before cells were perfused with 100nM ISO and the cGMP FRET signal was recorded. 
 
5.2.7. Whole cell β3AR dependent cGMP PDE study 
cGMP pools generated by the stimulation of β3ARs are known to derive from sGCs (Watts et 
al. 2013). Nevertheless they might be subject to degradation by different PDEs than the PDEs 
already identified as mainly responsible for the degradation of general NO derived cGMP 
pools. To establish which PDEs are responsible for β3AR-dependent cGMP cardiomyocytes 
expressing Red cGES DE5 were treated with 100nM ISO (dissolved in double-distilled water) 
plus 10µM of one of the specific PDE blockers Vinpocetine (dissolved in DMSO), erythro-9-
Amino-β-hexyl--α-methyl-9H-purine-9-ethanol (=EHNA, dissolved in double-distilled water), 
10µM Cilostamide (dissolved in DMSO) or 10µM Tadalafil (dissolved in double-distilled water) 
at a time and 100µM of the non-selective PDE blocker IBMX (dissolved in ethanol) while the 
cGMP FRET signal was recorded. It is known that cardiomyocytes produce constiutive levels 
of cGMP via the sGC (Götz et al. 2014). To determine if these cGMP levels are regulated by 
PDE5 control cardiomyocytes expressing Red cGES DE5 were furthermore treated with 10µM 
of the PDE5 blocker Tadalafil followed by 100µM of IBMX without prestimulation with ISO.  
 
5.2.8. FRET/SICM imaging of locally stimulated β3AR dependent cGMP levels in T-tubule 
openings and on cell crests  
10x 10 µm SICM surface scans of age matched control cardiomyocytes and cardiomyocytes 
at 16 weeks post-MI were taken to reveal T-tubule opening and crest structures. β1ARs and 
β2ARs were blocked through the superfusion of 100nM CGP20712A and 50nM ICI118,551 for 
at least 5 min. Then the SICM nanopipette was positioned either 500nm above T-tubule 
openings or crest areas, the coordinates of which were determined through SICM topography 
images, before β3ARs were stimulated locally for 50 seconds via the SICM nano-pipette 
containing 50µM ISO and 50µM CGP20712A and 25µM ICI118,551 by switching the relative 
electrical potential inside the scanning nano-pipette from negative (-200 mV) to positive 
(400mV). Throughout the procedure a gravity based perfusion system continuously replaced 
the bath solution in less than 5 seconds. The FRET response was calculated by averaging the 
values of 10 frames of the baseline signal and 10 frames of the response signal and by 
subtraction of the averaged response from the averaged baseline. 
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5.2.9. cGMP signal diffusion study 
To study cGMP diffusion inside the cytosol of cardiomyocytes from age matched control hearts 
and hearts at 16 weeks post-MI were transduced with virus encoding the cytosolic FRET 
sensor Red cGES DE5. Then the propagation of the cGMP signal was studied after localized 
β3AR stimulation via the nano-pipette at different distances from the original nano-pipette 
stimulation site. For this FRET data was opened in Micro-Manager 1.4 and regions of interest 
(ROI) of about 15 microns width were drawn repeatedly at ever more distant areas to the 
nano-pipette. Then the FRET response amplitude was measured in these ROIs. As before the 
obtained data was processed by using the baseline correction functions in the software Origin 
Pro 8.5 (Origin Lab Corporation) followed by 3 median smoothing and baseline plus response 
averaging over 10 consecutive frames. However the elicited, local cGMP FRET response was 
too small to correctly analyse diffusion distances. 
 
5.2.10. Cardiomyocyte transduction with β3AR-GFP  
Adult, ventricular cardiomyocytes from control rats and rats 16 weeks post-MI were plated and 
transduced with an adenovirus construct for the expression of β3ARs fused to GFP (Belge et 
al. 2014) provided by Prof. Nikolaev Viacheslav (Universitätsklinikum, Hamburg-Eppendorf). 
The medium used for 24h cell transduction with the β3AR-GFP construct was prepared from 
500ml cell culture grade water, 10,78mg modified eagle medium (MEM) with foetal growth 
restriction factor/ml, 750µg NaHCO3/ml, 50mg L-glutamine/ml and 10,000 IU Penicillin/mL 
plus 10,000 ug Streptomycin/mL .    
 
5.2.11. Immunocytochemical staining of Cav3 and sGC  
The β3ARs have been associated with the caveolae and T-tubule structures in cardiomyocytes 
and are thought to signal over sGC (Belge et al. 2014). In order to investigate the subcellular 
co-localization of β3AR and T-tubule associated sGC ventricular cardiomyocytes from control, 
rat hearts and hearts 16 weeks post-MI were immunocytochemically stained with an antibody 
selective for the structural protein Cav3 and the sGC (see chapter 2, paragraph 2.6.). Confocal 
Z-stack images were taken at the Imperial College London FILM facility at 63x magnification 
using its inverted Zeiss LSM-780 confocal microscope. Dr. Claire Poulet (Imperial College 
London) provided additional immunocytochemical staining and Z-stack imaging for the 
aforementioned proteins for increased n-numbers and improved double staining of proteins to 
detect colocalisation.  
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5.2.12. Measuring colocalisation of Cav3 and sGC 
The extent of colocalisation of Cav3 and sGC was determined using the freeware Fiji 
(Schindelin et al. 2012). For this analysis areas of interests were drawn manually around the 
respective cells in the confocal imaging software Zen. Then the colocalisation of the 
immunocytochemically double-stained proteins was determined automatically throughout 
each confocal Z-stack with the Zen “colocalisation” plugin. This plugin makes use of automatic 
thresholding, statistical significance testing, scatterplot creation and analysis of whole Z-
stacks to determine the suitability of images for analysis and their respective Pearson's 
correlation coefficient (PCC). The PCC is a non subjective measure of correlation, which is 
highly reproducible and can evaluate the overlap of fluorescent signals in images. The output 
value of the PCC is a number between -1 (negative correlation) and +1 (positive correlation). 
If the PCC is around 0 then no positive or negative correlation exists. If the PCC value lies 
between 0.8 and 1 or -1 and -0.8, the correlation is described as strong, whereas values 
between 0.5 and 0.8 or -0.8 and -0.5 are considered to be moderately correlated and values 
between 0.2 and 0.5 are said to be of a weak correlation.  
 
5.3. Results 
 
5.3.1. Perfusion does not elicit RedDE5 cGMP FRET signals during FRET measurements 
During whole cell FRET studies the investigated cells might experience a transient increase 
and change in flow conditions of the surrounding fluid when reagents are applied onto them 
via a pipette. This is increasingly so the case for cells which undergo SICM/FRET combination 
studies where it is necessary to attach a perfusion system to constantly exchange the 
surrounding fluid. To assure that no endothelial cells are in culture and produce NO in 
response to the usage of the perfusion system, cells expressing Red cGES DE5 were 
perfused while the FRET response was recorded. The perfusion did not elicit any detectable 
cGMP FRET response.   
 
5.3.2. DMSO can elicit RedDE5 cGMP FRET signals in cardiomyocytes 
Dimethyl sulfoxide (DMSO) is a hygroscopic, solvent oftentimes used under laboratory 
conditions to dissolve water insoluble, lipophilic substances (Capriotti and Capriotti 2012). In 
this case DMSO was used as a vehicle to dissolve the PDE inhibitors Vinpocetine and 
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Cilostamide. To determine potential effects of DMSO on the production of cGMP the vehicle 
itself was applied onto cardiomyocytes expressing the cGMP FRET biosensor Red cGES DE5 
and the resulting FRET response was recorded. The application of 1µl DMSO/ml indeed led 
to an increase in cGMP levels (see figure 39).    
 
Figure 39 DMSO dependent increase in cGMP FRET response. (A.) Representative cGMP FRET response 
curve to the application of 0.1% DMSO onto Red cGES DE5 transduced cardiomyocytes. (B.) cGMP FRET 
response to DMSO. Numbers above bars = number of single cells tested / number of animals utilized. Bar 
represents mean value ± standard error of the mean.    
 
5.3.3. NO and NP dependent cGMP signals in cardiomyocytes 
To test the ability of Red cGES DE5 transduced cardiomyocytes to sense cGMP stimulation 
with NO donors and natriuretic peptides, cells were stimulated with the NO donors SNP and 
GSNO or with the NPs ANP and CNP respectively. While the reagent SNP did not elicit a 
detectable cGMP FRET signal in the investigated cells (data not shown), GSNO and the 
natriuretic peptides ANP and CNP did. While GSNO and ANP lead to the production of similar 
amounts of cGMP of around 2% the natriuretic peptide CNP generated the highest levels of 
cGMP of around 6% (see figure 40). However it is important to draw attention to the relatively 
low response rate of only 19 out of 142 cells (~13%) to CNP stimulation, which was observed 
during FRET experimentation.  
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Figure 40 NO donor and NP dependent cGMP FRET response. cGMP FRET response curves to the 
application of (A.) the NO donor GSNO, (B.) the NP ANP and (C.) the NP CNP onto Red cGES DE5 
transduced cardiomyocytes. (D.) cGMP FRET response to GSNO, ANP and CNP. Bars represent mean 
values ± standard error of the mean. Numbers above bars = number of single cells tested / number of 
animals utilized. Statistical one way ANOVA test followed by Bonferroni correction post-hoc testing, ***p 
< 0.0001, p = ns; not significant.  
 
5.3.4. Relative, basal sGC dependent cGMP levels  
sGCs continuously generate cGMP (Götz et al. 2014). To establish the levels of basal sGC 
dependent cGMP production in cardiomyocytes expressing the cytosolic cGMP FRET sensor 
Red cGES DE5, cells were treated with the sGC blocker 1H-[1,2,4] oxadiazolo [4,3-a] 
quinoxalin-1-one (ODQ). Tests showed a clear reduction in FRET measured cGMP levels of 
around 3.5%, revealing the relative, basal cGMP producing activity of sGCs in cardiomyocytes 
after 48h of culture and transduction (see figure 41).  
 
Figure 41 1H-[1,2,4] oxadiazolo [4,3-a] quinoxalin-1-one (ODQ) dependent decrease in cGMP FRET 
response of control cardiomyocytes. (A.) cGMP FRET response curve to the application of the sGC blocker 
ODQ onto Red cGES DE5 transduced cardiomyocytes. (B.) cGMP FRET response to 50µM ODQ. Numbers 
below bar = number of single cells tested / number of animals utilized. Bar represents mean value ± 
standard error of the mean.    
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5.3.5. Cardiomyocytes produce β3AR dependent cGMP levels 
To see if the recorded FRET signal of around 4%, which was obtained during Red cGES DE5 
transduced cardiomyocyte stimulation with the β adrenergic agonist ISO stems from β3AR 
receptors, cells were treated respectively with specific β1AR and β2AR blockers (ICI118551 
and CGP 20712A) as well as a specific β3AR blocker (SR59230A) and a NOS blocker (L-
NAME) before ISO application. While inhibiting signalling over β1ARs and β2ARs did not lead 
to any significant changes the specific blocking of β3ARs or eNOS efficiently abolished the 
ISO induced rise in cGMP levels (see figure 42).   
 
Figure 42 β3AR dependent cGMP FRET response investigation. cGMP FRET response curves to the 
application of (A.) ISO, (B.) β1AR and β2AR blockage (with ICI118551 and CGP 20712A) followed by ISO, 
(C.) β3AR blockage (with SR59230A) followed by ISO and (D.) eNOS blockage (with L-NAME) followed by 
ISO onto Red cGES DE5 transduced cardiomyocytes. (E.) cGMP FRET response to ISO after no blockage, 
β1AR and β2AR blockage, β3AR blockage and eNOS blockage. Bars represent mean values ± standard error 
of the mean. Numbers above bars = number of single cells tested / number of animals utilized. Statistical 
one way ANOVA test followed by Bonferroni correction post-hoc testing, **p < 0.001, *p < 0.05, p = ns; not 
significant.   
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5.3.6. β3AR dependent cGMP levels decrease in HF 
To see if β3AR-dependent cGMP levels significantly alter in HF cardiomyocytes age matched 
control cardiomyocytes and cardiomyocytes 16 weeks post-MI expressing the cytosolic FRET 
sensor Red cGES DE5 were stimulated with ISO. Despite reported increases in β3AR 
expression in HF (Zaugg et al. 2008; Moniotte et al. 2001; Niu et al. 2012) in our rat MI model 
β3AR-dependent cGMP levels in failing cardiomyocytes were decreased by ~50% (see figure 
43). Interestingly only about half of all cells react to catecholamine stimulation via a 
measureable FRET response in cGMP levels in both control and HF cardiomyocytes. 
 
Figure 43 Whole cell cGMP response to ISO in control and HF cardiomyocytes expressing Red cGES DE5 
FRET sensor. Representative cGMP FRET curves to ISO application onto (A.) sham-operated control 
cardiomyocytes or (B.) cardiomyocytes 16 weeks post-MI. (C.) cGMP FRET response to ISO applciation in 
sham-operated control cardiomyocytes and cells 16 weeks post-MI. Bars represent mean values ± standard 
error of the mean. Numbers above bars = number of single cells tested / number of animals utilized. 
Statistical Student’s two-sided T-test, **p < 0.001. 
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5.3.7. β3AR dependent cGMP degraded by PDEs 2 and 5  
To determine which PDEs are responsible for hydrolysing β3AR-dependent cGMP pools age 
matched control cells and cells 16 weeks post-MI expressing the cGMP FRET sensor Red 
cGES DE5 were stimulated with ISO followed by PDEs 1, 2, 3 and 5 inhibition with the 
respective blockers (Vinpocetine, EHNA, Cilostamide, Tadalafil) followed by total, non-
selective PDE inhibition (with IBMX). The results indicate that it is PDE2 and PDE5 which 
decrease β3AR-dependent cGMP levels as cGMP increases the most after their inhibition by 
around 2% each (see figure 43). To see if basal cGMP levels which stem from constitutive 
sGC activity are regulated by PDE5, cells were furthermore treated with Tadalafil followed by 
IBMX. Interestingly this approach lead to no detectable increase in cGMP levels in this study 
(data not shown). In cardiomyocytes 16 weeks post-MI it was also PDE2 and PDE5 inhibition 
which lead to the highest accumulation of β3AR-dependent cGMP after ISO stimulation (see 
figure 44). Also a significant increase in cGMP levels after ISO stimulation and PDE2 inhibition 
or non-selective PDE inhibition via IBMX treatment was noticed, indicating that PDE2 activity 
increases during HF (see figure 45). The bar graphs in figures 43 to 45 show the additional 
FRET response after PDE inhibition on top of ISO stimulation in the respective cells.  
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Figure 44 Whole cell cGMP response to ISO and PDE blockers in control cardiomyocytes expressing Red 
cGES DE5 FRET sensor. Representative cGMP FRET curves to ISO application onto control 
cardiomyocytes followed by (A.) PDE1 inhibition (with Vinpocetine), (B.) PDE2 inhibition (with EHNA), (C.) 
PDE3 inhibition with Cilostamide (D.) PDE5 inhibition (with Tadalafil) and inhibition of all PDEs (with IBMX). 
Colors correlate to cGMP response of cells on top of ISO shown in (E.). n= number of single cells measured. 
Animals utilised n≥4. Bars represent mean values ± standard error of the mean. Statistical one-way ANOVA 
test followed by Bonferroni correction post-hoc testing, ***p < 0.001. 
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Figure 45 Whole cell cGMP response to ISO and PDE blockers in cardiomyocytes 16 weeks post-MI 
expressing the Red cGES DE5 FRET sensor. Representative cGMP FRET curves to ISO application onto 
control cardiomyocytes followed by (A.) PDE1 inhibition (with Vinpocetine), (B.) PDE2 inhibition (with 
EHNA), (C.) PDE3 inhibition with Cilostamide (D.) PDE5 inhibition (with Tadalafil) and inhibition of all PDEs 
(with IBMX). Colors correlate to cGMP response of cells on top of ISO shown in (E.). n= number of single 
cells measured. Animals utilised n≥3. Bars represent mean values ± standard error of the mean. Statistical 
one-way ANOVA test followed by Bonferroni correction post-hoc testing, ***p < 0.001. 
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Figure 46 cGMP FRET response in age matched control cardiomyocytes and in cardiomyocytes at 16 
weeks post-MI expressing the cGMP FRET sensor Red cGES DE5. PDE1 inhibition (with Vinpocetine), PDE2 
inhibition (with EHNA), PDE3 inhibition with Cilostamide and PDE5 inhibition (with Tadalafil) and inhibition 
of all PDEs (with IBMX). n= number of single cells measured. Animals utilised n≥3. Bars represent mean 
values ± standard error of the mean. Statistical one-way ANOVA test followed by Bonferroni correction 
post-hoc testing, *p < 0.05. 
 
5.3.8. Functional β3AR localisation in T-tubule openings and on cell crests in control and 
HF cardiomyocytes 
To determine the localisation of functional β3AR on the surface of cardiomyocytes combined 
FRET and SICM studies were performed. β1AR and β2ARs were blocked specifically and 
β3ARs were stimulated via ISO application either into the T-tubule openings or onto crest areas 
of age matched control cardiomyocytes and cardiomyocytes at 16 weeks post-MI. The results 
show that β3AR-dependent cGMP signalling in control cells of around 1% is localised almost 
exclusively inside T-tubules while in end stage HF β3AR-dependent cGMP signals of around 
0.5% are equally elicitable in both T-tubules and crests (see figure 46).   
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Figure 47 FRET based localisation of functional β3ARs via their localised cGMP response. (A.) 
Representative β3ARs-cGMP FRET response curves after local β3ARs stimulation either in T-tubule 
openings or on crest areas of (A.) sham-operated control cardiomyocytes and (B.) cardiomyocytes 16 
weeks post-MI. Local β3ARs-cGMP FRET response after agonist application into T-tubule or crest in (C.) 
control cardiomyocytes and (D.) cardiomoyctes at 16 weeks post MI. n= number of single cells measured. 
Animals utilised n=4 each.  Bars represent mean values ± standard error of the mean. Number above bars 
indicates responsive cells. Statistical Student’s two-sided T-test, *p < 0.05, p=ns; not significant. 
 
5.3.9. The subcellular location of Cav3, sGC and eNOS in control cardiomyocytes 
To investigate the presence and location of proteins involved in β3AR-dependent cGMP 
signalling in adult rat cardiomyocytes from age matched control hearts cells were fixed on the 
day of their isolation and single stained with an antibody selective for Cav3 and sGC. Confocal 
images of the immunocytochemical single-staining of the respective cardiomyocytes shows 
that Cav3 localises over the whole cardiomyocyte sarcolemma including the T-tubule 
membranes sGC appears to follow a Z-line localisation, which might colocalise with T-tubules, 
but not the whole cardiomyocyte sarcolemma (see figure 4). 
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Figure 48 Subcelllular location of the artificially expressed β3AR-GFP fusion protein and 
immunocytochemically stained Cav3 and sGC in cardiomyocytes. Representative confocal images of 
β3AR-GFP fusion protein expression and immunocytochemical single staining of Cav3 and sGC in age 
matched control cardiomyocytes. Scale bars equal 10 µm.  
 
5.3.10. Cav3 and sGC colocalise in control cardiomyocytes but this colocalisation is lost in 
HF cardiomyocytes 
 
To obtain insight into the subcellular co-localisation of proteins involved in the β3AR dependent 
signalling cascade age matched, control cardiomyocytes and cardiomyocytes at 16 weeks 
post-MI were fixed on the day of their isolation and double-stained Cav3 and sGC. The 
analysis of the obtained confocal Z-stacks show that Cav3 and sGC colocalise to some degree 
with a Pearson’s correlation coefficient (PCC) of over 0.20 around 0.24 while this 
colocalisation appears to be lost in failing cardiomyocytes whose PCC significantly decreases 
to less than 0.2 to around 0.17. From the confocal images it appears that this colocalisation is 
close to the sarcolemma and inside the T-tubules which are marked by Cav3 (see figure 48).   
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Figure 48 Subcellular colocalisation study of Cav3 and sGC. (A.) Representative immunocytochemical 
double staining of Cav3 and sGC in an age matched control cardiomyocyte and a failing cardiomyocyte at 
16 weeks post-MI. Scale bars, 20 µm. Images provided by Dr. Claire Poulet (Imperial College London). 
Representative scatter plots from control and failing cardiomyocytes which are used to determine potential 
correlation of staining of Cav3 and sGC in (C.) the cytosol or (D.) the sarcolemma via Pearson correlation 
coefficient (PCC) analysis. The averaged PCC of subcellular colocalisation of Cav3 with sGC in control 
cardiomyocytes and failing cardiomyocytes in (D.) the cytosol (F.) the sarcolemma.  
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5.4. Discussion 
 
5.4.1. The novel cGMP FRET sensor Red cGES DE5 enables NO, NP and β3AR-dependent 
cGMP FRET measurements 
 
The affinity and efficiency of the FRET sensor Red cGES DE5 for cGMP (=40nmol) is higher 
than that of any prior cGMP specific FRET construct and hence allows the measurement of 
even very low levels of the second messenger cGMP. A recent study (Götz et al. 2014) 
showed that it effectively detects cGMP levels after a combination of catecholaminergic with 
NO stimulation or pure NP stimulation of cardiomyocytes. The same study showed that the 
CNP represents the stimulus for the highest cytosolic cGMP production followed by a three 
times lower cGMP production after stimulation with the NO donor SNAP and an almost six 
times lower cGMP production after stimulation via the ANP. In the study presented in this 
thesis CNP also revealed to be the most effective stimulant of the highest cGMP levels, while 
the NO donor GSNO and the NP ANP elicited similar levels of cGMP which were around 3 
times lower in comparison to CNP elicited cGMP levels. However only a relatively low number 
of cells actually responded to CNP stimulation. The reason for this low response rate to CNP 
is unknown. We do not expect it to stem from variable levels of basal cGMP levels, which if 
excessively high might lead to the saturation of the FRET sensor, else the other 2 donors 
would have shown a similar response rate, which they didn’t. Also the measurements of basal, 
sGC dependent cGMP levels via ODQ showed that the basal cGMP levels are relatively stable 
and are not excessively high. It is possible that the cardiomyocytes with responsiveness to 
CNP belong to a subpopulation of cardiomoycytes while almost all cardiomyocytes appear to 
be responsive to ANP and NO.   Prior work has investigated the presence and functionality of 
β3AR-dependent cGMP signalling in human (Gauthier et al. 1998; Pott et al. 2006) and 
neonatal rodent cardiomyocytes (Mongillo et al. 2006). FRET measurements of β3AR-
dependent cGMP in isolated, adult cardiomyocytes were however impeded by the far lower 
levels of cGMP being produced in comparison to neonatal cells. Also no cGMP FRET sensors 
with high enough affinity and specifity were available. This limitation was only recently 
overcome by the generation of the cGMP FRET sensor Red cGES DE5 (Niino et al. 2009). 
This sensor was succesfully used for cGMP FRET measurements in transgenic mice (Götz et 
al. 2014) which have very low β3AR expression levels, so that β3AR overexpression has to be 
introduced before mice cardiomyocytes can generate a measureable β3AR-dependent cGMP 
FRET response (Belge et al. 2014). But the Red cGES DE5 sensor was not yet used for the 
transduction of adult rat cardiomyocytes. Hence as far as the writer of this thesis is aware the 
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β3AR-dependent cGMP FRET measurements in intact control and end stage HF 
cardiomyocytes described herein are the very first, published measurements of β3AR-
dependent cGMP signalling in adult, rat ventricular cardiomyocytes.  
 
5.4.2. DMSO elicits a detectable cGMP FRET signal in cardiomyocytes 
During pretesting of the novel cGMP FRET sensor Red cGES DE5 the solvent DMSO elicited 
low but clear levels of cGMP. How DMSO potentially leads to increased cGMP levels is not 
quite clear and was not investigated further. A general literature review of DMSO on Pubmed 
(http://www.ncbi.nlm.nih.gov/pubmed) reveals multiple possibilities for how DMSO might 
excert effects on cells. Among other chemical properties of DMSO are its reactivity with water 
molecules and its potential to affect cellular constituents (Szmant 1975). When limiting the 
literature search to “DMSO” in combination with “cardiomyocytes” Pubmed yields 132 
publications of which only 3 actually studied the effect of DMSO on primary adult 
cardiomyocyte structure and function. These papers ascribe DMSO’s effects on cells to its 
mitochondria improving function by scavenging hydroxyl radicals which form at the 
mitochondria during ischemia and to an associated decreased submitochondrial ATPase 
activity (Jacob and Herschler 1986). Interestingly DMSO also appears to have effects on the 
Ca2+ handling of cardiomyocytes and might lead to increased permeability of the sarcolemmal 
membrane (Jacob and Herschler 1986). DMSO was furthermore shown to induce increased 
heme oxygenase 1 (HO-1) enzyme expression. As its name indicates the enzyme HO-1 
catabolizes heme groups and as a byproduct produces carbon monoxide (Man et al. 2014). 
This carbon monoxide could potentially lead to or be the cause of consecutive cGMP 
generation via binding to sGC (Derbyshire and Marletta 2009). Therefore experimentalists 
should be aware of DMSO’s potential effects on cardiomyocyte function and cyclic nucleotide 
signalling.   
 
5.4.3. Whole cell and localised β3AR-dependent cGMP signalling 
Stimulation of cardiomyocytes expressing the FRET sensor Red cGES DE5 lead to a clear 
cGMP response in adult rat cardiomyocytes. Specific blocking of the β1AR and β2AR subtypes 
and alternative blocking of β3ARs or NO production via NOS showed that this signal with all 
likelihood stems from β3ARs, which have been shown to be present at a functional level in rat 
cardiomoyctes in the past (Mongillo et al. 2006; Watts et al. 2013). The localisation of these 
functional β3ARs in adult rat cardiomoyctes has however not been determined before. Studies 
in mouse specified the putative position of β3ARs inside the T-tubular membrane as 
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determined via proximity ligation assays which showed colocalisation of artificially 
overexpressed β3ARs with eNOS and Cav3 (Belge et al. 2014). Emulating the successful 
compartmentation study of β2AR-dependent cAMP conducted by our group in the past 
(Nikolaev et al. 2010) the localisation of functional β3AR on the surface of cardiomyocytes was 
studied by combining SICM with FRET measurements. The results confirmed functional β3AR 
are primarily located inside T-tubules in control cardiomoyctes but like β2AR (Nikolaev et al. 
2010) they change their position at the end stage of HF to the whole sarcolemma.  
 
5.4.3. β3AR dependent cGMP levels decrease in HF 
Despite reports of increased β3AR expression in senescence and HF (Birenbaum et al. 2008; 
Niu et al. 2012; Niu et al. 2014) during the FRET measurements described in this thesis β3AR-
dependent cGMP levels were significantly decreased at the end stage of HF. The reasons for 
this reduction in cGMP generation will have to be established in future work and could be due 
to a combination of causes. Speculatively, decreased β3AR-dependent cGMP levels could be 
due to significantly increased PDE activity, uncoupling/ decrease of downstream targets like 
the sGC and eNOS or even a switch between the NOS subtypes a phenomenon, which has 
been described before (Niu et al. 2012).  According to the FRET experiments using the 
cytosolic sensor Red cGES DE5 described in this thesis the major PDE to degrade β3AR-
dependent cGMP levels are PDE2 and PDE5. At 16 weeks post-MI PDE2 activity appeared 
to be significantly increased in the FRET experiments. This increase of PDE2 activity is at 
least partly accountable for the decreased cGMP levels which were observed in end stage 
HF. β3ARs have been shown to signal over eNOS and sGC (Mongillo et al. 2006). 
Immunocytochemical single staining of sGC shows that the  molecule distributes along the Z-
lines of cardiomyocytes and could potentially localise to the T-tubules or at least their vicinity. 
Consecutive double-staining with Cav3 and sGC showed partial colocalisation of cav3 and 
sGC in what is presumably the membrane of T-tubules. Additionally subcellular co-localisation 
studies of Cav3 with sGC showed significant differences between age matched control 
cardiomyocytes and end stage HF cardiomyocytes which could be indicative of either 
relocation or decrease of sGC levels in HF cardiomyocytes. Studies of potentially occuring 
activity changes of both sGC and eNOS remain to be conducted in the future. 
 
5.4.4. β3AR dependent cGMP degradation via PDEs 2 and 5 
The pretreatment of cardiomyocytes with specific PDE blockers and consecutive FRET 
measurements of β3AR-dependent cGMP identified PDE2 and PDE5 as major β3AR-
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dependent cGMP degradors. PDE2 dependent regulation of β3AR-dependent cGMP and 
retrospectively β1AR and β2AR dependent cAMP levels is corroborated by findings in neonatal 
rat cardiomyocytes, which revealed a NO and cGMP dependent decrease of cAMP levels 
close to the membrane through PDE2A hydrolysis (Mongillo et al. 2006). PDE5 acts solely on 
cGMP derived from sGC and is strongly influenced by the presence of its substrate cGMP 
which increases its hydrolytic capability by binding to the respective GAF binding domains 
(Kass 2012). It is therefore possible that PDE5 is generally active on constitutively produced 
cGMP levels by eNOS. In the investigation described in this thesis however no accumulation 
of cGMP was revealed after treating cardiomyocytes with the specific PDE5 blocker Tadalafil 
or with an unselective PDE blocker without prior βAR stimulation. Despite its low expression 
in cardiomyocytes under physiological conditions PDE5’s activity appears to increase during 
HF in humans. This is accompanied by a drop in cardiac cGMP levels. As cGMP is widely 
regarded to counter act excessive cAMP dependent signalling and to decrease cardiac 
hypertrophy it was concluded that PDE5 inhibition might ameliorate the pathological 
phenotype of the diseased myocardium (Kass 2012). Though PDE9 is also known to be 
expressed in cardiomyocytes and to degrade cGMP (Stangherlin and Zaccolo 2012) its role 
in regulating β3AR-dependent cGMP levels has not been assessed in this work for lack of a 
specific PDE9 inhibitor. However a recent study ascribing PDE9A a prominent role in 
natriuretic peptide pathways concluded that PDE9 primarily acts on NOS independent cGMP 
pools (Lee et al. 2015).   
 
5.4.5. Conclusion regarding cGMP signalling in cardiomyocytes 
The novel cGMP FRET sensor Red cGES DE5 is can be used for cGMP FRET measurements 
after cardiomoycyte stimulation with NO donors or NPs. Also β3AR-dependent cGMP 
production occurs in adult, rat cardiomoyctes at levels which are measureable with this cGMP 
FRET sensor. In HF cardiomyocytes this β3AR-dependent cGMP production is significantly 
decreased together with alterations in signalling molecules like sGC which are important 
members of the β3AR-dependent cGMP signalling pathway. In control cardiomyocytes β3ARs 
are situated inside the T-tubules but their location changes at the end stage of HF when they 
are also found on crest areas. In both control and HF cardiomyocytes the β3AR-dependent 
cGMP response to catecholaminergic stimulation is regulated by PDEs 2 and 5. In HF PDE2 
activity appears to be significantly increased, which might explain the overall decrease in 
cGMP levels in HF. All the aforementioned observations show that rat cardiomyocytes should 
be considered as a useful tool for further studying the β3AR ad its role in physiology as well 
as pathophysiology.  
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Chapter 6: Modelling of localised ISO application onto cardiomyocyte 
structures via electrical potential switch 
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6.1. Introduction 
In the general Introduction and Material and Methods section (see chapters 1 and 2) it was 
mentioned, that the mode of agonist application using the SICM nanopipette was changed 
from pressure-driven (Nikolaev et al. 2010) to voltage-driven (Babakinejad et al. 2013). The 
fact that the agonist used in this case, namely ISO, has a slightly positive net electrical charge 
(of +1e) in solutions makes its dynamics during application much more complicated, 
particularly due to the fact that the cells have a complex surface topography. Thus we 
developed a mathematical model to simulate its application onto the cell surface and hence 
understand the spreading process.  During the conduction of SICM experiments using voltage-
driven application a few electrochemical phenomena emerge: Firstly, when the surface of the 
nanopipette and the cell surface come into contact with the freely diffusible, electrolytic 
solution this generates a charged diffusive layer between the electrolyte solution and the 
surfaces (Babakinejad et al. 2013). This layer is called the electrical double layer (EDL). It 
possesses a specific electrical potential, the ζ potential, at the space where the liquid slips 
along the solid surfaces. However the ζ potential cannot be determined experimentally. 
Instead it is common practice to determine the electrophoretic mobility of molecules, which is 
the experimentally observable rate of movement of a charged particle in the electrolyte 
solution. As both the application outlet (the nanopipette) and the structures, which are dealt 
within this investigation, are on the nanoscale level, this will lead to the exertion of forces which 
will repel or attract a small, charged and dissolved molecule like ISO. Additional repelling and 
attracting forces arise in colloidal fluids like the physiological buffer used for FRET experiments 
described in this thesis (Hunter 1981). Together with the scale of the nanopipette and of the 
ISO molecule itself all the aforementioned forces will determine how fast ISO diffuses out of 
the nanopipette and how much of the underlying cardiomyocyte structures it will reach.  
The objective of chapter 6 is therefore to determine an appropriate experimental setup to 
collect sufficient experimental data to validate or improve the precision of our voltrage-driven 
SICM application mode via mathematical modelling. Hence the electrophoretic mobility of ISO 
in physiological buffer in a glass capillary and the averaged structural scale of the nanopipette 
and the cardiomyocyte structures as well as the optimal setup for voltage-driven application 
were determined. The parameters obtained were fed into the finite element model describing 
the problem through partial differential equations to find an approximate solution of which 
experimental settings to use for the precise application of ISO onto the cardiomyocyte surface.  
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6.2. Methods and Materials 
 
6.2.1. Determination of averaged cardiomyocyte surface and nanopipette structures and 
their translation into mathematical geometries 
Using the SICM imaging software (Ionoscope) the average size (height, width, length) and 
number of T-tubule openings, the amount of Z-grooves and of crests on control 
cardiomyocytes and cardiomyocytes during the progression towards HF were determined 
from SICM surface scans after 48 hours of cell transduction. The averaged scale of the nano-
pipette was taken from Babakinejad et al. 2013 who use the same nano-pipette make and 
puller (see chapter 2, paragraph 2.5.1.).  
 
6.2.2. Determination of the electrophoretic mobility of ISO 
As the attracting and repelling forces determine the direction and the velocity of freely diffusible 
particles in solution it was imperative to determine the electrophoretic mobility of ISO. 
Therefore a sample of 50µM of ISO diluted in physiological buffer (ddH2O containing NaCl 144 
mM, KCl 5mM, HEPES 10mM and MgCl2 1mM, pH 7.4) was sent to the company Brookhaven 
Instruments for measurements of the electrophoretic mobility of the agonist. Measurements 
were conducted by Dr. Dan Clarke. For the measurements the sample was analysed in 5 
consecutive runs at 25°C through a glass capillary using a NanoBrook ZetaPALS machine 
(model: NanoBrook Omni, Brookhaven Instruments Corporation, UK) and phase analysis light 
scattering (PALS). The correlation-function of the phase shift from which the electrophoretic 
mobility was determined via the Smoluchowski drift-diffusion equation is shown below (see 
figure 49). 
 
Figure 49 Determination of the electrophoretic mobility of the agonist ISO. Shown is a graph of the 
correlation-function (red line) used to determine the electrophoretic mobility of ISO in physiological buffer 
and the correlating measurements (red dots) taken with a phase analysis light scattering technique. Here 
the phase (given in radians corresponding to an angle of ~ 57.3°) defines the position of a particle at a 
specific point in time during a waveform cycle of 360°.  
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6.2.3. Numerical simulations of ISO application onto cardiomyocyte structures 
The following steps and finite element simulations were performed together with Dr. Peter 
Jönsson (University Lund, Sweden):  
The program COMSOL Multiphysics® 4.4 (COMSOL AB, Stockholm, Sweden) was used to 
solve for the concentration of ISO delivered from the nano-pipette due to a voltage drop () 
applied over the pipette. The time the concentration takes to reach steady state via voltage-
application is much faster than the time scales normally used for the delivery via pressure-
displacement and stationary equations can therefore be used. The following three sets of 
equations were solved: 
 
(Electrostatics) 02   (1) 
(Creeping flow) 0
2  up  (2a) 
 0 u  (2b) 
(Transport of diluted species) 0 J  (3a) 
 
  epuJ ccD  (3b) 
 
where  is the electric potential, p the hydrostatic pressure, u the liquid flow vector,  the 
viscosity of the liquid and J the molecular flux of ISO. Equation 1 gives the electric field in the 
pipette, and is solved for first. Next, Equation 2 is solved to determine the electroosmotic flow 
in the system, where the determined electric field E = - is used as input value. The 
concentration of ISO is finally determined by solving Equation 3 with the already simulated 
values of u and  as input values to determine the amount of ISO delivered.  
The boundary conditions used in the simulations of ISO application via a nano-pipette are 
given in Table 6 and the assumed parameter values in Table 7. It is noteworthy that the 
electrophoretic and electroosmotic mobility has the opposite sign, and that the latter dominates 
the delivery in this situation. When applying into a T-tubule opening the point on the surface 
below the pipette is (x,y,z) = (0,0,0), and each side of the simulation geometry is 10 µm (width 
and depth are equal to 9 m for the crest application simulations, where the point on the 
surface below the pipette corresponds to (x,y,z) = (1,1,1) µm.  
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Table 6 Boundary conditions of ISO application via the SICM nanopipette. 
 Boundary condition 
Electrostatics  
Top (inside) of the pipette at z = 10 µm1  = ×(1-R0/Rtop) 
x = 10 µm 
y = 10 µm 
z = 10 µm (outside the pipette) 
 = 0 
- ‘’ - 
- ‘’ - 
All other boundaries2 n· = 0 
Creeping flow  
Top (inside) of the pipette at z = 10 µm p = 0, (u+(u)T)n = 0 
x = 10 µm 
y = 10 µm 
z = 10 µm (outside the pipette) 
- ‘’ - 
- ‘’ - 
- ‘’ - 
Pipette walls (inside the pipette) u = -µeo 
x = 0 u·n = 0, (u+(u)T)n – ((u+(u)T)n·n)n = 0 
y = 0 - ‘’ - 
All other boundaries u = 0 
Transport of diluted species  
Top (inside) of the pipette at z = 10 µm c = c0 
x = 10 µm3 
y = 10 µm 
z = 10 µm (outside the pipette) 
c = cflat 
- ‘’ - 
- ‘’ - 
All other boundaries J·n = 0 
1 Rtop = 0.50 µm, inner radius at the top, inside of the pipette. 
2 n = unit vector to the surface boundaries. 
3 cflat is the analytical expression for the concentration on a flat surface using Eqs. 1 and 2. 
 
 
Table 7 Parameters and values for modelling the delivery of ISO. 
Name  Description Value 
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R0 Inner pipette tip radius 40 nm to 60nm 
R1 Outer pipette tip radius 90- 110 nm 
θ Inner pipette half-cone angle 3° 
h Pipette-cardiomyocyte surface distance 500 nm 
D Diffusivity of ISO (Venter 1978) 6.7×10-10 m2/s 
µep Electrophoretic mobility of ISO -7×10-9 m2/V s 
µeo Electroosmotic mobility of ISO in the pipette (Babakinejad et al. 2013) 1.4×10-8 m2/V s 
c0 ISO concentration inside the pipette at time point 0 50 µM 
∆ Applied voltage over the pipette 400 mV-600 mV 
 
Approximate expressions have been used to calculate the boundary conditions for the 
concentration far from the pipette in order to reduce the simulation volume, similar to what has 
previously been done (Babakinejad et al. 2013). As the features on the surface far from the 
pipette will have less influence on the concentration profile, they will approach the values for 
a flat surface. The concentration at those distances can thus be set to the values for a flat 
surface. Equations 1 to 3 were solved using linear MUltifrontal Massively Parallel sparse direct 
Solver (MUMPS), with a sufficiently fine mesh size to not produce any significant changes in 
the outcome of the simulations when further refining the mesh. 
 
6.2.4. Simulating ISO application onto cardiomyocyte structures 
In order to quantify the applied concentration and the diffusion of the applied agonist ISO, 
once it is unloaded from the nanopipette, it was necessary to generate a mathematical model 
and to simulate the application conditions onto the 3 dimensional structure of cardiomyocytes. 
Our collaborator Dr. Peter Jönsson (Lund University, Sweden) previously modelled and 
compared the application of molecules onto flat surface structures via pressure and voltage-
driven application (Babakinejad B. et al. 2013). Here he generated a mathematical description 
of ISO application onto differential cardiomyocyte structures according to my requirements 
and instructoins. The following description was kindly provided by him. The total flux Qtot of 
studied molecules out of the tip of the pipette is approximately given by equation 1 
(Babakinejad et al. 2013): 
      tan0eoep0tot RcQ  (1) 
taken from (Babakinejad et al. 2013), where c0 is the concentration of molecules in the bulk of 
the pipette, R0 is the inner tip radius of the pipette,  the inner half cone angle and  the 
Chapter 6: Modelling agonist application 
149 
 
voltage drop over the pipette. When the molecules leave the pipette they will be rapidly diluted 
due to diffusion. For a flat surface the concentration varies with the distance (x,y) from a point 
on the surface just below the pipette (0,0) according to the expression in equation 2 
(Babakinejad et al. 2013):  
  










  2220tot0 4exp12, hyxDcQcyxc 
  (2) 
 
where C0 is the concentration inside the pipette at time point 0, D is the diffusivity of the 
molecules and h is the distance between the tip of the pipette and the surface. When c << c0 
then equation 2 simplifies to:  
 
 
   
222
0eoep
0
tan
,
hyxD
R
cyxc




 (3) 
The concentration thus scales approximately inversely with the distance to the point (0,0) and 
increases linearly with the radius of the pipette and the applied voltage.  
 
6.2.5. Experimentally testing application precision 
10x 10 µM SICM surface scans of control cardiomyocytes were generated before lowering 
down the nanopipette to 500 nm above the respective structure onto which ISO was to be 
applied. To apply ISO, the SICM mode of application was changed from pressure to voltage-
driven using the settings, that had been mathematically determined through finite element 
modelling. A detailed description of the SICM and the β2ARs dependent second messenger 
signal measurements are given in the general material and methods section (see chapters 2, 
paragraphs 2.8.1. and 2.8.2.). It is important to note that the bath solution was continuously 
exchanged via a perfusion system in under 5 seconds.     
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6.3. Results 
 
6.3.1. Averaged, experimental structures for the simulation of ISO application 
The diameter of the T-tubule opening at the primary application site (x,y,z) = (0,0,0) was 
determined to be approximately 400 nm for both control cardiomyocytes and cardiomyocytes 
at 4, 8 and 16 weeks post-MI. This is explained by a bias on the part of the experimentalist 
during the procedure of application, where the agonist is applied preferentially into the most 
clearly visible T-tubule opening on the corresponding SICM surface scan. The nanopipette 
scale was taken from (Babakinejad et al. 2013). 
Based on the afore-mentioned values, a representative model of healthy cardiomyocytes was 
constructed from the SICM images (see Figure 50). The geometry consists of a 10 μm3 cube 
with parts subtracted to construct:  
(i) 0.4 μm wide and 1 μm high grooves along the y-direction, spaced 2 μm apart. 
(ii) 0.4 μm wide and 0.25 μm high grooves in the x-direction, spaced 2 μm apart.  
(iii) A pipette with an inner tip radius of 50 nm, an outer radius of 100 nm and an inner half 
cone angle of 3°. 
 
 
Figure 50 The geometry used in the numerical simulations for a healthy cardiomyocyte. (A) The simulation 
geometry consists of a cube with the side lengths 10 µm, in which parts have been subtracted to make up 
the Z-grooves and T-tubule openings as well as the pipette. (B) A zoom-in of the yz-plane at x = 0 together 
with some of the dimensions of the simulation geometry. (C) A zoom-in of the xz-plane at y = 0 together 
with some dimensions of the simulation geometry. The pipette has an inner tip radius of 50 nm, an outer 
tip radius of 100 nm and an inner half cone angle of 3º. All distances are given in µm. 
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6.3.2. The electrophoretic mobility of ISO 
According to the measurements performed for this study (by the company Brookhaven 
Instruments, UK), the agonist ISO possesses an electrophoretic mobility (µep) of -7×10-9 m2/V s 
and an electroosmotic mobility (µeo) of 1.4×10-8 m2/V s in the physiological buffer with high ion 
concentrations used for the experiments described herein. Hence this value was used to solve 
the finite element model of ISO application onto the cardiomyocyte surface.  
 
6.3.3. Parameters for ISO application onto cardiomyocyte surface structures 
Using the finite element model, we were able to simulate ISO application with variable 
nanopipette openings or application voltages and to predict the resulting concentration and 
the diffusion distance of ISO after its application onto the T-tubule openings or surface crest 
structures of cardiomyocytes. The concentration profile will change for different values of ∆ 
and R0, but will roughly scale according to the expression in equation. 3 (data not shown):  
 
   
222
0eoep
0
tan
,
hyxD
R
cyxc




 
This means that for a pipette with a 20% larger radius the concentration will be 20% larger if 
all other parameters are kept constant. Similarly, the concentration will scale roughly linearly 
with the applied voltage under the condition that c << c0. Therefore the experimentalist should 
strife to use pipettes of a constant size. 
The set of parameters that should be used for precise and reproducible experimentation is 
shown in table 8. 
 
Table 8 Parameters and values predicted for the precise delivery of ISO. 
Name  Description Value 
R0 Inner pipette tip radius 50 nm 
R1 Outer pipette tip radius 100 nm 
θ Inner pipette half-cone angle 3° 
h Pipette-cardiomyocyte surface distance 500 nm 
D Diffusivity of ISO (Venter 1978) 6.7×10-10 m2/s 
µep Electrophoretic mobility of ISO -7×10-9 m2/V s 
µeo Electroosmotic mobility of ISO in the pipette (Babakinejad et al. 2013) 1.4×10-8 m2/V s 
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c0 ISO concentration inside the pipette at time point 0 50 µM 
∆ Applied voltage over the pipette 400 mV 
 
 
6.3.4. Simulation of ISO application onto cardiomyocyte surface structures 
In the simulation of ISO concentration that results from using an electrical potential of 400mV 
in the pipette, we found that 7×105 molecules/s of ISO per second leave the nanopipette. ISO 
application was also modelled seperately in the T-tubule (see figure 51) openings and crest 
areas (see figure 52). In the case of T-tubule openings, the flux of ISO is initially guided along 
the Z-groove at x = 0 in the y-direction. The concentration along the lower edge at x = 0 and 
the lower edge at y = 0 is shown where the concentration is also compared to the 
corresponding value for a flat surface, h = 500 nm above the surface. The distance is given 
as the value of y for the edge at x = 0 (see Figure 54D) and as the value of x for the edge at y 
= 0. The simulated concentration over the T-tubule opening at (x, y, z) = (0, 0, 0) is ~3.5 µM, 
which is approximately 6.5 times higher than the concentration for a theoretical, flat surface at 
the same distance to the pipette. The reason for this behaviour is that the molecules are initially 
limited to diffuse along the length of the Z-groove, which results in a slower decrease of the 
concentration in this direction. At larger distances the molecules start to diffuse in all directions 
again and the concentration approaches that of a flat surface. In fact, the concentration at the 
T-tubule opening in the second groove at (x, y, z) = (2 µm, 0, 0) is only ~10% different from 
the value for a flat surface. This value is approximately 30 times lower than the concentration 
at the T tubule opening at (x, y, z) = (0, 0, 0). The concentration for the second T-tubule 
opening in the groove at (x, y, z) = (0, 2 µm, 0) is higher due to the guiding effect of the groove, 
but is still ~15 times lower compared to the concentration over the first opening (at x = y = 0), 
indicating that the delivery is mainly limited to the T-tubule opening beneath the pipette. When 
instead delivering to the crest (see figure 52) in between the Z-grooves (x = y = 1 µm) with h 
= 500 nm above the surface, the concentration in the nearest T-tubule is approximately 6.5 
times lower compared to when delivering directly to the T-tubule (see Figure 51 and 52).  
In order to improve the visualisation of the concentration profile of ISO outside the pipette, the 
colour scale shown in the following figures ranges between 0 and 5 µM, while the 
concentration in the bulk of the pipette is 50 µM. 
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Figure 51 Delivery of ISO to a T-tubule opening. (A) 3D image showing the simulated concentration of ISO 
when deliver-ing with  = 400 mV. The concentration in the bulk of the pipette is 50 µM. (B and C) 2D 
zoom-in at the plane x = 0 showing the concentration distribution at  = 400 mV and -200 mV, respectively. 
(D) Line profiles of the concentration at  = 400 mV along the lower edge at x = 0 (blue) and y = 0 (red) as 
a function of the distance y and x, respectively, from the point (x, y, z) = (0, 0, 0). The black line is the 
corresponding value for a flat surface using Eqs. 1 and 2. 
 
Figure 52 Delivery of ISO to the crest between T-tubule openings. (A) 3D image showing the concentration 
of ISO when delivering with  = 400 mV. The concentration in the bulk of the pipette is 50 µM. (B and C) 
2D zoom-in at the plane x = 1 µm showing the concentration distribution at = 400 mV and -200 mV, 
respectively. (D) Line profiles of the concentration along the lower edge at x = 1 µm (blue) and y = 1 µm 
(red) as a function of the distance y and x, respectively, from the point (x, y, z) = (1, 1, 1) µm. The black line 
is the corresponding value for a flat surface using Eqs. 1 and 2 (relative to the point (1, 1, 1) µm). 
 
6.3.5. ISO application via voltage is precise 
Under experimental conditions using control cardiomyocytes the β2ARs dependent second 
messenger signal of cardiomyocytes only changed when ISO was applied into the T-tubule 
opening on the cell surface and not on the crest area in between the Z-grooves (see Figure 
52). This was in accordance to prior work conducted in our group which elicited the same 
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results with a pressure-driven approach (Nikolaev et al. 2010). Hence the precision of local 
agonist application was assured both mathematically and experimentally.  
 
Figure 53 A 10×10 µm SICM surface scan, showing ISO application into an opening on the surface of a 
cardiomyocyte. Z-grooves are indicated by black dotted lines, openings by blue arrows and crests by green 
arrows. The respective Z-groove index as well as the number of openings on the 10×10 µm area are 
summarised in the bottom panel. (B and C) Graphs showing cell internal β2AR dependent second 
messenger response to agonist application into (B) the T-tubule opening and (C) onto the crest of the cell 
surface, obtained by moving the pipette to the respective coordinates on the computer-generated SICM 
scan and unloading ISO locally via a voltage switch from -200mV to +400mV.   
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6.4. Discussion 
In chapter 6 a mathematical model of ISO application onto variable surface structures was 
generated and finite element simulations were performed to establish the approximate amount 
of the molecule ISO being delivered from a nanopipette onto either T-tubule openings or crest 
structures. To obtain the required parameters for these simulations a representative model of 
the cell surface and the pipette dimensions was established and the ligands electrophoretic 
mobility was measured.Though the above described finite element model is highly specific for 
the SICM microscope this does not diminish its usefulness for further simulations to find out 
the approximate precision and molecule concentration for any molecule one might wish to 
apply onto the cardiomyocyte surface via the SICM nanopipette. An increasing number of 
investigations highlight the importance of compartment-specific signaling of this cell type and 
the investigation and manipulation of single compartments will become crucial for fully 
understanding their physiological and pathophysiological regulation. So far SICM is the only 
method that enables us to perform non-invasive experiments that are as localized as a single 
T-tubule opening. The analytical verification of this application method presented here 
encourages a range of further local application experiments. The technique allows delivering 
essentially any compound to multiple structured cell types with a precision determined by the 
pipette dimensions and the potential compound charge.  
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7.1. Study limitations: 
7.1.1. Human versus rodent cardiomyocytes: 
When working with model organisms such as the rat model of chronic MI used in this thesis it 
is of paramount importance to realise that not all of this study can be implemented in humans 
as there are strong species-dependent differences in the structure and in the signalling 
cascades of cardiomyocytes. These differences are visible in chapter 3 where actual human 
preparations were available for structural investigations (see chapter 3, paragraph 3.5). As 
can be seen the rodent cardiomyocytes of intact hearts and at different stages of HF exhibit 
more regular and more numerous T-tubule structures than human cardiomyocytes from MV 
surgery patients and hearts obtained from transplantation procedures. Partly the 
discrepancies between humans and rodent cyclic nucleotide signalling are discussed in 
chapter 1 when the cardiac PDEs are introduced (see chapter 1, paragraph 1.8.16). Therefore 
the findings in animal models cannot be translated readily into treatments for human conditions 
and great care has to be taken when drawing overarching conclusions without due regard to 
species differences.  
 
7.1.2. FRET measurements after 48h of cardiomyocyte culture 
It is well known, that primary cells in culture undergo dedifferentiation and structural loss 
(Mitcheson et al. 1998). The cardiomyocytes which were utilized for β2AR and β3AR 
dependent cyclic nucleotide signalling studies via FRET measurements were kept in culture 
and transduced with virus for 48h. The consequence of this loss of structural integrity of cells 
during prolonged culture might become visible in the FRET measurements themselves, when 
looking at second messenger diffusion after local agonist application through the SICM 
nanopipette. Theoretically, based on the dimensions of the TAT network and the size of a 
single sarcomere, a highly compartmentalised cAMP response in control cells might be 
expected to spread no further than 2 microns each side. As β2AR-dependent cAMP pools are 
regulated in great measure by PDEs in close association with the ACs, physiological cAMP 
diffusion might be expected to be even smaller. However, during our experiments local 
stimulation of the β2ARs in the T-tubule opening via the nanopipette generates a cAMP 
response that even in control cardiomyocytes diffuses much further (~15 microns) into the 
cardiomyocyte’s cytosol than would be expected in a physiological environment. This could 
potentially be due to the agonist extracellulary diffusing further inside the TAT network than 
expected or due to PDEs adhering to the vicinity of GPCRs like the β2AR and β3AR and acting 
like cyclic nucleotide “draining sinks” rather than physical barriers (Terrin et al. 2006). It could 
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also be due to the structural deterioration which primary cardiomyocytes experience in culture 
(Mitcheson et al. 1998). 
  
7.1.3. PDE blockers do not distinguish specific splice variants of PDEs 
In this thesis β3AR-dependent cGMP in adult rat cardiomyocytes was shown to be degraded 
by PDEs 2 and 5. However due to the nature of the PDE blockers, which were used for 
experimentation, no distinction was made between different isoforms of PDE2 and PDE5. 
cGMP binding to the PDE2 GAF domain boosts the PDE’s activity, which decreases both 
cAMP and cGMP at similar speed and efficiency. PDE2 possesses 3 splice variants, one of 
which is PDE2A (Omori and Kotera 2007). Based on published findings in neonatal rat 
cardiomyocytes showing that β3AR appears to be regulated via PDE2A (Mongillo et al. 2006) 
we assume that perhaps this splice variant might primarily fulfil the same function in adult, rat 
cardiomyocytes. Despite the identification of 3 isoforms of PDE5 with variable tissue specificity 
(namely PDE5 A1, A2 and A3) no functional variability was found between these isoforms 
(Kass 2012).  
 
7.1.4. Specificity of available inhibitory compounds  
Some of the compounds used for PDE inhibition in chapters 5 are known to provide only partial 
blockage for the respective PDEs, for which they were said to be specific. These compounds 
could potentially induce a rise in cAMP and/or cGMP response levels which could skew the 
data obtained and its respective interpretation. The first of these compounds is the PDE1 
blocker Vinpocetine. Even though Vinpocetine is widely used it does not exhibit high PDE1 
specificity (Bender and Beavo 2006; Kass 2007; Richter et al. 2011). Indeed, according to 
literature there is currently no cell permeable, PDE1 blocker, which is specific enough to use 
without off target effects (Bender and Beavo 2006). Furthermore EHNA, the PDE2 blocker 
used in this study, has shown to lead to side effects by inhibiting the enzyme adenosine 
deamidase, which catalyses adenosine into inosine (Miller and Yan 2010). This should 
however have no direct consequence on the cGMP measurements conducted here. Similarly 
Tadalafil, the blocker used for PDE5 inhibition, has shown some capacity to bind and block 
members of the PDE11 family (Omori and Kotera 2007). The PDE11 family appears to have 
no role in cardiomyocytes though (Miller and Yan 2010). Unlike the PDE inhibitors mentioned 
above the NOS blocker L-NAME is blocks all three types of NOS: eNOS, iNOS and nNOS. It 
can therefore not distinguish alterations in eNOS, iNOS and nNOS activity, which have been 
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reported to take place in HF (Sarker et al. 2001) and in sepsis in connection to β3ARs (Niu et 
al. 2014).  
 
7.1.5. Responsiveness of cells to cGMP eliciting reagents  
During the FRET investigation of cGMP levels in control and failing cardiomyocytes it was 
found that not all of the isolated cardiomyocytes responded to stimulation. Indeed only about 
50% of cells used for measurements exhibited a clear cGMP induced FRET response. This 
could be due to cell external reasons, like the solvability or shelf life of the used reagents in 
solution or to cellular reasons like potentially occurring cell subpopulations which of which 
some may not react to cGMP triggering stimuli.    
 
7.2. Study summary and future work 
7.2.1. Summary: Cardiomyocyte β2AR-dependent cAMP signalling and structure are 
altered progressively during the development of HF 
MI obliterates a great number of cardiomyocytes and results in the loss of crucial cardiac 
output as a result of decreased functionality of the remaining myocardium. This loss can only 
be transiently compensated by the remaining myocardium through the execution of multiple 
adaptive alterations in both cardiomyocyte structure and contractile function and, without 
clinical interference, this will progressively lead to end stage HF (Laflamme and Murry 2005) 
(this reference was in the reference list). The βARs are crucial in transducing the extracellular 
stimuli of the SNS into intracellular changes in cell contractility (Zipes, Jalife 2009). Signalling 
via cAMP has been shown to be gravely altered at the end stage of HF (Bristow et al. 1982; 
Nikolaev et al. 2010; Kishi 2012). Most strikingly, β2AR relocate from the cardiomyocyte T-
tubules to the sarcolemma at the end stage of HF (Nikolaev et al. 2010). The purpose of T-
tubules is to synchronize responses to the external stimuli and to serve as conduit from the 
sarcolemma into the cardiomyocyte body which creates a regulated environment of ions and 
ligands close to ion channels and receptors. Multiple studies including previous work of our 
own group have shown that T-Tubules are severely disrupted in both humans and animals at 
the end stage of HF (Lyon et al. 2009; Wei et al. 2010; Nikolaev et al. 2010; Wagner et al. 
2012). However an integrative study was lacking of alterations in cardiomyocyte structure and 
associated β2AR dependent cAMP signalling occurring progressively over time during HF 
development even though it could yield a vital insight into new treatment strategies of HF. 
Hence chapter 3 focused on the structural alterations of the TAT network and the surface 
membrane of cardiomyocytes during the progression of HF while chapter 4 dealt with the 
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FRET based investigation of β2AR-dependent cAMP signalling during the progression of HF. 
In healthy cardiomyocytes, where the external surface structure (Z-grooves and crests) and 
internal TAT network are intact, β2AR are exclusively situated inside the T-tubules (Nikolaev 
et al. 2010). At the same time JPH2 efficiently connects T-tubules with the SR (Han et al. 
2013). Furthermore in intact cardiomyocytes cAMP is efficiently contained close to the site of 
β2AR activation in specific functional compartments. Such cAMP signalling compartments 
have both physical components as well as virtual components. On the one hand the physical 
components comprise the TAT network with the β2ARs positioned inside of it and on the other 
hand JPH2 bridging of the T-tubule and SR. We now know that both of these are severely 
altered at the end stage of HF. The components are generally assumed to be additional factors 
such as the distribution of cAMP downstream targets and cAMP degradation via various 
PDEs, in particular PDE4 (Terrin et al. 2006; Nikolaev et al. 2010), as well as efficient β2AR 
coupling to Gi, as was shown in this thesis. In the experiments described in this thesis the TAT 
network is already disrupted during early hypertrophy as is visible by a severe loss of tubules 
(about 50%) in the transverse orientation. These findings are in agreement with observations 
that have been reported before by other groups (Wei et al. 2010; Wagner et al. 2012). This 
loss might be partially compensated with a transient increase in longitudinal elements during 
the early, compensatory phase of HF. This increase might occur due to decreased levels of 
JPH2, which is important for TAT network tubule orientation (Bennett et al. 2013; Pinali et al. 
2013). The increase in longitudinal elements could also be due to alterations in BIN1 which 
could lead to deformations of the plasma membrane (Hong et al. 2010) or due to a general 
return to the expression of early developmental genes (Wagner et al. 2012). Also at the early 
stage of HF the β2AR-dependent cAMP signal levels in T-tubules decrease significantly in 
comparison to control cells. At the same time the cAMP signal itself is no longer confined to a 
small intracellular area but diffuses throughout the whole cell cytosol. At the later, 
decompensated stage of HF, β2ARs partially leave their exclusive T-tubular position and 
probably also uncouple from Gi proteins. Finally at the end stage of HF, the overall TAT 
network structure and AC activity is disrupted and as a consequence so is the β2AR cAMP 
signal. In summary chapters 3 and 4 reveal a build up of time-dependent alterations in the 
composition of cardiomyocytes after the introduction of chronic MI, each of which might pose 
a leverage point for improved, differential treatment of HF thus slowing disease progression. 
The changes in both cardiomyocyte structure and β2AR-dependent cAMP signalling are 
summarised and reiterated in the schematic below (see figure 53).          
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Figure 54 Summary schematic of major changes occuring at the level of local β2AR dependent cAMP 
signalling and cardiomyocyte structure at consecutive time points during the progression of HF. In HF the 
surface structure deteriorates progressively; T-tubule regularity and density is perturbed after only 4 
weeks of MI, with the loss of most of JPH2; the number of longitudinal elements increases at 4 and 8 weeks 
after MI, perhaps as a compensatory mechanism; β2ARs start to migrate to the crest at 8 weeks of MI, with 
consequent higher diffusion of cAMP. The schematic was generated by Mr. Andrey Buzuk (Imperial College 
London) according to my instructions. 
 
7.2.2. Future work: Investigations of the whole heart in terms of cardiomyocyte structure 
and β2AR-dependent cAMP signalling investigations of the whole heart 
Chapter 3 sets out to elucidate left ventricular cardiomyocyte structure after chemical 
treatment and most importantly during HF progression. In parallel chapter 4 focussed on the 
elucidation of β2AR-dependent cAMP signalling changes in left ventricular cardiomyocytes 
during HF progression. Still there are many aspects which could be addressed in the future. 
Depending on their anatomical location in the heart, cardiomyoctes can exhibit structural 
differences that can range from striking (i.e. atrial versus ventricular cells) to very subtle (i.e. 
right versus left ventricular cells) in regard to the presence and arrangement of their structure 
as well as their reactivity to βAR stimulation. For example, the degree of the TAT network 
presence and function in the atrial cardiomyocytes is much more variable and less defined 
than in left ventricular cardiomyocytes. Three atrial cell types have been described with either 
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orderly, disorderly or no TAT systems (Frisk et al. 2014). This structural variability indicates 
strong differences in the function of atrial versus ventricular cardiomyocytes. Furthermore 
endocardial and epicardial differences in cardiomyocyte structures such as variations in size 
(Gerdes et al., 1986) and function (Haynes et al. 2014; Zygmunt et al. 2001; Cordeiro et al. 
2004) were observed transmurally.  Hence the first evident gap of this doctoral study is that 
the cardiomyocytes studied herein were primarily from the left ventricle, with no regard to 
transmural and position-dependent cell differences. Similarly, during the examination of 
cardiomyocyte structures in their progression towards HF no distinction has been made 
between cardiomyocytes isolated close or remote from the infarcted area, as cells from all 
over the remaining ventricular myocardial tissue were isolated together. However it might be 
difficult to ascertain that the quality of cell isolations remains the same for all anatomical 
portions, were they to be separated. Perhaps it would be more feasible to investigate 
cardiomyocyte structure as well as βAR dependent signalling in the entire heart or tissue 
context. In mouse such structural combined with functional βAR investigations were already 
performed in the epicardium of intact, Langendorff-perfused hearts through laser confocal in 
situ imaging combined with βARs inhibition (Wei et al. 2010; Chen et al. 2012). This showed 
that cardiomyocytes remote from the infarct zone experienced only moderate structural 
alterations while cardiomyocytes close to the infarct zone experienced more severe changes. 
These changes were in part reversible through βAR-dependent signal blocking. However such 
studies do not allow the localised stimulation of βARs, which was crucial for the investigations 
performed in this thesis. A further limitation of the studies described within this thesis regards 
cardiomyocyte motility. As cardiomyocytes are naturally contracting cells it must be 
determined what role motion might play in relation to receptor-dependent cyclic nucleotide 
signalling as well as in receptor localisation and in remodelling of cardiomyocytes. Cell motion 
is oftentimes conceived as introducing artefacts into live cell and tissue measurements (Tai et 
al. 2004). As a consequence many techniques consider forcing cells into artificially-induced 
mechanical arrest to cease unwanted cell movement. This can be achieved by withdrawal of 
molecules necessary for continuous motion, such as Ca2+ (O'Neill et al. 1990), or the F-actin 
polymerisation inhibitor cytochalasin D (Biermann et al. 1998). The deliberate quenching of 
motion may be justifiable in relatively static cell types, however, in highly motile cells such as 
contracting cardiomyocytes making all measurements under static conditions could lead to 
distorted understanding of GPCR-dependent cell signalling and pharmacology. Mechano-
sensitivity of GPRCs and conformational changes of these receptors as a result of shear stress 
have been shown in a range of cell types and pathways, including endothelial cells 
(Chachisvilis et al. 2006) and the angiotensin II pathway in cardiac cells (Yasuda et al. 2008). 
Therefore the induction of mechanical arrest should be considered an investigative limitation, 
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as motion itself in combination with sub-cellular structures might have an as of yet 
unappreciated role in helping to form sub-cellular microdomains.  
 
7.2.3. Summary: Rat cardiomyocytes possess functional β3AR which signal via cGMP  
Despite multiple publications from separate groups about the presence and function of β3AR 
in human and rodent cardiomyocytes (Gauthier et al. 1996; Mongillo et al. 2006; Amour et al. 
2007; Belge et al. 2014) scientists are still sceptical about the physiological importance and 
actual function of β3ARs in the heart (Kulandavelu and Hare 2012). This scepticism could in 
part be due to the low expression levels of β3ARs. For example only about 0.02% of all βARs 
present in neonatal rat cardiomyocytes appear to be β3ARs (Mongillo et al. 2006). However, 
jumping to the conclusion that something is unimportant just because something is hard to 
find is a conjecture which should be avoided. To illustrate this point one might cite as an 
example that, in a specific type of breast cancer, it only takes a single base mutation for the 
cancerous remodelling of a whole cell (Hart et al. 2015). The fact that there is a disagreement 
amongst published reports on whether β3ARs couple to Gs or to Gi further adds to the 
controversy surrounding this βAR subtype. Endogenous β3ARs in human heart tissue 
preparations (Gauthier et al. 1996) and in whole guinea pig hearts (Kitamura et al. 2000) 
showed negative inotropic effects on contractility, which indicates Gi-dependent signalling. 
When human β3ARs were however overexpressed relatively little response to catecholamines 
has been reported and the receptors appeared to signal via both Gs and Gi (Kohout et al. 
2001). The discrepancies in the aforementioned studies could have arisen due to species 
differences or differences in the stimulatory drugs which were used. Studies conducted in our 
group in adult rat cardiomyocytes detected no differences in cAMP levels when specifically 
blocking β3ARs before whole cell stimulation with ISO (Nikolaev et al. 2010). Therefore β3AR 
does not appear to signal via Gs in adult rat cardiomyocytes. This finding is corroborated by a 
study in neonatal rat cardiomyocytes (Mongillo et al. 2006) which ascribes β3ARs cAMP 
lowering effects by inducing increased PDE2 activity as a result of cGMP binding to the PDE’s 
GAF domain. The presence of functional β3ARs in adult, rat cardiomyocytes has been shown 
in this thesis after recording the β3AR-dependent cGMP signal using the novel cGMP FRET 
sensor Red cGES DE5. This sensor possesses high enough affinity and an EC50 around 
~50nM for cGMP to measure the cyclic nucleotide reliably in cardiomyocytes (Niino et al. 2009; 
Götz et al. 2014). Also in this thesis the PDEs responsible for β3AR-dependent cGMP 
signalling were identified; PDE2 and PDE5. Increased β3AR expression levels in the heart 
have been reported in various disease states including diabetes, sepsis and HF (Moniotte et 
al. 2001; Moniotte et al. 2007; Niu et al. 2012; Kulandavelu and Hare 2012) as well as in 
senescence (Birenbaum et al. 2008). Surprisingly despite these reports the cGMP-FRET 
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measurements in end stage HF cardiomyocytes described in this thesis showed a significantly 
decrease in the amount of cGMP signalling via β3AR in comparison to control cardiomyocytes. 
One of the reasons for this decrease has been shown to be the upregulation of PDE2 activity 
in end stage HF. Due to this low expression as well as the receptors membrane bound position 
it is difficult to determine its localisation in the intact cardiomyocyte via immunocytochemcial 
approaches. A recent study in transgenic mice overexpressing β3AR in cardiomyocytes used 
cell fractionation and Western blotting to deduce the putative localisation of β3ARs. 
Colocalisation with eNOS and Cav3 showed that the β3AR are most likely to be situated inside 
the T-tubules (Belge et al. 2014). The same study showed that β3ARs fused to the GFP, which 
were artificially introduced through adenovirus construct transduction, localise to the 
sarcolemma of neonatal cardiomyocyes (Belge et al. 2014). In this thesis the same fusion 
β3AR-GFP proteins were artificially overexpressed in adult rat control cardiomyocytes. The 
introduced receptor appeared to localise along the Z-lines and this once more indicates that 
the endogenous receptor might be situated inside the cardiomyocyte T-tubules. To additionally 
verify this potential localisation combined SICM/FRET studies were applied and indeed 
showed that β3AR in control cardiomyocytes sits primarily inside the T-tubules. Given this T-
tubular location of the endogenous β3ARs, one might deduce that their associated cGMP 
signals may produce an effect only onto confined signalling compartments similar to those 
displayed by β2ARs (Nikolaev et al. 2010). The physiological consequences of β3AR-
dependent cGMP production were not studied in this thesis. However prior reports of studies 
performed in neonatal rat cardiomyocytes suggested that β3ARs serve as negative inotropic 
counterbalance to the positive inotropic effects of β1AR and β2AR-dependent signalling 
through Gs. In this study we mainly found that β3ARs functions by eliciting a cGMP response 
which is able to trigger an increase in PDE2 activity which in turn probably impacts cAMP level 
(Mongillo et al. 2006). A similar function is ascribed by others to β3ARs in the human 
myocardium where stimulating β3ARs via a specific agonist BRL37344 as well as NOR while 
blocking the other two βAR subtypes leads to a significant decrease in contractility. This effect 
was reversible via the application of the NOS blocker L-NAME (Gauthier et al. 1998). Hence 
in intact control cardiomyocytes and hearts the function of β3ARs is assumed to be of an 
accessory, mitigating nature. The β3AR may potentially protect the heart from cardiomyocyte 
remodelling and damage induced via excessive β1ARs stimulation (Pott et al. 2006). However 
it has been shown recently that in the human atria the specific β3AR agonist, BRL37344 
elicited both β1AR and β2AR-dependent positive inotropic effects as well as β3AR-dependent 
negative effects, which might dispute the specificity and hence the effects of this agonist (Pott 
et al. 2003). A more recent study of the long term effects (≥ 10 days) of activating β3AR-
dependent cGMP signalling in control mice and a transverse aortic constriction (TAC) model 
of mice furthermore revealed a capacity of β3ARs to prevent chronic hypertrophic remodelling 
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arising due to excessive, neurohormonal stimulation the β1AR and β2AR subtypes (Belge et 
al. 2014). In another β3AR study in mice where MI was induced following LAD aorta ligation 
β3AR-dependent cGMP signalling over both the eNOS as well as nNOS furthermore protected 
cardiac tissue against fibrotic scarring and cardiomyocyte apoptosis (Niu et al. 2014). By 
generating a nNOS knockout mouse model in combination with TAC the same group 
established that β3AR signalling which primarily occurs via eNOS in the intact myocardium 
redirects its downstream signalling cascade to occur via nNOS in the failing myocardium (Niu 
et al. 2012). In MI nNOS has been shown to leave the vicinity of RyRs and to colocalise with 
Cav3 (Kulandavelu and Hare 2012). This switch between NOS isoforms and their localisation 
might be associated with β3AR relocalisation, which was observed in this thesis and might 
further explain the decrease in β3AR-dependent cGMP signalling which was observed in 
cardiomyocytes at the end stage of HF also described in this thesis.  
In summary chapter 5 has revealed the novel finding that β3AR-dependent cGMP signalling 
does occur in adult cardiomyocytes at a level measureable via a cytosolic cGMP FRET sensor. 
This signal which is generated via sGC is indeed regulated via PDE2 and PDE5 as was 
previously reported (Mongillo et al. 2006; Takimoto et al. 2007). Also SICM/FRET 
measurements showed that the β3ARs are situated inside the T-tubule domain of 
cardiomyocytes in health but alter their location at the end stage of HF to all over the 
cardiomyocyte sarcolemma just like β2ARs (Nikolaev et al. 2010).  
 
7.2.4. Future work: β3AR-dependent cGMP signalling in adult rat cardiomyocytes 
As the suitability of Red cGES DE5 to measure β3AR-dependent cGMP signalling in adult, rat 
cardiomyocytes is an entirely, novel finding a lot of research avenues are open for future 
investigation. Though the rat has hereby proven to be a valid model for the study of 
endogenous β3ARs it might be recommendable to see if similar measurements can be made 
in other animal models. In this thesis the β adrenergic stimulator ISO combined with specific 
blockage of the β1ARs and β2ARs was used to elucidate β3AR-dependent cGMP signalling in 
healthy and failing adult rat cardiomyocytes. The study described herein has not investigated 
any measureable influence of β3AR-dependent signalling on cardiomyocyte function. This 
could be the first future step of investigation. Some preliminary experiments might combine 
contractility studies of cardiomyocytes with the specific inhibition or stimulation of β3ARs in 
control cardiomyocytes. In consecutive work it will furthermore be interesting to test and 
measure the differences in β3AR-dependent cGMP signalling in intact and failing 
cardiomyocytes in more detail. For this it would also be desirable to test the specificity of the 
β3AR specific agonist BRL37344 to elicit β3AR-dependent cGMP pools and to obtain subtype 
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specific NOS inhibitors. If beneficial, functional effects of the β3ARs can be established in 
healthy and failing cardiomyocytes the β3AR might become a promising new therapeutic target 
in the treatment of HF.     
 
7.2.5 Summary: Mathematical modelling  
Chapter 6 of this thesis described a finite element mathematical modelling (FEM) approach to 
determine the approximate concentration of the agonist ISO applied via the SICM nanopipette 
during local stimulation of βARs via voltage-dependent dispersion of the pipette solution onto 
cardiomyocyte surface structures. The model allowed us to simulate the influence of variable 
parameters on agonist application. It also allowed us to determine the optimal settings 
necessary for localised receptor stimulation. The described mathematical model is very 
specifically tailored to our SICM/FRET measurement method as it for example showed a high 
dependency of agonist application on the nanopipette size and also on the cardiomyocyte 
structure lying underneath the nanopipette i.e. the T-tubule opening acts as a reservoir for the 
applied agonist. However despite its specificity the described mathematical model also shows, 
that the SICM nanopipette delivery of agonists onto cardiomyocytes opens up the possibility 
of very precisely affecting the ionic or ligand content of only a single T-tubule. No other 
currently available technique is capable of such focussed manipulation of a structural domain 
that is as important to cellular function as the T-tubule is to the cardiomyocyte.  
 
7.2.6. Future work: Modelling ISO diffusion through the TAT network 
As was stated in the prior paragraph the mathematical model described in this thesis is highly 
specific to determining the approximate amount of ISO which diffuses out of the SICM 
nanopipette after a switch of the electrical potential inside the nanopipette from negative to 
positive. Despite its specificity the model has the potential for further application. In the case 
of cardiomyocytes, the modelling principle described in this thesis could be applied for 
delivering fluorescent dyes and investigating diffusion dynamics within a single T-tubule or the 
whole TAT network, delivering universal and specific agonists as well as ions, for example 
Ca2+ to monitor Ca2+ induced Ca2+ release. The concept could also be expanded to local 
application following membrane sealing by the nanopipette, which would allow to avoid 
diffusion of the agonist into the extracellular space and to achieve higher concentrations inside 
the TAT structure. Therefore, the model also presents a universal approach to quantify local 
application and to adjust such parameters as precision, speed and ultimate concentration 
through modulating the ionic current and pipette structure. Even though the simulations 
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presented in this thesis were for the specific case of ISO delivery to cardiomyocytes the 
simulations could also be applied and made useful for other cell types and agonist delivery 
applications, as it allows the quantification, and possible optimization, of application processes 
that deal with nanoscale structures that evade experimental determination. 
 
7.3. Concluding statement: 
I, Sophie Schobesberger, would like to conclude this thesis by stating that I accomplished the 
goals I set out for myself and thereby contributed the following to the body of scientific 
knowledge:  
 
I elucidated progressive changes in the structure and β2AR-dependent cyclic nucleotide 
signalling during heart failure progression which could both compensate (i.e. increase of 
longitudinal elements in the TAT network) or exacerbate the disease phenotype (i.e. β2AR 
leaving their exclusive T-tubule position and unlimited cAMP diffusion throughout the cytosol 
due to a combination of factors).  
 
Furthermore, with the help of the novel cGMP FRET sensor Red cGES DE5, I generated 
evidence supporting the position of β3ARs as well as β3AR-dependent cGMP signalling in 
intact and failing, adult cardiomyocytes. Additionally I elucidated the position of β3AR 
downstream signalling partners like sGC and eNOS.      
  
Lastly I generated a mathematical model to validate the precision of the improved, voltage-
driven mode of agonist application via the SICM nanopipette.  
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